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Abstract 
In 2016, 216 million malaria cases with 445,000 associated deaths were recorded according to 
the World Health Organization (WHO). Schistosomiasis also remains a public health issue with 
207 million cases recorded globally and 280,000 deaths in the same year. Widespread 
emergence of parasite resistance to once-effective antimalarial options has rendered currently 
used drugs ineffective. Moreover, the current WHO-recommended first-line antimalarial drugs 
in clinical use, the artemisinin combination therapies (ACTs) are faced with the challenges of 
limited availability, unaffordable cost, and undesirable adverse effects. On the other hand, the 
treatment of schistosomiasis is severely limited to one treatment regimen, praziquantel (PQZ) 
which, unfortunately, has recently shown low curing rates in some parts of West Africa. 
Furthermore, this treatment option is far from ideal because its activity is limited to only adult 
schistosomes while displaying no activity towards young stages of the liver flukes. These 
challenges collectively provide a justification for stepping up drug discovery and development 
efforts aimed at identifying novel, safe and efficacious antimalarial and antischistosomal 
agents.  
Whereas, the pyrido[1,2-a]benzimidazole (PBI) scaffold is found in many pharmacologically 
relevant molecules including Rifaximin, an approved gastrointestinal antibacterial drug,  
medicinal chemistry explorations around the PBI nucleus have recently identified analogues as 
novel antimalarial and antischistosomal agents. Additionally, while promising antimalarial 
efficacy has been demonstrated in animal studies, preliminary in vitro studies of the PBI class 
of compounds have also demonstrated good activity against Schistosoma parasites. Recently, 
Mayoka reported the impressive dual antiparasitic potency of the lead compound GMP-19 
(figure 1) against Plasmodium and Schistosoma parasites in vitro (IC50 = 0.430 μΜ, drug-
sensitive strain (NF54) and IC50 = 0.210 μΜ, adult S. mansoni, (unpublished data)). However, 
GMP-19 and other PBI analogues in this series of compounds, have been beset by poor 
solubility. 
Towards addressing solubility issues while retaining and improving antiparasitic activity, in 
this MSc dissertation, the design, synthesis, structure-activity relationship (SAR) and solubility 
improvement studies of PBI analogues based on the GMP-19 template are reported. In this 
regard, chemical modification approaches such as disruption of molecular planarity, increasing 
saturation, incorporating water solubilizing groups such as the polar-ionizable and the neutral-
polar functionalities around the PBI nucleus were adopted. Consequently, we obtained SAR 1 
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analogues after substituting the 4-(trifluoromethoxy)phenyl (4-OCF3Ph) moiety of GMP-19 
with assorted α-methyl benzylamines. In addition, the phenyl 
ring on the left-hand side of the core scaffold was substituted 
with electron withdrawing groups such as the chloro and fluoro 
atoms (SAR 1.1 – 1.4), (figure 1). Although some analogues 
demonstrated a significant loss of antiparasitic activity (> 6.00 
μM), strong submicromolar antiparasitic activity was observed 
with most analogues (IC50 = 0.022 -0.940 μM, PfNF54 and 30 
- 69% inhibitory effect at 0.370 μM, against young forms of S. 
mansoni). Moreover, some analogues demonstrated poor solubility as low as < 10 μM while 
others showed highly improved solubility as good as 80 μM. 
In SAR 2.1 – 2.2, the 4-OCF3Ph and the trifluoromethyl (CF3) on the right-hand side (RHS) of 
the scaffold were fixed while introducing amino moieties (R) on the lipophilic phenyl ring on 
the left-hand side (LHS) of the PBI core (figure 2). Upon identifying the moiety with the best 
balance of solubility and biological activity, the 4-OCF3Ph was 
replaced with various acyclic amino (SAR 2.3) while the CF3 
was maintained on C-3 of the core scaffold. Finally, the CF3 was 
replaced with the 4-CF3Ph (SAR 2.4 and 2.5) while keeping 
fixed the optimal basic amine and the acyclic amino moieties on 
the LHS, respectively. Interestingly, the pursued structural 
modifications delivered analogues with a wide diversity of 
pharmacological and physicochemical properties. While some 
analogues demonstrated significant loss of pharmacological 
activity, others exhibited potent submicromolar antiparasitic activity (IC50 < 0.012 – 0.990 μM, 
PfNF54 and 0.360 – 0.850 μM, adult S. mansoni). Similarly, some analogues demonstrated 
poor solubility as low as < 10 μM while others demonstrated improved solubility as good as 
180 μM.  
 
Figure 1: SAR 1 design 
 
    Figure 2: SAR 2 design 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Malaria  
1.1.1 History, introduction and aetiology 
The word “malaria” was derived from two Italian words “mal” (bad) and “aria’’ (air). The 
malaria parasites were first detected in a patient’s blood by the French army officer Charles 
Louis Alphonse Laveran in 1880. Before then, malaria had been associated with marshy areas 
whose foul air was assumed responsible for its causation.1 In the year 1897, the parasites’ blood 
sexual stages and the elucidation of the transmission cycle in culicine mosquitoes and birds 
infected with Plasmodium relictum were respectively discovered by William McCallum and 
Ronald Ross.1,2 These discoveries laid a landmark in understanding the cause and transmission 
of malaria and thus, paved the way to the conclusive evidence by an Italian malariologist 
Giovanni Battista Grassi in 1898,1 that human malaria was transmitted by various species of 
female Anopheles mosquitoes.1–3 The consequent discovery of the development of malaria 
parasites in the liver before entry into the bloodstream by Henry Shortt and Cyril Garnham in 
1948 facilitated the ultimate discovery of the presence of dormant stages of the parasite in the 
liver as was proved by Wojciech Krotoski in 1982.2  
Malaria is caused by over 100 known single-celled protozoan parasite species of the genus 
Plasmodium of which, P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi are the 
main five (5) species known to infect humans.4 P. falciparum is the highest in disease 
transmission, most lethal and is responsible for the world’s most acute cases of sickness, organ 
dysfunction and deaths.3,5  Although P. vivax and P. ovale only cause a milder form of the 
disease and aren’t as life-threatening as P. falciparum, they are associated with relapses due to 
the persistence of dormant hypnozoite forms in the liver.3,6,7 P. malariae is usually associated 
with infections of a chronic nature and can persist in blood asymptomatically for long periods 
of time.8 A fifth species, zoonotic P. knowlesi that was only known to infect macaques has 
surprisingly been traced to cause human malaria in some parts of South-East Asia.3,9  
Malaria has continued to pose devastating effects on human health and the economy worldwide 
due to vector resistance to commonly used insecticides,10 unavailability of an effective malaria 
vaccine,7,11,12 excessive cost, toxicity and severe adverse effects of existing antimalarials 
besides parasite resistance to these therapeutic agents.13–16  
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1.1.2 Epidemiology 
Malaria is a public health problem whose endemicity spans more than 91 countries worldwide 
affecting more than 40% of the global population. The highest rates of infection and 
transmission are confined within the tropical and sub-tropical regions, Amazon and the 
temperate zones of the world. The highest disease cases and deaths are contributed by sub-
Saharan Africa, Amazonia and South-East Asia.17,18 Factors contributing to a huge malaria 
burden in these regions include their auspicious tropical climatic conditions conducive for 
mosquito breeding and political instability in some resource-poor economies which limit 
investment in malaria prevention strategies.19 Although only dealing with the challenges of 
imported malaria due to international travels and some consequent occasional secondary 
transmission, regions such as Australia, Europe, North America and some parts of Southern 
and Northern Africa (figure 1.1) have been classified as non-malaria endemic.1,20–23   
 
Figure 1.1: World malaria map.24 
The 2017 World Health Organization (WHO) malaria report revealed that about 216 million 
people were infected and roughly, 445 000 malaria-related deaths were recorded globally of 
which 90% and 91% of the infections and deaths, respectively, occurred in tropical regions of 
sub-Saharan Africa in 2016.18,25,26 In the same region, about 125 million pregnant women have 
been reported to be at risk of infection and over 200,000 maternal-infant deaths occur each 
year, translating into a worrisome statistic that one child dies of malaria every two minutes. 
Records also show that 13 out of the 32 most endemic countries of sub-Saharan Africa account 
for about 76% and 75% annual global malaria cases and deaths, respectively.27,28 
  
Chapter 1 
 3 2018 MSc Thesis: Kelly Chisanga 
1.1.3 Malaria parasite life cycle  
Although there are some minor variations, four-major malaria-causing parasites (P. 
falciparum, P. vivax, P. malariae and P. ovale) exhibit similar development steps and life cycle 
which completes in two phases including the human and mosquito phases. The human phase 
of Plasmodium’s life cycle starts with an exoerythrocytic asymptomatic stage lasting between 
9 and 16 days inside the host’s liver.1 The cycle inception involves a female Anopheles 
mosquito that inoculates salivary sporozoites into the host’s punctured dermis during its blood 
meal (figure 1.2).1,3 The sporozoites enter hepatocytes and form a parasitophorous vacuole 
(PV) where they undergo development and maturate into liver schizonts each of which contains 
tens of thousands of the first generation merozoites.29,38 In the case of P. vivax and P. ovale 
infection, some exoerythrocytic schizonts undergo a dormant period known as the hypnozoite 
stage (which may result in relapses months or even years after the first infection).17,32 As 
infected hepatocytes rapture, free merozoites invade circulatory erythrocytes to begin the 
erythrocytic infection stage. At this stage, a schizont is formed which, upon maturation, bursts 
open to release even more merozoites that are infectious to new erythrocytes and the cycle 
continues until death of, or parasites get cleared from the host by chemotherapy.33 It is at this 
blood stage infection that malaria symptoms such as intermittent fever attacks, convulsions and 
vomiting among others, are manifested. These symptoms arise from the simultaneous rupture 
of the infected erythrocytes and the associated release of antigens and waste products into the 
blood.4 The mosquito phase of Plasmodium parasite life cycle commences with the 
intraerythrocytic differentiation of merozoites to male and female gametocytes.34 These sexual 
forms of the parasite are ingested by a healthy mosquito taking a blood meal. Once in the 
mosquito’s gut, gametocytes undergo exflagellation to form microgametes, which fuse and 
undergo fertilization to yield a zygote. The zygote then develops into an ookinete, which 
penetrates the midgut epithelial cells of the carrier mosquito and develops into an oocyst that 
further undergoes sporogony to produce sporozoites.35 The resulting sporozoites lodge in the 
vector’s salivary glands, which can be injected into the human host to continue the cycle. 
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Figure 1.2: Life cycle of the Plasmodium parasite.36 
1.1.4 Control, prevention and treatment of malaria 
A combination of malaria control strategies such as sleeping under insecticide-treated bed nets 
(ITNs), indoor residual spraying (IRS),10 use of repellents and the intermittent preventive 
therapy for pregnant women (IPTp) have significantly mitigated maternal illnesses and 
prevented infected vector contacts within the high-malaria-risk groups.1,17,38 In addition, filling 
or draining stagnant water pools (mosquito breeding sites), as a mean of vector control, has 
supplemented efforts toward preventing the spread of malaria.39,40 The awareness campaigns 
and provision of chemoprophylaxis to travellers to high-risk malaria infested areas ensure 
informed decision making on disease prevention and management in case of infection. In the 
case of infection, there is a need for the deployment of appropriate chemotherapies. 
In 2005, the WHO issued malaria treatment guidelines and recommended synergistic 
artemisinin combination therapies (ACTs) as first-line regimens for uncomplicated P. 
falciparum malaria.37,41 ACTs are formed by combining a rapid but short-acting artemisinin or 
a synthetic derivative with a slowly-eliminated but longer-acting partner drug. Such 
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combinations were envisaged to mitigate parasite resistance to the artemisinin component, 
facilitate dosing convenience and reduce treatment duration from 7 to 3 days. The artemisinin 
components of ACTs include artemisinin (1) itself and its synthetic derivatives; 
dihydroartemisinin (DHA) (2), artemether (3), arteether (4), artesunic acid (5) and artelinic 
acid (6) (figure 1.3). When administered to patients, the derivatives 3 – 6 are rapidly 
biotransformed to the active metabolite DHA (2). Apart from its ability to rapidly kill other 
blood stage forms of the parasite, DHA is also parasiticidal to the sexual forms of the parasite 
thereby blocking human-to-vector parasite transmission.38,42  
 
Figure 1.3: Chemical structures of artemisinin (1) and its derivatives- DHA (2), Artemether 
(3), Arteether (4), Artesunic acid (5) and Artelinic acid (6). 
The use of a combination of any one of the fast-acting artemisinins (figure 1.3) with a long-
acting schizonticide such as lumefantrine (figure 1.4) is known to minimise chances of 
recrudescence after clearance of initial parasitaemia and/or mitigate emergence of parasite 
resistance to partner drugs in ACTs.43 A typical example of such an ACT is coartem, a 
combination of artemether and lumefantrine (AL)44 which was developed by Novartis 
Pharmaceuticals in collaboration with Medicines for Malaria Venture (MMV) in 2009.45,46 A 
further formulation of coartem into the “child-size” and sweet-tasting therapeutic doses, among 
other malaria control measures, led to significant decline in the global malaria morbidity and 
mortality in the period 2010 - 2016;10,47 compared to the yesteryears. Other examples of ACTs 
include artesunate-amodiaquine, artesunate-mefloquine, DHA-piperaquine. For pregnant 
women, the pyrimethamine (8) and sulphadoxine (11) combination (SP) (figure 1.4) has been 
recommended.48  
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Figure 1.4: Chemical structures of partner drugs used in ACTs: Mefloquine (7), 
pyrimethamine (8), halofantrine (9), amodiaquine (10), sulfadoxine (11), piperaquine (12) and 
lumefantrine (13). 
The second line options for treatment of complicated P. falciparum malaria generally consists 
of either individual components of ACTs such as artemether (3), artesunate (5) etc which are 
administered as monotherapies or, quinine (14), atovaquone (15) and proguanil (16) that are 
administered in combination with an appropriate antibiotic partner drug, which mainly includes 
clindamycin (17), doxycycline (18) and tetracycline (19) shown in figure 1.5. Additionally, a 
combination of 15 and 16 has been established for therapeutic application as well as 
prophylaxis of malaria.49,50 Primaquine (20) remains the only antimalarial known to deliver a 
radical cure by targeting the liver stage hypnozoites of P. vivax and P. ovale. It also targets the 
sexual forms of the malaria parasites thereby blocking transmission into the mosquito 
vector.3,51–53 Regrettably, it is not recommended for pregnant women and individuals with 
glucose-6-phosphate dehydrogenase (G6PD) deficiency because it causes severe haemolysis 
in such patients. Thus the requirement that G6PD status of patients is known before initiation 
of primaquine therapy54 makes it an obvious limitation in malaria treatment in resource-limited 
African countries. Lastly, chloroquine (21), the oldest, once effective and cheapest antimalarial 
(figure 1.5) has experienced widespread resistance, and has been withdrawn from clinics and 
markets in areas of endemic P. falciparum malaria.55,56 
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Figure 1.5: Chemical structures of selected second line antimalarial drugs and the antibiotics– 
quinine (14), atovaquone (15) proguanil (16), clindamycin (17), doxycycline (18) and 
tetracycline (19), primaquine (20) and chloroquine (21). 
Malaria treatment is currently challenged with the spread of resistance to artemisinin-based 
antimalarial drugs in both Cambodia and Africa.57 The emerging resistance, especially in 
Cambodia and its bordering areas of Vietnam, Laos, Thailand and the Myanmar-Indian border, 
is threatening to reduce the efficacy of all ACTs.16,47,58,59 The issues of limited use of ACTs,41,60 
patient’s poor adherence to previously prescribed long doses (7 days)61 or under-dosing, low 
efficacy, poor safety (counterfeit drugs) and unaffordable cost of malaria treatment, have 
contributed to the emergence of resistance.62,63 Parasite resistance to artemisinins has been 
manifested in the phenomenon of delayed parasite clearance following exposure to the fast-
acting artemisinin component in ACTs.57,59,64 This incomplete parasite clearance is thought to 
increase the chances that some parasites will spontaneously develop genetic resistance to long-
acting ACT partner drugs as well. 
While estimates of disease burden have been reduced in between the years 2010 and 2014, the 
impact of resistance in areas of endemic malaria has resulted in an increase in both statistical 
malaria cases (figure 1.6) and deaths (figure 1.7) between the years 2013 and 2016.  
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Figure 1.6: Annual world malaria cases- 2010 – 2017 WHO reports.65 
The confirmed reports of spreading resistance and the resulting increase in malaria cases pose 
a significant threat to the strides made in the control and eradication of malaria so far as can be 
exemplified by the latest statistics in which 212 million malaria cases and 429 000 deaths 
reported in the year 2015, increased to 216 million cases and 445, 000 deaths in 2016.57 This 
translates into 4 million new malaria cases (figure 1.6) and about 16 000 additional malaria-
related deaths (Figure 1.7).  
 
Figure 1.7: Annual world malaria deaths- 2010 – 2017 WHO reports.65 
The devastating global morbidity and mortality record, with one child dying of malaria every 
two minutes, and drug resistance collectively provide justification for stepping up global efforts 
in antimalarial drug discovery and development research. Intensive efforts should be aimed at 
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developing new, safer, affordable and effective antimalarial drugs with alternative mechanisms 
of action so as to impede resistance,66 roll-back malaria, mitigate morbidity and mortalities 
while improving the economic livelihoods and wellbeing of the world’s poor majority. 
1.1.5 Current antimalarials in clinical development 
To combat the increasing malaria illnesses, deaths and parasite resistance to chemotherapy, 
research and development have been instituted globally to develop malaria vaccines and drugs, 
which are meant to backup current antimalarials. Currently, a total of fourteen (14) MMV-
supported antimalarial candidates, among others, have been developed and are in preclinical 
and clinical development. It is noteworthy that nine (9) of these drug candidates provide 
entirely novel mechanisms of action compared with partner drugs used in ACTs.67 In addition 
to these chemotherapeutic candidates, a vaccine candidate (RTS, S/AS01) has been developed 
and discovered to offer immunity against malaria. Its potential to prevent P. falciparum malaria 
infection has been assessed and proven in infants aged 6–12 weeks and children aged 5–17 
months in a phase (III) clinical trial. The clinical trial conducted between 2009 and 2014 proved 
the concept and revealed that RTS, S/AS01 exhibited at least 50% protection against malaria 
infections.68  
Among  the newer antimalarial candidates which have advanced into clinical development 
includes OZ439 (22),69 KAE609 (23),70 KAF156 (24),71 DSM265 (25),72 AQ-13 (26)73 and 
MMV390048 also known as MMV048 (27),74 whose structures have been summarised in 
figure 1.8 below. In addition to their unique modes of action, these antimalarial candidates have 
been studied and found potent with favourable properties such as multiple stage activity, 
parasite transmission blocking and chemo-protection.50 A newly discovered artefenomel-based 
antimalarial candidate OZ439 has been evaluated and found to be a fast-acting schizonticidal 
agent in addition to its activity at the symptomatic stage of P. falciparum malaria. Moreover, 
OZ439 has been assessed and found to have a good safety profile and is well-tolerated in 
healthy volunteers.69  
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Figure 1.8: Chemical structures of selected clinical and pre-clinical antimalarial candidates 
On the other hand, a spirotetrahydro-β-carboline (spiroindolone) based antimalarial candidate, 
KAE609 has been studied and shown to target the parasite plasma membrane Na-ATPase and 
inhibit plasma membrane Na+ efflux pump (PfATP4) leading to the ultimate disruption of the 
parasite’s sodium homeostasis.77 Most favourable properties of KAE609 include its activity 
against the asexual and sexual stages of parasite development and its ability to provide parasite 
to vector transmission blocking. Conversely, an imidazolopiperazine based antimalarial, 
KAF156 has shown potent antiplasmodium activity by inhibiting gametocytogenesis. Due to 
its multistage activity; at pre-erythrocytic liver stages as well as asexual and sexual blood stages 
of parasite development, KAF156 provides parasite-to-vector transmission blocking and 
chemoprotection which makes it a suitable chemotherapy for the malaria eradication 
agenda.70,71 Further in clinical development, is a novel antimalarial candidate DSM265 which 
provides a totally different mode of action. The compound targets the pyrimidine biosynthesis 
pathway where, has been shown to inhibit plasmodial dihydroorotate dehydrogenase (Pf 
DHODH).72 In addition, it has also been shown to be active against the asexual stage of P. 
falciparum development as well as provide chemoprotection. The 4-aminoquinoline-based 
antimalarial candidate AQ-13 (26) showed activity against both chloroquine susceptible and 
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resistant P. falciparum parasite strains with a good safety profile in human volunteers and thus 
has been progressed to the clinical development stage.73  Finally, amongst the antimalarial 
candidates in clinical development is MMV390048 (27). Except for hypnozoites, compound 
27 was found active against all Plasmodium parasite lifecycle stages thus, possessing both 
transmission blocking and chemo-protection properties.74,76 This novel aminopyridine-based 
antimalarial candidate was identified from a phenotypic whole cell high-throughput screening 
of commercially available SoftFocus kinase library followed by medicinal chemistry 
optimization.74 Moreover, compound 27 has been shown to exert its antimalarial activity by 
inhibiting Plasmodium falciparum phosphatidylinositol 4-kinase (PfPI4K) which also 
represents a novel mechanism of action in antimalarial drug research.25,75,76 However, 
compound 27 was found to have low solubility in biorelevant media resulting in variable 
pharmacokinetic profiles in healthy volunteers and prompting time-consuming formulation 
studies. As a result, further research at the University of Cape Town (UCT) led to the 
identification of a back-up candidate, UCT943 (28) (figure 1.8) which was developed with an 
improved solubility profile.78  
If successfully developed, compounds 27 and 28 would not only be part of the first new 
antimalarial drugs in many years to provide a completely new mode of action and treatment 
option but also, they will be the first-ever antimalarial drugs to be discovered by an African-
led international team. 
In addition to the above mentioned antimalarials candidates, other compounds which have 
entered the drug development portfolio with unique modes of actions include (+)-SJ733 (29),79 
P218 (30)80 and CDRI 9778 (31)81. These compounds have been assessed in animal models 
and healthy human volunteers and found to be well tolerated with good safety margins and oral 
bioavailability. As such, the dihydroisoquinolone-based antimalarial candidate, 29 has been 
identified with properties that are likely to effect radical cure and prophylaxis in a single 
exposure. Moreover, the drug candidate has been studied and observed to be well-tolerated and 
exhibited good oral bioavailability in multiple species.79 On the other hand, the dihydrofolate 
reductase (PfDHFR) inhibitor drug candidate, 30 has been identified with excellent ADME-
PK profile while exhibiting full activity against the pyrimethamine-resistant parasite strains.80 
The trioxane peroxide based antimalarial candidate 31 is among the inhibitors of plasmodial 
phospholipid metabolism and is highly efficacious against multidrug-resistant P. falciparum 
strains.81 In addition to the drug candidates discussed above, various drugs in the antimalarial 
development portfolio are summarised in figure 1.9 below:  
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Figure 1.9: Medicines for Malaria Venture antimalarial drug pipeline-2018.76,82 
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1.2 Schistosomiasis 
1.2.1 History, introduction and aetiology 
Schistosomiasis, commonly known as bilharzia, is caused by the bisexual blood flukes of the 
genus Schistosoma,83,84 which are transmitted by various species of gastropod molluscs 
(snails). Snails and schistosomes have a coevolutionary relationship spanning more than 200 
million years.85 The predominant pathogenic species of human schistosomiasis, however, were 
only discovered in the middle of the 18th century and include, in chronological order of 
detection, S. haematobium (1852), S. japonicum (1904), S. mansoni (1907), S. intercalatum 
(1934) and S. mekongi (1978).85–87 However, the three trematode species that are most 
prevalently associated with human infections include S. mansoni, S. haematobium and S. 
japonicum. The respective vectors include Biomphalaria, Bulinus and Oncomelania snails.84,88 
Schistosomiasis is an important, highly prevalent (figure 1.10) and infectious disease that is 
ranked second to malaria in causing long-term chronic human morbidity in many parts of the 
world.51  Since its discovery, schistosomiasis has adversely impacted human health and socio-
economic development. It has affected mainly both the growth and intellectual development of 
children, increased women exposure to HIV and other sexually transmitted infections (STIs) 
and compromised women’s reproductive health leading to infertility.90 Additionally, it has 
decreased the production and working capacity of adults leading to poor economies and poverty 
in areas of endemicity.88–90 Despite the severe and devastating effects of schistosomiasis on 
both human health and the economy, no new drug nor vaccine to date has been developed to 
treat or prevent the infections and transmission of the disease, besides Praziquantel (PQZ), the 
only chemotherapy of choice. 
 
Figure 1.10: World schistosomiasis distribution.91 
Schistosomiasis is mostly predominant in the tropical regions of the world with sub-Saharan 
Africa accounting for over 90% of the world’s disease burden (figure 1.10). 
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1.2.2 Epidemiology 
Approximately 779 million and about 207 million people are at risk of, and infected with 
schistosomiasis respectively, leading to about 280,000 annual deaths globally. In the year 2003, 
sub-Saharan Africa accounted for 90% of the total cases of the disease.92 However, reduction 
in the number of disease cases has been observed and reported in 2017 WHO report on 
schistosomiasis. According to this report, approximately 95.2 million people are at risk of 
infection while 90 million others are infected, leading to about 41,000 annual deaths globally 
in the year 2016. In the same report, the number of treated cases increased from ~66.5 to ~90 
million people in between the years 201593 and 2016,90 of which 70.9 million were school-aged 
children and 18.3 million people were adults.90 
1.2.3 Responsible parasite species and life cycle  
Schistosomes are parasitic, with a life cycle alternating between a snail and the vertebral host 
as shown in figure 1.11. The three most prevalent schistosome species associated with human 
infections (S. mansoni, S. haematobium and S. japonicum) share a common life cycle and 
development stages. Adult schistosome worms living in the blood venules of a human host lay 
about 300 eggs per day,94 some of which become trapped in the tissues while others are released 
through faeces or urine, depending on the schistosome species. Upon contact with freshwater, 
the eggs hatch into free-swimming miracidia, which seek and infect specific species of snails. 
The intramolluscan development takes about 4–6 weeks. Within the snail, the miracidia 
transform into mother sporocysts that undergo asexual replication to produce daughter 
sporocysts. Each daughter sporocyst undergoes further replication, ultimately yielding 
cercariae – a second free-swimming form of the parasite, which is infective to humans. 
Cercariae lose their tails during penetration of the host’s dermis and become schistosomulae. 
These migrate via the blood circulation to the portal veins of the liver where they differentiate 
and mature into adult worms. Adult male and female worms pair up, mate, and then migrate to 
the mesenteric venules of the bowel and rectum or the venous plexus of the bladder to complete 
the life cycle (figure 1.11). It takes about 6–8 weeks from cercariae penetration to the 
maturation of worms and laying of eggs.94–96 
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Figure 1.11: Life cycle of schistosome parasites.97 
1.2.4 Control, prevention and treatment 
Between 1930 and 1985, control of schistosomiasis was based on chemical molluscicides 
(niclosamide or copper sulphate) for snail control. In 2015, the WHO recommended mass drug 
administration (MDA) alongside various preventive measures, which include improved 
sanitation as has been demonstrated by using modern bio-composting toilets, which have 
effectively killed parasite eggs. Additionally, draining marshes and swamps is another 
recommended strategy for vector control and prevention of parasite transmission. Public 
education campaigns which highlight the risk of employing irrigation methods that involve 
long-standing still waters have been launched. Furthermore, awareness talks are given to 
visitors going to schistosome-infested areas about dangers of immersing in potentially 
contaminated waters. In addition to preventive and control measures, most schistosomiasis 
affected countries have adopted curative methods in mitigating schistosomiasis.98  
PQZ (32) (figure 1.12) has been the only readily available drug for treatment of schistosomiasis 
in about five decades and is characterised by broad spectrum activity against the prevalent three 
schistosome species while providing good therapeutic efficacy and safety.99 The drug has 
shown curative effects at the adult stage of the liver fluke. Antimonium tartaratum (33), the 
Chapter 1 
 16 2018 MSc Thesis: Kelly Chisanga 
antique drug used to treat S. haematobium infections dating back to 1918 was terminated and 
withdrawn from the market for safety reasons, that mainly involved the bioaccumulation of 
antimony in the body.100 In the 1960s and 1970s, furapromidum (34), metrifonate (35) and 
oxamniquine (36), which were active against S. japonicum, S. haematobium and S. mansoni, 
respectively, entered WHO’s model list of essential drugs until the late 1990s.44 Since then, 
these drugs (see figure 1.12) are no longer available commercially.101 
 
Figure 1.12: Chemical structures of selected antischistosomal drugs- PQZ (32), Antimonium 
tartaratum, (33) Furapromidum (34), Metrifonate (35) and Oxamniquine (36).101,102 
However, PQZ has exhibited a number of challenges that include its bitter taste,44 high 
production costs as the drug is produced as a racemic mixture of dextrorotatory [D(-)] and 
laevorotatory (L(-)] of which only the L(-) isomer has schistosomicidal activity.44,101–103 In 
addition, the drug has a limited activity to only adult schistosomes and has shown no activity 
towards young stages of the liver flukes,44,104 thus posing risks of relapse of the disease after 
treatment. Moreover, slow curing rates have recently been noted in some parts of West Africa, 
thus, posing a risk of the emergence of resistance.105  
1.2.5 Antischistosomal drug pipeline 
Schistosomiasis is one of the most neglected infectious tropical diseases to which, little to no 
attention has been paid in terms of research and development of new chemotherapeutic agents 
in about five decades. Several lead compounds including artemisinin (1) artemether (2), 
artesunate (3), mefloquine (7) (figures 1.3 – 1.4), the ozonides (1,2,4-trioxolanes; OZ288 (37) 
and OZ418 (38)),106 trioxaquine (the aminoquinoline linked 1,2,4-trioxane; PA-1259 (39)) and 
aryl hydantoins (Ro 11-3128 (40) and Ro 13-3978 (41))44,100(figure 1.13), have been shown to 
possess antischistosomal properties. Although most of these lead compounds were pursued as 
antimalarials, they were discovered to have good activity at various stages of the schistosomal 
liver flukes.44 Nevertheless, none are currently being actively pursued for further 
antischistosomal drug development due to lack of funds, prospects of poor investment return 
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from the product and the widespread belief that PQZ is a sufficient curative control for 
schistosomiasis.107  
 
Figure 1.13: Structures of antischistosomal lead compounds 
There is a need to speed up research and development activities to develop new more affordable 
and effective antischistosomals to serve as alternatives to PZQ, and which would potentially 
prevent devastating effects of total resistance to the only available treatment option. 
1.3 Approaches to antimalarial and antischistosomal drug discovery 
The duration, high labour intensity and the huge cost associated with the development of a drug 
from scratch is an enormous challenge. Cutting down on such costs requires the strategic 
adoption of some drug candidates which might have gone through various developmental 
stages hence, whose pharmacokinetic parameters, formulation and safety or potential toxicity 
profiles are documented.108,109 Two cost reduction drug discovery approaches namely, drug 
repurposing and drug repositioning become useful choices. Drug repurposing involves 
discovering a new therapeutic application of an existing drug that has been approved by the 
regulatory body for use in a specified medical indication. Upon identification of the therapeutic 
effect on a totally different medical condition, the next step in development may only involve 
optimising the dosing regimen for the new application. On the other hand, drug repositioning 
involves the use of a dispensary or candidate drug as the scaffold for the development of other 
drug derivatives that possess a therapeutic effect for a totally different medical indication. Drug 
repurposing and repositioning approaches have been, in the past, effectively exploited in 
antimalarial, antischistosomal and antitubercular drug discovery and development.110 For 
instance, sulfa-based drugs for malaria, and fluoroquinolones for tuberculosis (TB) were 
initially developed for the treatment of non-malaria and non-TB diseases. In principle, a clear 
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identification of the drug’s target enzyme and understanding of the mode of action of the drug 
may allow for treatment of two or more different parasites using one drug.  
This dissertation research will take advantage of the findings that Schistosoma spp., have the 
same blood-feeding characteristics as Plasmodium parasites and coherently share the same 
haem degradation mechanisms.111–114 In this mechanism, the parasite digests host haemoglobin 
as a major source of amino acids they need to supplement nutritional requirements and 
complete their sexual development. Toxic free-heme (ferriprotoporphyrin IX) is released in the 
process, which can produce oxygen radicals or damage cell membranes and parasite proteins. 
To avoid the toxic effects, Schistosoma and Plasmodium parasites bio-crystallise heme 
molecules into inert and insoluble hemozoin.111–114 
The postulate that the antimalarial drug candidates could positively effect a similar 
pharmacological response toward both the blood-digesting liver flukes and Plasmodium spp. 
is deemed logical, since their mechanism of action shares a common pathway.44 Recently, 
clinically useful antimalarial drugs and drug candidates have been discovered and found with 
antischistosomal properties upon tests in rodents.44 Such drugs include mefloquine,115 
artemisinin and its semi-synthetic derivatives such as artemether and artesunate.44,84,116,117 
Additionally, the ozonide class of compounds (1,2,4-trioxolanes: OZ288 (37) and OZ418 
(38)),106,118 and trioxaquines (PA-1259 (39)),119,120 (figure 1.13), are some of the other 
antimalarial drug candidates discovered to possess antischistosomal properties as well. These 
antischistosomal lead compounds were developed in antimalarial research programs and were 
at various stages of drug development.44   
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1.4 Solubility in drug design and development: importance and strategies for 
improvement 
In the context of medicinal chemistry, solubility can be defined as the property of a drug 
molecule to dissolve in an aqueous solvent to form a homogeneous solution at a specified 
temperature and pH.121 Solubility is a significant physicochemical property in drug discovery 
that impacts a drug’s pharmacokinetics and how it is used in the clinic.121,122 With the exception 
of the first-pass metabolism in the liver, oral bioavailability is highly dependent on intestinal 
absorption, which is a function of the compound’s solubility and permeability.123 Thus, an 
orally ingested drug with optimal solubility and dissolution rate is most likely absorbed, and 
permeated which brings about a desired pharmacological response. Conversely, a sub-
optimally soluble drug is frequently associated with formulation challenges, limited and 
variable absorption, poor permeation and bioavailability (in oral administration), and is likely 
to precipitate if administered intravenously leading to poor tissue distribution and 
metabolism.124 Such a drug may further present inconsistencies in clinical response due to the 
drug’s suboptimal pharmacological effect and is likely to result in adverse and side effects.125  
1.5 Strategies to improve solubility 
Various techniques to enhance the solubility of poorly soluble drug candidates are principally 
based on physical126 and chemical modifications.127  The choice of the solubility-improving 
method to apply depends on the drug property, site of absorption and required dosage form 
characteristics.121 Although a drug’s solubility can be improved upon by physical means and 
formulation efforts, these approaches have limitations and are expensive. Therefore, it is 
important that the drug’s sub-optimal solubility is addressed early in the discovery phases using 
chemical modification approaches.121,128  These methods are discussed in greater detail in the 
following section. 
1.5.1 Chemical methods 
Although arduous, chemical structure modification is a key factor in influencing intrinsic 
solubility properties of a drug candidate.129 Substituent groups bonded to the drug scaffold 
determine overall lipophilicity, size and ionisability of the final drug molecule. Approaches 
that are frequently employed by synthetic medicinal chemists in improving aqueous solubility 
mainly involve modifying the drug core by incorporating hydrogen-bond donors and acceptors, 
introducing polar-ionisable or neutral polar groups, salt formation,  saturation (increasing sp3 
character) and disruption of planarity. 127,129–131 
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1.5.1.1 Introducing hydrogen-bonding groups  
The hydrogen-bond donors and acceptors such as amino, carbonyl and hydroxyl substituents 
play a significant role in enhancing aqueous solubility due to their strong hydrophilic aqueous 
interactions.78,130 In this regard, and as an example, Le Manach et al., have reported improved 
aqueous solubility by incorporating a water solubilizing hydrogen bonding group to afford a 
potential clinical candidate UCT943 (figure 1.14A).78 Molecules containing such functional 
groups can donate and accept hydrogen bonds, are basic in nature, and thus, have influence on 
the pKa of a compound and can exist in ionized forms at a suitable pH. These substituents are 
thus important and useful groups that have found widespread application in improving aqueous 
solubility and frequently given primary consideration in the medicinal chemistry optimization 
programs.78,129–132 Scheme 1.14A – 1.14D in figure 1.14 summarizes this and other solubility 
enhancing approaches discussed in this subsection. 
1.5.1.2 Polar ionisable and neutral-polar groups  
The amino, amide and carboxylic acid functional groups have strong solubilizing potential due 
to their polar functionality. Improving solubility through the incorporation of such molecular 
features has found application in different therapeutic areas including antimalarial drug 
discovery. For instance, artemisinin derivatives containing a carboxylic acid and its 
corresponding salts (figure 1.14B) are more water soluble than the parent artemisinin.133 
Furthermore, the presence of acidic and basic functionalities in the candidate drug provides 
opportunities for further manipulations such as formulations that may result from the salt 
formation,134  (figure 1.14B) leading to significant improvement of the drug’s solubility. Many 
other drug discovery programmes have employed this strategy.108–110  
1.5.1.3 Reducing aromaticity by introducing saturation  
Increasing saturation by reducing the aromatic character of the analogue is a modification that 
has also been used in improving the oral aqueous solubility of various drug molecules as has 
been exemplified in figure 1.14C.131 This approach involves increasing the fraction of sp3- 
hybridized (Fsp3) carbons which in turn, leads to the reduced structural planarity and less 
crystal-stacking capability of the drug analogue. Ultimately, the melting point of the saturated 
final analogue is reduced, thus, leading to improved drug solubility.131  
1.5.1.4 Disrupting molecular planarity 
Approaches to improve drug solubility may also focus on disrupting planarity of the drug 
molecule by incorporating substituents which may twist the scaffold out of the plane as has 
been exemplified in figure 1.14D. In this approach, introducing either chirality on suitable 
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positions of the scaffold or an electron-rich mono or polyatomic group on ortho positions of a 
bi-aryl system, includes some of the frequently used approaches to disrupt planarity. The 
resulting increased dihedral angle makes the drug molecules unsuitable for π-stacking and 
crystal packing thus, leading to low melting point and improved solubility.127,128,132  
1.5.1.5 Pro-drug approach 
A pro-drug may be defined as a poorly active or inactive compound,  which upon undergoing 
an in vivo biotransformation, either through chemical or enzymatic cleavage, releases the active 
molecule at efficacious levels at the active site.135 Pro-moieties such as acyl, carbamate, ether, 
phosphate, ester, among others, are some commonly used bio-reversible derivatives associated 
with enzymatic hydrolysis to release the active parent drug in vivo (figure 1.14E).136 These 
groups are associated with ideal water solubilizing potential, good absorptivity and permeation 
properties to bring about improved overall drug efficacy. 
In general, pro-drugs have achieved superior physicochemical properties compared to parent 
drugs. Thus, based on prodrug approach, Zimmermann et al., have successfully improved the 
solubility and bioavailability of a broad spectrum anthelmintic and anticancer drug 
(mebendazole) by  > 10, 000 and 2-fold, respectively.136 
1.5.1.6 Reducing lipophilicity  
Phenyl-polycyclic aromatic analogues are lipophilic and tend to form hydrophobic crystals 
because of intermolecular π-π interactions.127,128,132 By so doing, molecules tend to form 
crystals, which have reduced surface area for aqueous interactions and thus, making drug 
molecules hydrophobic. Approaches such as substituting the lipophilic phenyl rings with 
pyridyl or pyrimidinyl rings have been studied and observed to reduce lipophilicity leading to 
improved solubility.128 
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Figure 1.14: Selected approaches used to improve aqueous solubility 
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1.6 Drug metabolism and pharmacokinetics 
In drug discovery, lead optimisation, evaluation of drug pharmacology and safety, clinical 
testing and development, and the final positioning of the drug product into the market are all 
significantly dependent upon the pharmacokinetics and drug metabolism profile. Medicinal 
chemists are usually tasked to identify the target enzyme or receptor and use experimental 
structure-activity relationships to increase the in vitro activity. However, in vitro activity alone 
does not guarantee good in vivo activity unless the drug is associated with good absorption, 
permeation, bioavailability and a desirable action duration or half-life.137  
The drug’s pharmacokinetic and metabolism profiles are the key determinants of 
bioavailability and the resulting in vivo therapeutic effect. A parent drug may, upon 
administration, be metabolised to either an active metabolite (metabolite that is able to exert 
the desirable therapeutic effect) or a reactive metabolite (a metabolite that is able to exert a 
toxic effect on biomolecules of the body such as glutathione thus, leading to metabolism-
induced cytotoxicity). Such drug metabolism profiles should also be explored for regulatory 
purposes.138 The kinetics of active metabolite formation, the basic mechanisms of the events 
involved in absorption, distribution, metabolism and excretion (ADME); the interaction of 
chemicals with the drug-metabolising enzymes, particularly cytochrome P450 (CYP) should 
as well be understood to facilitate prediction of the therapeutic outcome and provide ability to 
explain a drug’s toxicity.137 
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1.7 Pyridobenzimidazoles: introduction and pharmacological properties 
Pyridobenzimidazoles (PBIs) are fused ring heterocyclic aromatic compounds which have 
recently attracted attention in antimalarial, antischistosomal and antimycobacterial drug 
discovery.63,111,139,140 The PBI pharmacophore comprises a tricyclic fused ring system that 
constitutes a benzene, the central imidazole and a pyridyl ring (figure 1.15). 
 
Figure 1.15: Pharmacophore of PBI 
The PBI pharmacophore is synthetically diverse, chemically stable, and possesses vast 
biological and medicinal properties.  These properties include inhibition of the synthesis of b-
1,6-glucan, a cell wall component in fungus, anti-cancer, antiviral, analgesic, antibacterial, 
antitumor and antitubercular properties.139,141–143 Selected compounds amongst numerous other 
chemotherapeutic agents are as shown in figure 1.16:  
 
Figure 1.16: Bioactive PBIs- antibacterial (42), anticancer (43) antiviral (44) and 
antituberculosis (45). 
The PBI scaffold is found in many pharmacologically relevant molecules including Rifaximin, 
an approved drug.143 The PBI pharmacophore is, therefore, regarded as a privileged scaffold.140 
The scaffold has been used as a building block with many sites of modification to yield drug-
like compounds. Consequently, medicinal chemistry explorations around the PBI nucleus have 
recently identified PBI analogues as novel antimalarial and antischistosomal agents.63,111,140 
1.7.1 Antimalarial and antischistosomal properties of PBIs  
The PBI core was recently shown to be a novel antimalarial chemotype.63,140 The discovery of 
antimalarial properties of the PBI core stemmed from a medium-throughput screening (MTS) 
of 1440 commercially available compounds against the multidrug-resistant strain of P. 
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falciparum (K1).63 Consequently, the hit compound TDR15087 (46) (figure 1.17), was 
identified with moderate in vitro activity (IC50 = 170 - 370 nM) against P. falciparum GHA 
and W2 strains. Furthermore, 535 additional compounds were screened against the multidrug-
resistant P. falciparum K1 strain but this time, with a view to exploring the effect of structure 
diversity around the PBI core. This led to the identification of the N-benzylpiperazinyl 
derivatives TDR35885 (47) and TDR44047 (48) (figure 1.17), which, in addition to greater in 
vitro antiplasmodium activity, were found to have better selectivity over the mammalian L-6 
cell line.63 Particularly, the activities against P. falciparum of these hit compounds which were 
uncovered in the second phase of PBI medium throughput screening showed an IC50 = 52 nM 
for the chloroquine sensitive (NF54) strain and IC50 = 50 - 78 nM against the resistance (K1) 
strain for TDR35885 (47), whereas, IC50 = 53 nM for NF54 strain and 23 - 95 nM for the K1 
strain was found for TDR44047 (48). 
 
Figure 1.17: The PBI hit compounds identified from MTS. 
However, all the 3 hit compounds (46 – 48) proved to be inactive in the standard in vivo P. 
berghei mouse model at doses of up to 4 x 100 mg/kg (ip), most likely because of a combination 
of poor solubility and metabolic stability.63,140 Since there was no prior art with respect to the 
antimalarial activity of PBIs, compounds 46 – 48 inspired further medicinal chemistry 
explorations toward the design and synthesis of structural analogues, which were aimed at 
realising compounds with improved pharmacokinetic properties as well as enhanced 
pharmacological profiles. Consequently, the synthesis, structure-activity and structure-
property relationship (SAR/SPR) studies of the 3-aryl derivatives with alkylamino side chains 
(at R1, figure 1.15) were undertaken. As a result, compound 49 (figure 1.17) with improved in 
vitro activity (IC50 = 47 nM) and about 3.5-fold more active than chloroquine (IC50 = 170 - 200 
nM) on the drug-resistant K1 strain of P. falciparum was identified. Compound 49 was also 
found to be metabolised in vitro into an active metabolite, compound 50 (figure 1.18).  Despite 
its reduced selectivity over L-6 mammalian cell line, compound 50 exhibited moderate activity, 
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about 10-fold higher metabolic stability and a relatively improved half-life compared to the 
parent compound 49.63 Thus, further medicinal chemistry exploration around compound 50 
identified compound 51 (figure 1.18) with a combination of good in vitro antiplasmodium 
activity against the chloroquine-sensitive (CQ-S) and the resistant strains of P. falciparum. 
Moreover, compound 51 demonstrated an improved in vivo antimalarial efficacy when tested 
using the standard P. berghei-infected mouse model (figure 1.18).63,140 Regrettably, like the 
others, this compound was associated with poor solubility.111,140  
 
Figure 1.18: Antimalarial PBIs- Ndakala 2011 (50) and Singh 2017 (51) and GMP19-
unpublished (52). 
Amongst other front-runner compounds researched on and found to have a solubility liability 
albeit good antimalarial and interestingly, antischistosomal activity is GMP-19 (52) (figure 
1.18) which was derived in the year 2015 (unpublished). 
Toward addressing sub-optimal solubility, while retaining or improving antiparasitic activity, 
this research endeavoured to synthesise and undertake SAR/ SPR exploration using the 
frontrunner compound, GMP-19 as a template, having demonstrated good in vitro activity on 
schistosomes and Plasmodium parasites.  
The strategies used in optimising solubility, involved the introduction of water-solubilising 
amines, amides and saturation, while the SAR/SPR expansion campaign involved the 
incorporation of chirality, germinal and -methylbenzylamine substituents on the PBI core of 
GMP-19.  Details of these strategies are outlined in subsequent chapters. 
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1.8 Aims and objectives 
1.8.1 Objective 
The main objective of this research was to enhance the solubility of antimalarial and 
antischistosomal pyrido[1,2-a]benzimidazole-based frontrunner compound GMP-19. 
1.8.2 Hypothesis 
Pyrido[1,2-a]benzimidazole-based compounds are potential novel antimalarial and 
antischistosomal drug leads with favorable potency, pharmacokinetics and physicochemical 
properties. 
1.8.3 Specific Aims 
i. To synthesise and characterise the antimalarial and antischistosomal Pyrido[1,2-
a]benzimidazoles designed to improve solubility. 
ii.  To profile the synthesised compounds with respect to antiplasmodium and 
antischistosomal activities and solubility. 
iii. To derive the antiplasmodium and antischistosomal as well as solubility profiles. 
iv. To investigate the factors (e.g., melting point, cLogP, and retention time on 
Reverse-Phase HPLC) affecting solubility and deduce relationships. 
v. To submit the selected frontrunner compounds with potent antiplasmodium and/or 
antischistosomal activities with good solubility for in vitro microsomal metabolic 
stability, and cytotoxicity profiling. 
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2. SYNTHESIS AND CHARACTERIZATION OF TARGET COMPOUNDS 
2.1 Introduction 
Here, the design, synthesis, and spectroscopic and physical characterization of the synthesized 
PBI analogues are discussed. The expansion and exploration of structure-activity relationship 
(SAR) and structure-property relationship (SPR) studies on this series of compounds involved 
carrying out chemical modifications around the PBI core scaffold. Substituent groups with 
molecular features likely to improve solubility as well as drug metabolism and pharmacokinetic 
(DMPK) properties of the target analogues were incorporated.  
In the preliminary stage, the design of SAR/SPR studies involved incorporating α-
methylbenzylamine moieties into the PBI motif. The incorporation of these features was 
postulated to disrupt molecular planarity, introduce saturation, and enhance hydrogen bonding 
properties. Recently, Cui et al. reported an anticancer medicinal chemistry optimization 
campaign in which an α-methylbenzyl substituent (2,6-dichloro-3-fluoro-α-methyl-benzyl) 
was incorporated into a lead anticancer drug scaffold to deliver the anticancer drug crizotinib.1 
Furthermore, Tanaji incorporated a gem-dimethyl group to obtain clinically relevant drugs.2 
This report highlighted the importance of protruding lipophilic methyl groups in improving 
target binding efficiency, and thus increasing bioactivity. Additionally, phenyl ring substituents 
were selected in such a way as to incorporate representative Craig plot groups from each of the 
four quadrants depicted in figure 2.1. In this regard, a plot of Hammett constants (σ) which 
represents the electronic effect of various atoms or groups of atoms relative to hydrogen against 
hydrophobicity (π) values3,4 played a significant role in guiding the selection of various 
substituents. The selected Craig plot groups and their corresponding quadrants include F, Cl, 
and OCF3 (1
st), CH3SO2 (2
nd), OCH3 and OH (3
rd), and Me (4th). These groups were fixed at 
the para-position of the substituent benzylamine ring, and a few were added to the ortho-
position for control purposes.  
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Figure 2.1: Craig plot substituents incorporated in structure-activity and -property relationship 
studies around novel antimalarial and antischistosomal pyrido[1,2-a]benzimidazole analogues3 
With the next phase of SAR/SPR studies, factors that would affect the solubility of PBI 
compounds will be evaluated. Established organic synthetic methods were used to synthesize 
the target compounds.  
The asexual blood stage antiplasmodium activities of all analogues synthesized were evaluated 
against both the chloroquine-sensitive P. falciparum NF54 and the multi-drug-resistant K1 
strains. The in vitro gametocytocidal activity of the compounds was also determined using the 
P. falciparum NF54 strain. Furthermore, compounds were subjected to in vitro 
antischistosomal activity evaluation against both NTS and adult Schistosoma mansoni liver 
flukes. Finally, the apparent solubility of the analogues was evaluated using turbidimetric and 
HPLC-based kinetic solubility assays. 
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2.2 Design  
2.2.1 α-Methylbenzylamine-substituted PBI analogues in SAR 1.1 to 1.4 
In the design of SAR 1 target analogues, it was postulated that making structural modifications 
at position C-1 of the pyridinyl ring, and at positions, C-8 and -9 of the phenyl ring of the PBI 
motif would be essential in exploring and expanding the SAR/SPR studies on this series of 
compounds. Consequently, although compounds synthesized in SAR 1.1 to 1.4 and SAR 2.1 
to 2.5 studies were diversified, the PBI motif was maintained (figure 2.2). 
 
Figure 2.2: Design of PBI analogues in structure-activity relationship (SAR) studies 1.1 to 
1.4 
In order to introduce structural diversity and explore different chemical spaces, the 4-
(trifluoromethoxy)aniline moiety of GMP-19 was replaced with assorted α-
methylbenzylamine substituents at C-1 of the PBI core (SAR 1.1). Consequently, analogues 
showing high biological activity were further modified by incorporating electron-withdrawing 
mono-atomic substituent groups such as chloro and fluoro atoms, respectively (SAR 1.2 and 
1.4). These substitutions were made at positions C-7 and/or C-8 of the core scaffold, while the 
α-methylbenzylamine substituents that retained high biological activity were maintained at C-
1. These modifications were, in addition to SAR expansion, envisaged to improve metabolic 
stability and/or solubility. 
 X= Craig Plot substituent 
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2.2.2 α-Methylbenzylamine-substituted PBI analogues in SAR 2.1 to 2.5 
The design of SAR 2 analogues incorporating molecular features known to improve compound 
solubility. In this regard, polar hydrogen-bonding and water-solubilizing groups were 
incorporated into the phenyl (SAR 2.1 and 2.2) and pyridinyl rings at C-1 (SAR 2.3, figure 
2.3). Thus, amides (SAR 2.1) and amino moieties, such as morpholinyl and piperazinyl groups 
(SAR 2.2), were introduced into the left-hand side (LHS) of the core scaffold. 
 
Figure 2.3: Design of PBI analogues in structure-activity relationship (SAR) studies 2.1 to 
2.5  
Initially, the 4-(trifluoromethoxy)aniline (4-OCF3Ph) moiety of GMP-19 was maintained 
while making structural changes to the phenyl ring. Once the R portion of the core scaffold was 
optimized to a degree with respect to solubility and biological activity, the optimal group was 
fixed at this position. In this regard, the morpholino group was identified as showing the best 
balance of aqueous solubility and biological activity. Consequently, the 4-OCF3Ph moiety was 
replaced with basic side chains (SAR 2.3). Upon optimization of the right-hand side (RHS) 
with respect to solubility and biological activity, the next phase of SAR focused on replacing 
the trifluoromethyl (CF3) moiety of the GMP-19 template with a 4-trifluoromethylphenyl (4-
CF3Ph) group at C-3 on the RHS. Although replacing CF3 with a 4-CF3Ph group resulted in 
increased lipophilicity, the overall design strategy was to combine the highly improved 
solubility of SAR 2.4  analogues with an improved antiplasmodium activity that is associated 
with the 4-PhCF3 moiety.
5 
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2.3 Synthesis of SAR 1 and 2 compounds 
Although numerous synthetic studies have reported diverse protocols for the synthesis of the 
same heterocyclic PBI core, the synthesis technique used in this study was based on the work 
of Rida et al.6 and Ndakala et al.5 Furthermore, the work of Paul et al.7 formed the basis and 
reference for the synthesis of target analogues that required carbon-to-amine coupling (C-N 
bond formation). In this regard, the Buchwald-Hartwig palladium (0)-catalyzed amination 
protocol was used. A 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)-mediated 
coupling protocol8–10 was used to synthesize the target amides.  
Target compounds for the initial phase of the SAR study were synthesized using the synthetic 
protocol outlined below in figure 2.4. Condensation of a commercially available and 
appropriately substituted benzene-1,2-diamine with an ethyl 2-cyanoacetate under reflux 
conditions produced a bicyclic-benzimidazole acetonitrile intermediate, which underwent 
further condensation to yield a suitably substituted oxo-/hydroxyl-functionalized tricyclic PBI 
intermediate that was subsequently converted into a chlorinated intermediate. Microwave-
assisted regio-selective amination was performed to produce target molecules for the SAR 1.1 
to 1.4 study. Among the intermediate analogues at this stage, those with suitable functionalities 
were subjected to further reactions, such as base-catalyzed hydrolysis of the ester group to 
deliver intermediate acids for subsequent amide coupling. Moreover, the analogues that 
possessed suitable halogens on the phenyl ring of the core scaffold underwent Buchwald-
Hartwig palladium-catalyzed amination reactions to produce SAR 2.1 to 2.5 compounds. SAR 
1.1 to 1.4 and SAR 2.1 to 2.5 target compounds were obtained via the 4 and 6-step synthetic 
procedures outlined in figure 2.4 and 2.7, respectively. The isolated yields are tallied in figures 
2.5, 2.6, and 2.8.
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Figure 2.4: Synthesis of compounds in structure-activity relationship (SAR) studies 1.1 to 1.4 
Reagents and conditions: (a) Ethyl cyanoacetate, dimethylformamide (DMF), 160 °C, 3 h; (b) ethyl 4,4,4-trifluoro-3-oxobutanoate, NH4OAc, 145 
°C, 2 h; (c) POCl3, 130 °C, 3 h; (d) amine, triethylamine (TEA), tetrahydrofuran (THF), 80 °C, microwave (150 W), 20 min; (e) i. 2.0 M KOH, 
MeOH, 25 °C, 10 min.; ii. 2.0 M HCl; (f) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 4-dimethylaminopyridine, methylene dichloride 
(DCM), 0-25 °C, 2 h; (g) CBr4, PPh3, DMF, 25 °C, 10 min.; (h) K2CO3, DMF, 75 °C, 2 h. 
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Figure 2.5: Yield for compounds synthesized in structure-relationship (SAR) studies 1.1 (compounds 1-11), 1.2 (12-14), and 1.3 (15) 
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Figure 2.6: Yield for compounds synthesized in structure-relationship (SAR) study 1.4 (compounds 16-34) 
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Figure 2.7: Synthesis of compounds in structure-activity relationship (SAR) studies 2.1 to 2.5 
Reagents and conditions: (a) Ethyl cyanoacetate, DMF, 160 °C, 3 h; (b) NH4OAc, 145 °C, 2 h; (c) POCl3, 130 °C, 3 h; (d) TEA, THF, 80 °C, 
microwave (150 W), 20 min; (e) NH4Cl, Fe, MeOH:H2O (1:1), 65 °C, 45 min; (f) DCM, EDCI, DMAP, 0 °-25 °C, 6-12 h; (g) amine, Pd2(dba)3, 
RuPhos, Cs2CO3, 1,4-dioxane/ DMF (1:1), 80 to 110 °C; (h) 2.0 M HCl, 25 °C, 1 h
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Figure 2.8: Yield for compounds synthesized in structure-relationship (SAR) studies 2.1 (compounds 35-41), 2.2 (42-45), 2.3 (46-47), 2.4 (48-
49), and 2.4 (50-55) 
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2.4 Mechanistic details and spectroscopic analyses of SAR 1 intermediate and target 
compounds  
Details of selected key reaction steps leading to the formation of critical intermediates and 
selected final analogues and the proton nuclear magnetic resonance (1H NMR) spectroscopy 
analyses of representative compounds are described here. The unsubstituted benzimidazole 
acetonitrile intermediate 1.1a (figure 2.4) was commercially available and used as purchased, 
and the symmetrically and asymmetrically substituted benzimidazole acetonitrile intermediates 
1.2a, 1.4a, 2.1.1a, 2.1.2a and 2.2a (figures 2.4 and 2.7) were obtained from commercially 
available and appropriately halogenated and nitro-substituted benzene-1,2-diamine precursors. 
These precursors include the 4-chloro (1.2), 4,5-dichloro (1.3), 4,5-difluoro (1.4), 3-chloro 
(2.2), and 3-nitro (2.1) benzene-1,2-diamine moieties (figures 2.4 and 2.7). The formation of 
various benzimidazole acetonitrile intermediates used in this study is exemplified by the 
formation of the symmetrically substituted 2-(5,6-difluoro-1H-benzo[d]imidazol-2-
yl)acetonitrile (compound 1.4a, figure 2.9). The consecutive steps involved in the condensation 
reaction required for the formation of 1.4a include the nucleophilic addition of the amino group 
in compound 1.4 to the carbonyl carbon of ethyl cyanoacetate (figure 2.9).  
 
Figure 2.9: Mechanism of formation of 2-(1H-benzo[d]imidazol-2-yl)acetonitrile (1.4a) 
Next, ethoxide ion-mediated deprotonation of the intermediate 1.4.1 occurs. An intramolecular 
nucleophilic addition takes place, leading to a ring closure and a subsequent proton transfer to 
form 1.4.3. A dehydration reaction leads to the formation of 2-(cyanomethyl)-1H-
benzo[d]imidazol-3-ium ion, intermediate 1.4.4. Charge stabilization of 1.4.4 then occurs by 
means of a hydroxide mediated proton abstraction that leads to the formation of the desired 
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product, 1.4a. The mono-, di-chlorinated, and 7-nitro benzimidazole acetonitrile intermediates 
(1.2a, 1.3a, 2.1a, and 2.2a) were synthesized following the steps outlined in figure 2.9. 
The structure of 1.4a was confirmed via 1D 1H NMR spectroscopy, and the following signals 
were identified: highly deshielded NH proton (H4) peak at δ = 12.8 ppm, two electronically 
equivalent aromatic proton signals at δ = 7.6 ppm (H2 and H3), and a sharp singlet peak at δ = 
4.4 ppm, corresponding to the two relatively shielded methylene protons (H1). Although the F-
H-coupling was not evident at this stage, the 19F-NMR showed the presence of the two fluorine 
atoms and the 1H NMR spectrum obtained (figure 2.10) was consistent with the structure of 
compound 1.4a.  
 
Figure 2.10: 1D 1H nuclear magnetic resonance spectroscopy spectrum of 1.4a showing the 
NH (H4) and the methylene (H1) proton singlet peaks at δ = 12.8 ppm and δ = 4.4 ppm, 
respectively in DMSO-d6 at 300 MHz 
The intermediate 1.4a was progressed further to a condensation reaction. The ammonium 
acetate ion then deprotonates one of the partially acidic methylene protons of 1.4a and forms a 
resonance-stabilized methanide ion. The nucleophilic addition of the methanide ion onto a 
more electrophilic carbonyl (keto) carbon of the beta-ketoester occurs next. Consequently, the 
hydroxyl group is converted into a suitable leaving group by protonation. The dehydration that 
occurs via an E2 elimination mechanism leads to the formation of the C-C π-bond (figure 2.11). 
Furthermore, the protonation of the carbonyl oxygen of the ester group increases the 
electrophilicity of the carbonyl carbon and thus facilitates an intramolecular nucleophilic 
addition, which is followed by elimination and aromatization steps to form the oxo/hydroxyl 
intermediate 1.4b. The spectroscopic results in figure 2.12 indicate an increase in the number 
of the aromatic signals and confirm the formation of the compound. 
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Figure 2.11: Mechanism of formation of intermediate 1.4b 
 
 
Figure 2.12: 1D 1H nuclear magnetic resonance spectrum of 1.4b showing aromatic signals in 
DMSO-d6 at 300 MHz 
A singlet peak that integrates for one proton (1H) is evident at δ = 6.4 ppm, and this corresponds 
to the newly introduced proton H1. Additionally, a separation of signals and a change in the 
splitting pattern of H2 and H3 in 1.4b were observed. The presence of the OH on the RHS 
affected the electronic environment between the two protons, thus leading to the observed peak 
separation, which was not previously observed on the 1D 1H NMR spectrum of 1.4a. Moreover, 
the observed doublet of doublets (dd) splitting pattern is attributed to the presence of fluorine 
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atoms, which influence the electronic environment of the protons via fluorine-to-proton spin-
spin coupling. The β-fluorine splits a proton into a doublet whereupon the magnetic influence 
of the γ-fluorine nucleus through long-range coupling leads to further splitting. Therefore, the 
two fluorine atoms present between the two protons on the LHS of compound 1.4b caused H2 
and H3 to split into the observed pattern. 
Chlorination of 1.4b led to the formation of the common amination intermediate 1.4c, which 
displayed downfield migration of the singlet peak from δ = 6.4 in 1.4b to δ = 7.7 ppm in 1.4c 
(figure 2.13). The shift is attributed to the stronger deshielding effect of the chloro atom on H1 
compared to that of the hydroxyl group.  
 
Figure 2.13: 1D 1H nuclear magnetic resonance spectrum of 1.4c showing aromatic signals in 
DMSO-d6 at 600 MHz 
The amination of 1.4c involved nucleophilic aromatic substitution involving an amino group 
of the -methylbenzylamine (or any appropriate amine) (figure 2.14). 
 
Figure 2.14: Mechanism of the aromatic nucleophilic addition (SNAr) of amines 
The successful formation of compound 18 was confirmed via 1D 1H NMR spectroscopy (figure 
2.15). The spectrum signals are consistent with the structure of the compound. 
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Figure 2.15: 1D 1H nuclear magnetic resonance spectrum of compound 18 showing the newly 
introduced protons corresponding to the amino, methyl, methylene, and additional aromatic 
groups in DMSO-d6 at 300 MHz 
Two symmetrical signals typical of a para-substituted phenyl ring were identified in the 
aromatic region.11  The clear separation of the symmetrical doublet peaks arising from 1H8 (δ 
= 7.6 ppm, J = 8.5 Hz) and 1H7 (δ = 7.4 ppm, J = 8.5 Hz) is attributed to the presence of a 
deshielding chloro atom at the para-position of the benzyl ring. In addition, the methine proton 
(1H6: δ = 5.2 ppm) at the -position, which appeared as a slightly deshielded multiplet was a 
key diagnostic feature to confirm the formation of the target compound. Furthermore, a doublet 
peak identified upfield in the aliphatic region integrating for three protons (3H5, δ = 1.8 ppm, 
J = 6.7 Hz), indicating the presence of a methyl group. Moreover, the existence of a doublet 
peak identified downfield at 1H4 (δ = 8.3 pm; J = 6.4 Hz) indicates the presence of an amino 
functional group on the molecule, which is attributed to the vicinal spin-spin coupling with H6 
(figure 2.15).   
Several other analogues in this section were derived and characterized and showed similar 
spectral features to those of compound 18. The 1D 1H NMR spectrum of analogue 15 and the 
structure of this compound is also shown in figure 2.16. Unlike the complex multiplicities 
observed with compound 18, compound 15 showed well-resolved singlet peaks corresponding 
to 1H3 (δ = 7.9 ppm) and 1H2 (δ = 8.4 ppm). Further diagnostics performed to confirm the 
structure of compound 15 included identification of the presence of the symmetrical doublet 
peaks due to para-fluoro substitution on the benzylamine moiety. In this regard, the newly 
introduced protons 2H8 (δ = 7.2 ppm, J = 8.9 Hz) exhibited a well-resolved triplet (t) due to 
equal vicinal spin-spin coupling with H7 and the fluoro (F) atom. On the other hand, 2H7 (δ = 
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7.6 ppm, J = 8.5, 5.4 Hz) split into dd arising from a vicinal coupling with H8 and a long-range 
coupling to F. 
 
Figure 2.16: 1D 1H nuclear magnetic resonance spectrum of compound 15 showing the 
presence of a symmetrically-substituted benzyl moiety in DMSO-d6 at 600 MHz 
 
The appearance of a multiplet peak corresponding to 1H6 (δ = 5.2 ppm) upfield confirmed the 
presence of an -methine proton.  Another vicinal coupling of H6 to the neighbouring amino-
NH proton H4 led to further splitting which brought about the observed multiplet splitting 
pattern. On the other hand, a broad singlet was observed at δ = 8.4 ppm due to H4. Moreover, 
the presence of the methyl group was confirmed by the appearance of a clearly resolved doublet 
peak upfield at δ = 1.8 ppm, J = 6.7 Hz, which integrated into three protons (3H), 
corresponding to the methyl protons H5.  
Furthermore, analogues with an unsubstituted phenyl ring of the PBI nucleus, such as 
compound 9, are among the target compounds synthesized in this SAR study. The 1D 1H NMR 
spectrum confirming the formation of this representative compound is displayed in figure 2.17.  
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Figure 2.17: 1D 1H nuclear magnetic resonance spectrum of compound 9 showing methyl (H7) 
and methylene (H8) protons at δ = 1.8 ppm and δ = 5.2 ppm in DMSO-d6 at 400 MHz 
The diagnostic features identified as characteristic of aminated final molecules such as 
compounds 18 and 15 are also evident in the 1H NMR spectrum of compound 9. Briefly, such 
features include the symmetrical splitting of the para-substituted benzyl protons (H10 and H9, 
δ = 7.6 and δ = 7.4 ppm, respectively), the presence of the methine peak (H8, δ = 5.2 ppm), the 
methyl peak (H7, δ = 1.8 ppm), and a broad doublet peak corresponding to the NH (H6) at δ = 
8.3 ppm downfield. Additionally, as theoretically expected, the core scaffold showed doublet 
of doublets peaks downfield corresponding to 1H2 (δ = 8.6, ppm, J = 8.5, 1.9 Hz) and 1H5 (δ 
= 7.9 ppm, J = 8.2, 1.7 Hz). The peak identified as H4 coalesced with H10 at approximately δ 
= 7.6 ppm, thus making it difficult to determine the multiplicity. A doublet of triplets (dt) and 
singlet peaks corresponding to the aromatic protons 1H3 (δ = 7.5 ppm) and 1H1 (δ = 6.2 ppm) 
were observed. 
Furthermore, unsubstituted core scaffold-based analogues possessing a carboxylate group were 
derivatized by the introduction of water-solubilizing amide functionality. An amidated 
analogue (5), its precursors, and the corresponding 1D 1H NMR spectra are shown in figure 
2.18. 
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Figure 2.18: 1D 1H nuclear magnetic resonance spectra of compounds 3 (ester), 4 (acid), and 
5 (amidated target product) in DMSO-d6 at 400 MHz 
The existence of a singlet peak corresponding to the methyl ester protons 3H6 (δ = 3.8 ppm) of 
3 and its consequent disappearance from the spectrum of 4 indicates the presence and 
successful demethylation of the methyl group of compound 3. Consequently, the appearance 
of the symmetrical 1,1-dioxidothiormopholinyl doublet peaks in 5 (H9 and H8, δ = 4.1 and 3.1 
ppm, respectively) on the lower spectrum indicates the presence of this amidated compound. 
Although the chemical shifts in 5 appeared slightly migrated downfield, the α-methine proton 
of compounds 3, 4, and 5 are represented by the synonymous signals at H7, H6, and H7 
respectively (δ = 5.9, 5.8, and 6.4 ppm, respectively). Although the NH proton was not visible 
in precursors 3 and 4, its presence in 5 (1H6) at δ = 8.0 ppm confirms the presence of the amino 
group. Additionally, other characteristic features were observed, such as a singlet peak 
corresponding to H1 at approximately δ = 6.2 to 6.5 ppm, unsubstituted benzyl aromatic proton 
signals at approximately δ = 7.5 to 7.8 ppm and shielded and unshielded phenyl protons 
appearing at approximately δ = 7.4 to 7.8 ppm and δ = 7.9 to 8.6 ppm, respectively. 
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2.5 Mechanistic details and spectroscopic analyses of SAR 2 intermediate and target 
compounds  
Here, the formation of key intermediate analogues and selected representative synthesized 
target compounds modified with various water-solubilizing groups at different positions of the 
phenyl and pyridyl rings of the PBI core scaffold are discussed. Because most of the starting 
precursors were asymmetric, the core scaffolds formed in isomeric forms. Nitro-substituted 
analogues showed the cleanest separation of the isomers, and their corresponding intermediate 
and target analogues are therefore used to facilitate spectroscopic evaluations and discussions 
here. 
2.5.1 Synthesis of amide compounds 
Although the symmetrical disubstituted benzimidazole acetonitrile intermediates derived in 
figure 2.7 only produced a monomeric compound, the corresponding monosubstituted 
asymmetric benzimidazole acetonitrile intermediate formed isomers. The presence of the 
isomeric compounds was confirmed via liquid chromatography-mass spectrometry (LC-MS), 
which revealed two distinct signals with the same m/z value (200.9) at 3.06 and 3.18 minutes, 
respectively. The formation of isomers is thought to arise from deprotonation of the 
benzimidazolium ion via two possible routes (figure 2.19). 
 
Figure 2.19: Mechanistic details of the formation of isomeric compounds 2.1.1a and 2.1.2a 
Interestingly, the two isomers were separated by trituration in diethyl ether and obtained as 
solid residue (yellow) and etheryl solution (orange solid after drying). The spectroscopic 
analysis of these isolates confirmed the formation and existence of the two isomeric products. 
The two structures were distinguished by the spin-spin coupling constants and the splitting 
patterns on their respective 1D 1H NMR spectra shown below in figure 2.20.  
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Figure 2.20: 1D 1H nuclear magnetic resonance spectra of regio-isomeric compounds 2.1.1a 
and 2.1.2a showing the difference in splitting patterns of 2.1.1a-H4 and 2.1.2a-H4 in CD3CN-
d3 at 400 MHz 
Possible spin-spin coupling interactions that are likely to bring about the observed 
spectroscopic results from the two isomers are shown in figure 2.20. The H3 of compound 
2.1.1a exhibited a doublet of the doublets of doublets with coupling constants J = 8.0, 7.5, 1.0 
Hz (figure 2.20).  
The observed splitting pattern is due to a vicinal coupling with H4 (magenta), which is further 
split by two long-range couplings with H5 (blue) and the NH proton 
H2 (green), respectively (figure 2.21). On the contrary, H3 of 
compound 2.1.2a exhibited a clearly resolved doublet of doublet (dd) 
peak (J = 8.0, 1.0 Hz) due to vicinal coupling with H4 (t, J = 8.1 Hz, 
magenta) and only one long-range coupling with H5 (dd, J = 8.2, 1.0 
Hz, blue). This implies that H2 on 2.1.1a occupies a different position, 
as has been proposed with compound 2.1.2a. The new position (five 
bonds away) prevents any long-range coupling that would bring 
about further splitting as observed with 2.1.1a. Additionally, the 
spectrum of compound 2.1.1a showed widely separated double 
doublets corresponding to 1H4 and 1H5 (δ = 7.4 and 8.0 ppm, J = 7.5, 
1.5 and 8.8, 1.5 Hz, respectively), while compound 2.1.2a exhibited 
closely spaced double doublets (1H3 and 1H5, δ = 8.1 and 8.2 ppm, J = 8.0, 1.0 and 8.2, 1.0 
Figure 2.21: H4-
spin-spin interactions 
on 2.1.1a and 2.1.2a 
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Hz, respectively). The deshielding effect of the Sp2-hybridized nitrogen (red) appears to be 
responsible for the downfield migration of the signals. 
Next, compounds 2.1.1a and 2.1.2a (figure 2.21) underwent the reaction shown in step (ii), 
figure 2.7. The proposed mechanistic steps and details leading to the formation of monomeric 
intermediate compounds 2.1.1b and 2.1.2b are similar to those outlined in figure 2.9. Both 
compounds were diagnostically characterized by the loss of a proton and the downfield 
migration of the respective singlet peaks from δ = 3.7 and δ = 4.3 ppm, corresponding to the 
aromatic proton H1 of compounds 2.1.1a and 2.1.2a respectively, to δ = 6.1 and δ = 6.4 ppm, 
corresponding to H1 of compounds 2.1.1b and 2.1.2b, respectively (figure 2.22). 
 
Figure 2.22: 1D 1H nuclear magnetic spectra of the isomeric hydroxyl intermediates 2.1.1b 
and 2.1.2b in CD3CN-d3 at 400 MHz 
Respective aromatic nucleophilic substitution reactions (SNAr, section 2.4) 
on hydroxyl-functionalized intermediate compounds 2.1.1b and 2.1.2b 
delivered the corresponding chlorinated compounds 2.1.1c and 2.1.2c (Fig. 
2.22.1). The 1H NMR spectrum (data not shown) was consistent with the 
structure of the chlorinated compounds. Consequently, the amination of 
2.1.2c produced the nitro-substituted intermediate compound 42. The 
formation of compound 42 was confirmed via 1D 1H NMR spectroscopy. 
The newly introduced para-substituted phenyl group resulted in the 
Fig. 2.22.1:  The 
Chloro analogues 
2.1.1c &. 2.1.2c 
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symmetrical and clear doublet peaks at approximately δ = 7.4 to 7.5 ppm corresponding to H5 
and H6, respectively (figure 2.23). 
 
Figure 2.23: 1D 1H nuclear magnetic resonance spectrum of compound 42. The symmetric 
doublet peaks at approximately δ = 7.4 to 7.5 ppm confirm the amination and the presence of 
a para-substituted benzyl moiety in DMSO-d6 at 300 MHz 
The nitro group was selectively reduced to form compound 43, whose structure was confirmed 
via 1D 1H NMR spectroscopy. A singlet peak at δ = 3.3 ppm, which integrated for two upfield 
protons, was identified and corresponds to the new aniline protons (H5, figure 2.24). 
 
Figure 2.24: 1D 1H nuclear magnetic resonance spectrum for compound 43, showing a sharp 
singlet peak at δ = 3.3 ppm corresponding to the new aniline protons (H5) in CD3CN-d3 at 400 
MHz 
The subsequent amidation of compound 43 with appropriate carboxylic acids led to the 
formation of the desired amide compounds 44 and 45, as shown in figures 2.25 and 2.26.  
Formation of the amide bond involves deprotonation of the substituent carboxylic acid by the 
nitrogen lone electron pair of EDCI, thereby making the imide carbon even more electrophilic 
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(figure 2.25). A nucleophilic attack on protonated EDCI by the carboxylate ion produced the 
O-acylisourea mixed ester, which was trapped by DMAP.12 The addition of a suitable amino 
substrate to the activated complex (Y) led to the formation of the desired amide bond. 
 
Figure 2.25: Amide bond formation mechanism13,14 
 
 
Figure 2.26: 1D 1H nuclear magnetic resonance spectrum of amidated compound 45 showing 
the upfield singlet peaks corresponding to carbamate (H7, δ = 3.3 ppm) and methylene protons 
(H6, δ = 3.3 ppm) in CD3CN-d3 at 400 MHz 
The appearance of upfield aliphatic proton signals corresponding to carbamate and methylene 
protons (H7, δ = 1.5 ppm and H6, δ = 4.1 ppm, respectively, figure 2.26), in addition to the 
other spectral features described earlier with regard to compound 43 (figure 2.24), confirmed 
the formation and the structure of amidated product compound 45. 
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2.5.2 Synthesis of amine-substituted analogues 
In addition to polar carbonyl-functionalized analogues, aryl-aminated analogues were also 
explored with regard to solubility improvement. The steps involved in the synthesis of aryl 
halide intermediates are outlined in figure 2.7 (steps i-iv), and the proposed formation 
mechanisms are similar to those outlined in figures 2.9, 2.11, and 2.14. A typical aryl chloride 
(37) (ortho-chloro) with its 1D 1H NMR spectrum is shown in figure 2.27. 
 
Figure 2.27: 1D 1H nuclear magnetic resonance spectrum of compound 37, showing the four 
methoxy aniline protons coalescing as a single peak in DMSO-d6 at 300 MHz 
A Buchwald-Hartwig amination reaction was conducted to transform aryl halides into target 
aryl amine analogues. as shown below in figure 2.28. 
 
Figure 2.28: The Buchwald-Hartwig amination: reagents and conditions: i) amine, Pd2(dba)3, 
RuPhos, Cs2CO3, 1,4-dioxane/DMF, 80 to 110 °C
13  
The Buchwald-Hartwig cross-coupling reaction proceeds via a catalytic cycle as shown in 
figure 2.29. Four major steps, including oxidative addition, ligand coordination, 
transmetalation, and reductive elimination, are involved in completing this amination reaction. 
The oxidative addition of the aryl halide to the palladium (0) complex (Pd2(dba3)) catalyst 
occurs, after which the amine coordinates to the palladium metal centre. Deprotonation of the 
amine by a base, in this case, Cs2CO3, generates the highly nucleophilic amide ion, which then 
substitutes the chlorine atom. The final aminated product is formed via a reductive elimination 
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step while the ligand-bound palladium (Pd(0)) catalyst is regenerated to continue the cycle 
(figure 2.29).5  
 
Figure 2.29: Catalytic cycle for the Buchwald-Hartwig amination7,15,16 
Analogues synthesized via the Buchwald-Hartwig cross coupling protocol shown in figure 2.29 
include piperazinyl- and the morpholinyl-substituted analogues, among others. A 
representative Buchwald-Hartwig aminated analogue (41) and its 1D 1H NMR spectrum is 
shown in figure 2.30. Successful amination was confirmed by the appearance of the 
symmetrical 1,1-dioxidothiomorpholinyl signals in the aliphatic region upfield. The well-
resolved triplet peaks identified at δ = 4.2 ppm and δ = 3.2 ppm correspond to H5 and H6, 
respectively, integrating for four methylene protons (4H) each. Furthermore, thiomorpholinyl 
signals were identified with very close spin-spin coupling constants (H5 and H6, J = 5.2 and 
5.2 Hz, respectively) suggesting that the protons H5 and H6 are next to each other. Moreover, 
the four protons of the para-substituted phenyl group resonated into unclearly resolved 
symmetrical signals integrating for four (04) protons (4H7, 8 δ = 7.4 ppm) in the aromatic 
region. Although the symmetry of the phenyl signal was not clearly separated into the expected 
doublet peaks, it was not as coalesced as was observed for compound 37 (figure 2.27). 
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Figure 2.30: 1D 1H nuclear magnetic resonance spectrum of compound 41 showing typical 
thiomorpholine dioxide protons signals upfield in CD3CN-d3 at 400 MHz 
Generally, the ortho-substituted aryl amine target analogues were obtained in low yields 
presumably due to the competitive and dominant formation of the dehalogenated-hydrogenated 
by-product shown in figure 2.30.1. The bulkiness of the cyclic amine moiety may have affected 
ligand coordination during the amination process at 9th position (ortho) of the core-scaffold 
leading to 90% formation of the side-product at the expense of the 
desired product whenever amination was attempted at this position. 
On the other hand, the meta position (C-7) was less sterically 
hindered and thus readily facilitated amine couplings. Highly 
improved yields (>70%) were accordingly observed. An example of 
a meta-aminated target analogue (49) and its 1D 1H NMR spectrum 
are shown in figure 2.31 below. Diagnostic spectral features include 
a high number of aliphatic signals upfield. Here, a triplet peak that 
integrated for six protons (6H) at δ = 1.1 ppm corresponding to two methyl group protons (H11) 
was observed. Additionally, a well-resolved quartet that integrated for four protons (4H, H10) 
corresponding to the two electronically equivalent methylene groups was identified slightly 
downfield at δ = 2.8 ppm. Moreover, the presence of the symmetrical triplet peaks 
corresponding to the methylene protons 2H9 and 2H8 (δ = 3.0 and 3.6 ppm, J = 5.9 and 6.1 Hz, 
respectively) further indicated the presence of the ethylene linker of the basic side chain (figure 
2.31). 
 
Fig. 2.30.1: Structure of 
the arene: halogenated-
hydrogenated by-product 
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Figure 2.31: 1D 1H nuclear magnetic resonance spectrum of the morpholine-acyclic-base 
substituted final analogue 49 in DMSO-d6 at 400 MHz 
 
Moreover, the presence of the morpholino group was identified by the appearance of two 
symmetrical morpholinyl multiplet peaks that integrated for four protons (4H) each at δ = 3.8 
ppm and δ = 3.2 ppm, corresponding to the methylene protons H4 and H5. Additionally, the 
meta-aminated core scaffold was distinguished from the para-substituted by the existence of a 
doublet peak (J = 2.1 Hz) that integrated for one proton (1H, H6) resonating downfield at δ = 
7.9 ppm. Its poorly resolved doublet peak is rationalized by the small spin-spin coupling 
constant resulting from long-range coupling with H3 Additionally, a dd peak that integrated 
into one proton H3 (J = 8.9, 2.1 Hz) was identified at δ = 7.3 ppm. This splitting pattern is 
explained by the strong vicinal spin-spin coupling of H3 with H2 and long-range coupling with 
H6, respectively. Finally, as expected, H2 split into a clear doublet that was identified at δ = 7.7 
ppm (J = 8.9) due to strong vicinal spin-spin coupling with H3. 
A total of 55 analogues were synthesized for SAR/SPR studies. 1D 1H NMR spectroscopy was 
used to characterize the synthesized analogues. The characterization details are outlined in 
Chapter 6. The 1D 1H NMR results were consistent with the various structures of the analogues 
and no advanced techniques were employed to complete the characterization of any compound. 
The analogues were submitted for solubility and in vitro pharmacological evaluations. In the 
next chapter, the pharmacological activity and solubility of the compounds synthesized are 
discussed. 
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3. PHARMACOLOGICAL AND SOLUBILITY EVALUATION 
3.1 Introduction 
In this chapter, the in vitro antiplasmodium activity against asexual blood-stage parasites, 
gametocytocidal and antischistosomal activities, as well as the solubility of the synthesized PBI 
target compounds are discussed. The antiparasitic activities of the analogues were evaluated in 
the chloroquine-sensitive NF54 (SAR 1.1 to 1.4 and SAR 2.1 to 2.4 compounds) and the 
chloroquine-resistant K1 (SAR 2.1 to 2.4) strains of the human malaria parasite P. falciparum. 
Furthermore, the in vitro antischistosomal activities of SAR 1.1 to 1.4 analogues were assessed 
against both newly transformed schistosomula (NTS) and adult worms or adult liver flukes of 
Schistosoma mansoni. SAR 2.1 to 2.4 analogues were only screened against the adult liver 
flukes of S. mansoni. Besides the antiparasitic activities, compound solubility is also discussed 
here. 
3.2 SAR 1: Assessment of the solubility and in vitro antiplasmodium, gametocytocidal, 
and antischistosomal activities of SAR 1.1 to 1.4 analogues 
Here, the 4-(trifluoromethoxy)aniline moiety at C-1 on the pyridyl ring of GMP-19 was 
replaced with various α-methylbenzylamine moieties (figure 3.1). 
 
Figure 3.1: Design of SAR 1.1 to 1.4 analogues 
Various moieties were incorporated to introduce moderate saturation and to potentially disrupt 
molecular planarity. Indeed, the introduction of saturation has been shown to lead to improved 
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solubility.1,2 Furthermore, although electron-withdrawing atoms such as fluoro and chloro 
groups were incorporated on the phenyl ring at C-7 and C-8, the 3-CF3 group on the pyridyl 
ring of the PBI core was kept constant. Previous studies have shown that the left-hand side 
(LHS) phenyl ring of the PBI core is a metabolic hotspot (Mayoka, unpublished data). In efforts 
to potentially block metabolism on this site, fluoro and chloro groups were appended onto the 
LHS phenyl ring. This is in view of the fact that drug molecules containing electron-
withdrawing groups undergo reduced cytochrome P450 (CYP)-mediated oxidation.3,4 A 
diverse set of target compounds with varying antiparasitic activities and solubility were 
identified. The in vitro antiplasmodium and antischistosomal activities and solubility values 
are summarized in figure 3.2.  
3.2.1 Assessment of the solubility and in vitro antiplasmodium activities of SAR 1 
analogues 
A PBI core scaffold with no substitution on the phenyl ring was used in the first phase of this 
SAR study (figure 3.2). Fully saturated amino moieties such as (R) and S-1-cyclohexylethan-
1-amine (analogues 1 and 2) were randomly sampled and incorporated at C-1 of the PBI core. 
However, these substitutions were detrimental to antiplasmodium activity (1, IC50 = 3.070 μM; 
and 2, IC50 = 2.757 μM) relative to IC50 = 0.430 μM of the frontrunner GMP-19. Additionally, 
both analogues demonstrated poor solubility (< 10 μM), which may be attributed to the highly 
lipophilic nature of the incorporated substituents. In the same SAR, -carboxylate 
benzylamine-substituted analogues and their corresponding amide derivatives exhibited 
improved solubility at the expense of antiplasmodium activity. In this regard, the methyl ester 
3 (solubility = 30 μM), its carboxylic acid form 4 (solubility = 150 μM), and the 1,1-
dioxidothiomorpholinyl amidated derivative 5 (solubility = 50 μM) exhibited 6-, 30-, and 10-
fold increases in solubility, respectively, compared to GMP-19 (solubility = 5 μM). All three 
analogues (IC50 = 6.000 μM) exhibited a 14-fold reduction in antiplasmodium potency relative 
to GMP-19 (IC50 = 0.430 μM, figure 3.2). Furthermore, the effect of introducing an electron-
withdrawing group on the phenyl ring of the substituent benzylamine was investigated. 
Although not as active as GMP-19, the para-fluorinated racemic compound 6 (IC50 = 1.274 
μM) demonstrated a 5-fold increase in potency compared to compounds 1 to 5, but a 3-fold 
reduction in potency compared to GMP-19. Compound 7, the resolved pure R-enantiomer, 
showed even higher activity (IC50 = 0.875 μM), with a 2-fold increase in antiplasmodium 
potency compared to the racemic form, compound 6, and the S-enantiomer, compound 8 (IC50 
= 2.039 μM).  
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Figure 3.2: Solubility and in vitro antiplasmodium activity of SAR 1.1 to 1.3 compounds 
SAR 1.1, black; SAR 1.2, purple, and SAR 1.3, pink 
aMean values were calculated from at least two independent experiments on the P. falciparum strain NF54 (individual values within ± 2-fold). Artesunate (IC50 
= 0.007 µM) and chloroquine (IC50 = 0.012 µM) were used as reference drugs.  
bDetermined using a turbidimetric method5 
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Thus, the reduced activity of the racemic form 6 may be attributed to the antagonistic effect of 
the S-enantiomer. In addition, compound 9 (IC50 = 1.020 μM), a racemate similar to the fluoro-
substituted analogue 6 but possessing a chloro group, was equipotent to compound 6. This 
indicates that the nature of the halogen at the para position of the substituent phenyl ring is 
irrelevant to antiplasmodium potency. Furthermore, incorporating a 2-carbon methylene spacer 
between the two nitrogen atoms (the PBI core scaffold-linked N and the -methylene carbon-
linked N of the substituent benzylamine moiety) resulted in improved solubility at the expense 
of biological activity, as demonstrated by compounds 10 and 11 (10: solubility = 180 μM, IC50 
= 2.896 μM; 11: solubility = 150 μM, IC50 = 3.177 μM), which exhibited 2- and 7-fold lower 
antiplasmodium activity relative both compounds 10, 11 and GMP-19, respectively.  
The next phase of SAR exploration involved introducing substitutions on the phenyl ring of 
the PBI core scaffold. Initially, a mono-substitution involving a chloro atom was introduced on 
the phenyl ring of the core scaffold at C-8. The effect of 8-chloro substitution on 
antiplasmodium activity was evaluated at the same time, thus providing prospects for SAR 
expansion. The poor antiplasmodium activity of compound 13 (IC50 = 4.35 μM) was 
comparable to that of the unsubstituted compound 3 (IC50 = 6.00 μM). Generally, 8-chloro 
mono-substitution had a negative impact on antiplasmodium activity. Compounds 12, 13, and 
14 showed 14-, 10-, and 7-fold decreases in potency relative to that of GMP-19. Although poor 
antiplasmodium activity was demonstrated, the amide-substituted analogue 12 exhibited the 
highest improvement in solubility (solubility = 80 μM) compared to the other two analogues 
13 and 14 (solubility = 30 and 20 μM, respectively). The difference in solubility between the 
amide-substituted compound 12 and the methyl ester-substituted compound 13 may be 
attributed to the enhanced hydrogen-bond donor and acceptor properties of compound 12. 
In the next SAR study, double substitution on the phenyl ring of the core scaffold was 
investigated. This modification resulted in drastically improved antiplasmodium activity, as 
demonstrated by the 7,8-dichlorinated analogue 15 (IC50 = 0.220 μM, figure 3.2). Although 
this analogue exhibited the strongest antiplasmodium activity compared to both GMP-19 and 
the rest of the compounds in SAR 1, further generation of dichlorinated analogues in this series 
was not undertaken due to the increased lipophilicity in such analogues. Thus, substitutions 
that could provide reduced lipophilicity while retaining antiplasmodium activity were 
explored. Consequently, the chloro groups in compound 15 were replaced with fluoro atoms, 
producing a slightly less lipophilic 7,8-difluorinated racemic analogue (compound 16, figure 
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3.3). Interestingly, compound 16 demonstrated improved antiplasmodium activity (IC50 = 
0.140 μM) and was three times more potent compared to GMP-19. This increase in 
pharmacological activity triggered interest in the respective pure enantiomers. The pure R-
enantiomer (compound 17) demonstrated even greater antiplasmodium potency (IC50 = 0.022 
μM), with 7- and 20-fold improvements in antiplasmodium activity compared to the racemic 
analogue compound 16 and the front-runner compound GMP-19, respectively. This indicates 
that the S-enantiomer may be antagonizing the antiplasmodium activity of its R-counterpart. 
However, the S-enantiomer should be obtained and tested to confirm these hypotheses. 
Similarly, while the fluoro groups were maintained at the C-7 and C-8 positions of the PBI 
core scaffold, the fluoro atom at the para-position of the -methylbenzylamine moiety was 
replaced with a chloro atom to produce a racemic analogue (compound 18). The resulting 
racemic mixture was three times more potent (IC50 = 0.051 μM) than the corresponding para-
fluorophenyl-based racemic compound 16. Unfortunately, the enantiomerically pure 
derivatives of compound 18 could not be obtained as none of the pure forms of the amine 
starting materials were available at the time of completing the programme. Furthermore, as the 
7,8-difluoro substitution on the phenyl ring of the PBI core was maintained, the introduction 
of additional Craig plot substituents possessing positive and negative inductive effects on the 
phenyl ring of the -methylbenzylamine moiety was investigated. The unsubstituted pure 
enantiomeric compounds 19 (S) and 20 (R) served as controls for the enantiomerically pure 
analogues, which demonstrated similar sub-micromolar antiplasmodium activities (IC50 = 
0.340 and 0.250 μM, respectively, figure 3.3). 
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Figure 3.3: Solubility and in vitro antiplasmodium activity of SAR 1.4 compounds 
aMean values were calculated from at least two independent experiments on the P. falciparum strain NF54 (individual values within ± 2-fold). Artesunate (IC50 
= 0.007 µM) and chloroquine (IC50 = 0.012 µM) were used as reference drugs. 
bDetermined using a turbidimetric method5  
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Amongst the representative substituent groups, the OCF3-substituted analogue 21 (IC50 = 0.940 
μM) exhibited higher antiplasmodium activity than the sulfone-substituted compound 22 (IC50 
= 6.000 μM). In addition, although the ortho-chloro R- -methylbenzylamine-substituted 
compound 23 (IC50 = 0.153 μM) demonstrated equipotent antiplasmodium activity compared 
to the unsubstituted analogue 20 (IC50 = 0.250 μM), its S-counterpart (25, IC50 = 0.155 μM) 
demonstrated a 2-fold increase in potency relative to compound 19 (IC50 = 0.340 μM). 
Similarly, the enantiomerically pure isomers 23 and 25 demonstrated equipotent 
antiplasmodium activities (IC50 = 0.153 and 0.155 μM, respectively), thus suggesting that 
potency is not stereoselective. Similarly, the ortho-chloro racemate forms 26, 25 (S), and 23 
(R; IC50 = 0.153, 0.155, and 0.170 μM, respectively) all demonstrated equipotent activity 
relative to each other. Furthermore, the substitution of the H with an OH group on the ortho 
position resulted in significant loss of antiplasmodium activity as demonstrated by compound 
24 (IC50 = 1.100 μM), which exhibited a 4-fold decrease in antiplasmodium activity relative to 
the unsubstituted compound 20. Additionally, when the electron-withdrawing and electron-
donating groups were compared, the ortho-chloro analogue 23 exhibited greater activity (IC50 
= 0.153 μM) than the ortho-phenolic analogue 24 (IC50 = 1.100 μM). This demonstrates a 7-
fold increase in potency in favour of the lipophilic electron-withdrawing chloro group. 
Additionally, as demonstrated by the racemic mixtures 18 (para, IC50 = 0.051 μM) and 26 
(ortho, IC50 = 0.170 μM), para-chloro substitution resulted in a 3-fold increase in activity 
compared to ortho substitution. Moreover, the racemic para-tolylamine-substituted analogue 
27 (IC50 = 0.099 μM) exhibited comparable activity to the para-fluoro compound 16 (IC50 = 
0.140 μM) and demonstrated a 2-fold decrease in potency compared to the para-chloro-
substituted analogue 18 (IC50 = 0.051 μM). Furthermore, compound 27 demonstrated 9- and 
>60-fold increases in antiplasmodium potency relative to the electron-rich OCF3-substituted 
analogue 21 (IC50 = 0.940 μM) and the sulfone moiety-substituted analogue 22 (IC50 = 6.000 
μM), respectively. The effect of lipophilic benzylamine substituent moieties and the 
corresponding activity can be summarized as follows: chloro (18: IC50 = 0.051 μM) > methyl 
(27: IC50 = 0.099 μM) > fluoro (16: IC50 = 0.140 μM) > OCF3 (21: IC50 = 0.940 μM). 
Further antiplasmodium SAR studies on the 7,8-difluorinated PBI core scaffold involved 
variations on the -methylene carbon of the -methylbenzylamine moieties. The -
cyclopropyl-substituted benzylamine moiety conferred the greatest potency to compound 30 
(IC50 = 0.045 μM), while the -germinal dimethylbenzylamine-substituted analogue 28 (IC50 = 
0.286 μM) and the -ethylbenzylamine-substituted analogue 29 (IC50 = 0.497 μM) showed 
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lower activities. The closed ring cyclopropyl group at the -carbon in compound 30 appears to 
be crucial to antiplasmodium potency, with 6- and 11-fold increases in activity observed in 
relation to its linear counterparts 28 and 29, respectively. -Carboxylate benzylamine 
substituents on the same 7,8-difluorinated core scaffold were revisited. Although a significant 
improvement in the antiplasmodium activities of the -carboxylate benzylamine analogues was 
achieved compared to the unsubstituted versions shown in figure 3.2, the carboxylate analogues 
generally exhibited lower activity (S-enantiomer 32: IC50 = 1.010 μM, and R-enantiomer 33: 
IC50 = 1.900 μM, figure 3.3). A snapshot contracted heterocyclic aromatic amine SAR revealed 
significant loss in antiplasmodium activity from the five-membered ring pyrazolylamine-
substituted analogue 34 (IC50 = 5.810 μM). 
A few analogues of the 7,8-difluorinated PBI core scaffold exhibited encouraging solubility 
profiles. Although only one analogue (30) of this part of the SAR also demonstrated sub-
micromolar antiplasmodium activity (IC50 = 0.045 μM), the other analogues demonstrated high 
solubility at the expense of in vitro antiplasmodium potency. The para-phenolic compound 24 
(solubility = 80 μM), -carboxylate compounds 32 and 33 (solubility = 80 μM), and the 
pyrazolylamine-substituted analogue 34 (solubility = 80 μM) were amongst the analogues 
showing encouraging solubility but low antiplasmodium potency. The OCF3-substituted 
analogue 21 (solubility = 20 μM) showed low solubility in combination with sub-micromolar 
antiplasmodium potency. Unfortunately, the rest of the compounds in this series demonstrated 
poor solubility (< 10 μM).  
3.2.2 In vitro gametocytocidal activity evaluation of SAR 1 analogues 
In this section, the gametocytocidal activities of the previously described -
methylbenzylamine-substituted PBI analogues are discussed. Preliminary evaluation of these 
analogues revealed potency at both the early and late stages of gametocytogenesis. Their 
inhibitory effects were determined after treatment with 1.0 and 5.0 µM (figure 3.4). 
Interestingly, some analogues showed gametocytocidal activity at both the early and late stages. 
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 Reference drugs (1.0 µM)  Early gametocytes Late gametocytes 
1 Methylene blue 93% (luc) 90% (luc), 50% (ATP) 
2 Dihydroartemisinin 75% (luc) 70% (luc), 15% (ATP) 
3 MMV048  77% (n=3) 92% (n=3) 
Figure 3.4: In vitro gametocytogenesis inhibitory effect of SAR 1.1 to 1.3 compounds on early- 
and late-stage Plasmodium falciparum NF54 gametocytes 
luc, parasite viability measured via luciferase reporter assay; ATP, parasite viability measured via ATP 
bioluminescence assay6 
Although the monochlorinated core scaffold (SAR 1.2) exhibited inactivity at the sexual stages 
of parasite development, analogues derived from the unsubstituted phenyl ring of the core 
scaffold displayed <32% gametocytogenesis inhibition at both 1.0 and 5.0 µM test 
concentrations. Analogue 15, which contained a 7,8-dichlorinated core scaffold, demonstrated 
significant improvement in gametocytocidal activity at 5 µM. However, this compound 
exhibited approximately 37- and 3-fold decreases in potency against the early and late stages 
of parasite development, respectively, at 1.0 µM relative to the control drug and Phase II 
clinical candidate MMV048. Moreover, the analogues derived from a 7,8-difluorinated core 
scaffold generally exhibited significantly improved gametocytocidal activity (figure 3.5). 
Compound 16 showed 15 and 72% inhibition of early- and late-stage parasites at 1.0 µM, 
respectively, or 7- and 2-fold increases in potency relative to analogue 15. Additionally, 
compound 16 exhibited late-stage activity at 1.0 µM equal to that of MMV048 (72 and 92% 
inhibition at 1.0 µM for compound 16 and MMV048, respectively), and 5-fold lower early-
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stage gametocyte inhibition (15 and 77% early-stage inhibition at 1.0 µM, respectively). 
Furthermore, compound 16 (racemate) demonstrated equipotent gametocytocidal activity to 
that of the pure R-enantiomer 17 (15 and 19% early-stage inhibition at 1.0 µM, 88 and 90% 
early-stage inhibition at 5.0 µM, 72 and 77% late-stage inhibition at 1.0 µM, and 88 and 90% 
late-stage inhibition at 5.0 µM for compounds 16 and 17, respectively). Moreover, although 
compound 16 exhibited late-stage activity comparable to that of compound 18, a 2-fold increase 
in early-stage gametocytocidal potency was observed relative to compound 16 (19 and 42% 
inhibition at 1.0 µM for compounds 16 and 18, respectively). In addition, the presence of a 
fluoro atom on the para-position of the benzylamine ring was essential to gametocytocidal 
activity, as was demonstrated by the lack of activity of the unsubstituted R-enantiomer 
(compound 20). Furthermore, replacement of a fluoro or chloro group with OCF3, SO2Me, or 
Me was detrimental to gametocytocidal activity, as was demonstrated by compounds 21, 22, 
and 27, which generally exhibited poor activity at both the early and late stages of 
gametocytogenesis. In this regard, gametocytocidal activity appears to be favoured by electron-
withdrawing lipophilic substituents on the benzylamine substituents as demonstrated by the >4-
fold reduction in activity of the electron-rich analogue 24 (21% early-stage gametocytes 
inhibition at 5.0 µM) relative to that of the lipophilic analogue 25 (90% early-stage gametocyte 
inhibition at 5.0 µM). Although the open -germ-dimethylbenzylamine-substituted analogue 
28 and its isomeric analogue 29 exhibited negligible gametocytocidal activity, the -
cyclopropyl benzylamine-substituted analogue 30 demonstrated the highest early-stage 
gametocytocidal activity (72 and 97% inhibition at 1.0 and 5.0 µM, respectively). Although 
compound 30 only displayed stage-specific activity toward early gametocytes, this compound 
demonstrated activity equal to that of MMV048 (77% inhibition at 1.0 µM) against this stage. 
The R- and S- -carboxylate benzylamine-substituted analogues showed comparably low 
gametocytocidal activity. This weak activity is demonstrated by compounds 32 and 33 (56 and 
64% inhibition at 5.0 µM, respectively) against late-stage gametocytes, while the 5-membered 
heterocyclic amine-substituted analogue 34 exhibited a complete lack of gametocytocidal 
activity. 
Although some compounds such as 16, 17, 18, and 25 demonstrated dual-stage activity, 
compound 30 exhibited stage-specific action against early gametocytes. Lipophilic 
substitutions conferred greater gametocytocidal activity relative to electron-rich hydrophilic 
substitutions.
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Figure 3.5: In vitro gametocytogenesis inhibitory effect of SAR 1.4 compounds on early- and late-stage Plasmodium falciparum NF54 
gametocytes  
luc, parasite viability measured by luciferase reporter assay; ATP, parasite viability measured by ATP bioluminescence assay6 
 Reference drugs Early gametocytes Late gametocytes 
1 Methylene blue 93% (luc) 90% (luc), 50% (ATP) 
2 Dihydroartemisinin 75% (luc) 70% (luc), 15% (ATP) 
3 MMV048  77% (n=3) 92% (n=3) 
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3.2.3 In vitro antischistosomal evaluation of SAR 1 analogues 
This antischistosomal activity of the previously described -methylbenzylamine-substituted 
PBI analogues is described here. Although the IC50 values of the analogues described here 
(compounds 1 to 34) were not determined, a preliminary single-point screen of some of these 
compounds revealed strong antischistosomal properties. The compounds’ inhibitory effects 
were determined at 10.00 µM, 1.00 µM, and 0.37 µM test concentrations. Interestingly, 
although a few analogues showed high activity against both NTS (juvenile worms) and adult 
schistosomes, most of the compounds tested showed greater inhibition against juvenile worms. 
Activity against NTS does not only attract attention for further exploration of this series of 
compounds but is also an indicator of the potential of this class of compounds to supplement 
the medical gap in treating schistosomiasis, as the current clinical drug (praziquantel) is only 
active against adult worms. Details of these compounds and their antischistosomal activities at 
various concentrations are presented in figures 3.6, 3.7, and 3.8. 
3.2.4 In vitro activity against adult schistosomes 
Except for the four analogues shown in figure 3.6, SAR 1.1 to 1.4 compounds generally 
demonstrated poor activity against adult schistosomes at both 10.00 µM and 1.00 µM. Of all 
the analogues synthesized from the unsubstituted ring of the PBI core (SAR 1.1), only three 
compounds (6, 7, and 8, figure 3.6) exhibited inhibitory effects (29 to 60% inhibition at 10.00 
µM). Although inactivity was also observed with analogues bearing a 7,8-difluorinated PBI 
core scaffold (SAR 1.4), one analogue (compound 18) demonstrated strong antischistosomal 
activity with 100% inhibition at both 10.00 and 1.00 µM, as shown in figure 3.6. Other 
compounds showed no activity and are therefore not included in this figure. 
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Figure 3.6: In vitro antischistosomal activity of SAR 1.1 to 1.4 compounds against adult 
Schistosoma mansoni worms 
Control: praziquantel, 100 % inhibition at 0.37 µM 
3.2.5 In vitro activity against newly transformed schistosomula (NTS) 
Similar to that observed against adult worms, analogues derived from the PBI core scaffold 
bearing an unsubstituted phenyl ring showed little to no activity against NTS. In addition, the 
-carboxylate benzylamine-substituted analogues and their corresponding amide derivatives 
exhibited poor antischistosomal activity against NTS even at the highest test concentration, as 
demonstrated by compounds 4 and 5 (35 and 55 % inhibition at 10.00 μM, respectively, figure 
3.7). The most active analogue in this category, compound 6, showed 100, 38, and 19% 
inhibition at 10.00, 1.00, and 0.37 µM respectively. Although still low, the chloro-substituted 
core scaffold showed improved antischistosomal activity against NTS as demonstrated by the 
-carboxylate benzylamine-substituted analogues. A significant improvement in 
antischistosomal activity was observed by the introduction of a chloro atom on the phenyl ring 
of the PBI core. In this regard, the antischistosomal inhibitory effects of compound 4 increased 
from 35% and 0% to 100% and 24% for compound 13, at 10.0 and 1.0 µM, respectively, after 
introducing a chloro atom at C-8 (SAR 1.2).  
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Figure 3.7:  In vitro antischistosomal activity of SAR 1.1 to 1.3 compounds against newly 
transformed schistosomula (NTS) 
SAR 1.1, black (unsubstituted core); SAR 1.2, magenta (8-chloro); SAR 1.3, pink (7, 8-dichloro) 
Control: praziquantel, 100% inhibition at 0.37 µM 
 
This improvement in antischistosomal activity corresponds to a 3-fold increase in favour of the 
monochlorinated phenyl of the PBI core scaffold. The primary amide (compound 12) also 
exhibited improved activity (100% inhibition at 10.00 μM, and 30% inhibition at 1.0 μM) 
compared to the -carboxylate benzylamine-substituted analogues derived from the 
unsubstituted phenyl ring of the PBI core. The para-sulfonyl benzylamine-substituted analogue 
showed 60% inhibition at 10.0 μM while no activity was observed at both 1.0 and 0.37 μM test 
concentrations. The effect of phenyl ring disubstitution of the PBI core scaffold on activity was 
also examined. The benzylamine moiety of compound 6, which resulted in the greatest activity 
in this portion of the SAR study, was incorporated into the 7,8-dichlorinated (SAR 1.3) PBI 
core scaffold to produce compound 15. An improvement in activity was observed from 100, 
38, and 19% to 100, 58, and 35% by compound 6 and 15 respectively, at 10.00, 1.00, and 0.37 
µM test concentrations. 
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Introduction of the 7,8-difluoro substitution on the phenyl ring of the PBI core scaffold (figure 
3.8) provided further opportunities to expand the SAR study by reducing the cytotoxicity that 
was observed with the dichlorinated core scaffold (Mayoka, unpublished data), in addition to 
reducing both molecular weight and lipophilicity. Interestingly, analogues that were derived 
from this portion of the SAR study demonstrated a drastic improvement in antischistosomal 
activity, as shown by the 7,8-difluoro-substituted phenyl analogue 16 (100% inhibition at both 
10.0 and 1.0 μM, and 48% inhibition at 0.37 μM, figure 3.8) in comparison with the 7,8-
dichloro-substituted analogue 15 (100, 58, and 35% inhibition at 10.00, 1.00, and 0.37 µM test 
concentrations, respectively, figure 3.7). Enantiomerism did not affect antischistosomal 
activity, as was demonstrated by the racemic analogue 16 and the pure enantiomer 17 (R), both 
of which exhibited 100% inhibition at both 10.0 and 1.0 μM, and 48 and 35% inhibition at 0.37 
μM, respectively. Equipotency was also observed in the enantiomerically pure analogues 19 
(R) and 20 (S), both of which exhibited 100% inhibition at 10.0 and 1.0 μM, and 21 and 25% 
inhibition at 0.37 μM, respectively. Furthermore, the R- and S- -carboxylate benzylamine-
substituted analogues also displayed similar antischistosomal activities, as was demonstrated 
by compound 32 (S; 100, 73, and 17% inhibition at 10.00, 1.00, and 0.37 µM, respectively) and 
compound 33 (R; 100% inhibition at both 10.0 and 1.0 μM, and 19% inhibition at 0.37 μM). 
Moreover, the -methyl ester substitution on the substituent amine did not affect activity, as 
shown by compound 19 (100% inhibition at both 10.0 and 1.0 μM, and 21% at 0.37 μM), 
compound 33 (100% inhibition at both 10.0 and 1.0 μM, and 19% at 0.37 μM), compound 20 
(100% inhibition at 10.0 and 1.0 μM, and 25% at 0.37 μM), and compound 32 (100, 73, and 
17% inhibition at 10.00, 1.00, and 0.37 µM, respectively). Interestingly, -cyclopropyl 
benzylamine-substituted analogue 30 exhibited impressive potency against NTS at 0.37 μM 
(69% inhibition), while demonstrating 100% inhibition at both 10.00 and 1.00 μM. 
Furthermore, substitution of the fluoro with the chloro group at the para-position of the 
benzylamino moiety did not affect the antischistosomal potency as shown by compounds 16 
and 18, which both showed 100% inhibition at 10.0 and 1.0 μM, and 48 and 31% inhibition at 
0.37 μM, respectively.
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Figure 3.8: In vitro antischistosomal activity of SAR 1.4 (7,8-difluorinated core) compounds against newly transformed schistosomula (NTS) 
Control: praziquantel, 100% inhibition at 0.37 µM 
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Similarly, the presence or absence of the fluoro atom on the benzyl ring did not affect 
antischistosomal activity, as shown by compounds 17 and 19, which both exhibited 100% 
inhibition at 10.0 and 1.0 μM, and 35 and 21% inhibition at 0.37 μM, respectively. However, 
compound 16 (100% inhibition at both 10.0 and 1.0 μM, and 48% inhibition at 0.37 μM) and 
compound 27 (52% inhibition at 10.0 μM and no inhibition at both 1.0 and 0.37 μM) 
demonstrate the importance of including an electron-withdrawing group on the benzyl ring. 
The presence of the hydroxyl, trifluoromethyl, and sulfone groups led to a loss of 
antischistosomal activity. The inactivity of the analogues following the substitution of these 
groups is demonstrated by the trifluoromethyl-substituted analogue 21 (100, 44, and 15% 
inhibition at 10.00, 1.00, and 0.37 µM, respectively), the sulfone-based analogue 22 (100 and 
38% inhibition at 10.00 and 1.00, respectively, and no activity shown at 0.37 µM), and the 
meta-hydroxyl-substituted analogue 24 (100, 33, and 6% inhibition at 10.00, 1.00, and 0.37 
µM, respectively). The contraction of the ring of the substituent amino moiety resulted in the 
loss of antischistosomal activity as demonstrated by the pyrazolylamine-substituted analogue 
34, which showed 67% inhibition at 10.0 µM and <10% inhibition at 1.0 and 0.37 µM. 
3.3 SAR 2: Assessment of the solubility and in vitro antiplasmodium and antischistosomal 
activities of LHS-modified PBI analogues 
This phase of SAR and structure-property relationship (SPR) studies were aimed at improving 
physicochemical properties. Although enhancement of solubility was the major focus, 
modifications that could produce analogues with improved in vitro antiparasitic activity were 
highly sought. The PBI nucleus underwent modifications including the incorporation of 
hydrophilic amino moieties (figure 3.9). Antiplasmodium activity evaluation of the analogues 
was carried out in both NF54 and K1 P. falciparum strains, and the antischistosomal evaluation 
was performed against S. mansoni. Compounds with a range of low to high solubility and 
antiparasitic activities were obtained. The in vitro antiparasitic activities (IC50 values) and 
corresponding solubility values for various target compounds are shown in figures 3.10-3.12. 
For the sake of brevity, the discussion of all the antiplasmodium results will be based on 
potency against the chloroquine-sensitive (PfNF54) malaria parasite strain. 
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Figure 3.9: Points of modification in the SAR 2 study 
3.3.1 Assessment of the solubility and in vitro antiplasmodium activities of SAR 2 
analogues 
The front-runner compound GMP-19 (compound 35) was used as a control in the 
antiplasmodium evaluation. Although similar IC50 values were obtained for the resynthesized 
material of GMP-19 (compound 36, IC50 = 0.25 μM) and previously synthesized material 
against the K1 strain, an unexpected 3-fold difference in activity was noted against the NF54 
strain (IC50 = 0.43 and 0.17 µM for compound 35 and 36, respectively). The derivatives 
demonstrated antiplasmodium potencies ranging from low to high, as shown in figure 3.10. 
Generally, moderately lipophilic groups around the PBI core influenced potency. The loss of 
potency observed upon replacing the morpholine with a piperazine group (compound 39, IC50 
= 0.18 µM, and 40, IC50 = 9.60 µM) indicates that introduction of the polar NH group was 
detrimental to activity. Furthermore, the phenyl ring on the LHS of the PBI core was modified 
by incorporating polar non-ionizable amide functionalities. These analogues include a 
lipophilic N-ethylated amide compound 44, which demonstrated poor antiplasmodium activity 
(IC50 > 10 µM). However, the moderately lipophilic N-des-ethyl amidated analogue 45 
demonstrated a >37-fold improvement in antiplasmodium activity (IC50 = 0.27 µM) compared 
to compound 44 (figure 3.10). 
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Figure 3.10: Solubility and in vitro antiplasmodium activity of SAR 2.1 to 2.3 compounds 
SAR 2.1, blue; SAR 2.2, brown; SAR 2.3, red 
aMean values were calculated from at least two independent experiments on the P. falciparum strains NF54 and K1 (individual values within ± 2-fold). 
Artesunate (IC50 = 0.007 µM in NF54 and 0.930 ng/mL in K1) and chloroquine (IC50 = 0.012 µM in NF54 and 86 ng/mL in K1) were used as reference drugs. 
bKinetic solubility determined via UHPLC 
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The introduction of polar heterocyclic aromatic amino moieties was detrimental to 
antiplasmodium activity but caused a significant improvement in solubility, as demonstrated 
by compounds 46 (IC50 = 5.87 µM; solubility = 50 µM) and 47 (IC50 = 6.00 µM; solubility = 
105 µM). However, the highly polar and basic piperazinyl-substituted analogue 40 (solubility 
= 150 µM) demonstrated a 2-fold improvement in solubility compared to the less polar 
morpholinyl-substituted analogue 39 (solubility = 80 µM). However, a 4-fold decrease in 
solubility was observed when the morpholine moiety of compound 40 was substituted with a 
1,1-dioxidothiomorpholine group as in compound 41 (solubility = 20 µM). Sulfone- and the 
nitro-substituted compounds have been reported to have the unfavourable energy for hydrogen-
bonding interactions with water molecules (this is discussed in more details in chapter 4).7,8 
Moreover, a 2-fold improvement in aqueous solubility was observed upon substituting the nitro 
group of compound 42 (solubility = 20 µM) with an amino group in analogue 43 (solubility = 
40 µM). The improvement in solubility was further observed with polar non-ionizable amide-
functionalized analogues such as the N-ethylated amide compound 44 (solubility = 50 µM) and 
the N-des-ethyl amidated compound 45 (solubility = 85 µM). Thus, amide derivative 45 
showed a 2-fold improvement in solubility compared to compound 44. Except for compound 
38 (solubility <5 µM), aromatic moieties conferred greater solubility, as shown by compounds 
46 and 47 (solubility <50 and 105 µM, respectively).  
Based on the antiplasmodium and solubility evaluation, compound 39 was identified as an 
optimally active analogue and the morpholinyl substituent was therefore fixed on the phenyl 
ring in the next phase of the SAR study. As a result, the 4-(trifluoromethoxy)aniline substituent 
on the pyridyl ring of the core scaffold was substituted with saturated basic amino moieties to 
produce target analogues shown in figure 3.11 below. However, such substitutions initially 
produced analogues with reduced in vitro antiplasmodium activities, translating to a >30-fold 
loss in potency against the PfNF54 strain compared to that of compound 39. Such analogues 
include compounds 48 (IC50 = 6.000 µM) and 49 (IC50 = 4.940 µM, figure 3.12). In an attempt 
to probe the effect of re-introducing aromatic properties, the 4-(trifluoromethyl)phenyl moiety 
was incorporated in place of the trifluoromethyl group at C-3. A drastic improvement in 
antiplasmodium activity was observed as demonstrated by compound 53 (IC50 = 0.670 µM). 
Although low, the carbamate-substituted analogue 51 demonstrated antiplasmodium activity 
comparable to that of the N-ethylated amino analogue 50 (IC50 = 0.710 µM).  
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Figure 3.11: Solubility and in vitro antiplasmodium activity of SAR 2.4 and 2.5 compounds 
SAR 2.4, pink; SAR 2.5, brown 
aMean values were calculated from at least two independent experiments on the P. falciparum strains 
NF54 and K1 (individual values within ± 2-fold). Artesunate (IC50 = 0.007 µM in NF54 and 0.0024 µM 
in K1) and chloroquine (IC50 = 0.012 µM in NF54 and 0.270 µM in K1) were used as reference drugs. 
bKinetic solubility determined via UHPLC   
 
Interestingly, a dramatic improvement in antiplasmodium activity was observed in the N-des-
ethyl aminated compound 52 (IC50 < 0.012 µM), thus demonstrating a >40-fold improvement 
in antiplasmodium activity compared to that of the N-ethylated analogue 50. Moreover, 
compound 52 demonstrated >59-fold improvement in antiplasmodium potency compared to 
the carbamate N-carbamate aminated analogue 51. A slight loss of antiplasmodium activity 
was observed with the morpholine substituted analogue 53 (IC50 = 0.670 µM) relative to that 
of the chloro-substituted analogue 50. Furthermore, similar activities were observed in the 
carbamate-based analogues 54 and 51 (IC50 = 0.870 and 0.710 µM, respectively). Interestingly, 
sub-micromolar antiplasmodium potency was retained with the fully substituted (N-des-
ethyl/morpholine aminated) analogue 55 (IC50 = 0.250 µM). The final analogue (55), however, 
demonstrated a >12-fold decrease in activity compared to compound 52. Similar sub-
micromolar antiplasmodium activities were observed in the N-ethylated and N-carbamate 
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approximately a 3-fold increase compared to both the N-ethylated and N-carbamate aminated 
analogues 53 and 54. Moreover, these analogues demonstrated low to moderate solubility, 
although the analogues with a trifluoromethyl group at position C-3 did so at the expense of 
antiplasmodium potency. Compounds that demonstrated improvement in kinetic solubility at 
the expense of antiplasmodium activity include compounds 48 and 49 (solubility = 105 and 
150 µM, respectively). The substitution of a CF3 group with a 4-CF3Ph moiety at the C-3 
position resulted in low solubility for the chloro-substituted intermediate analogues 50 to 52 
(solubility = 20 µM). The poor solubility of these analogues may be attributed to the anticipated 
π–stacking due to the planar conformations. Not surprisingly, solubility was restored upon 
substitution of a chloro group with a morpholine moiety on the core scaffold. Compounds 53 
and 54 (solubility = 100 and 105 µM, respectively) demonstrated a 5-fold improvement in 
solubility compared to the corresponding chloro-substituted analogues 50 and 51. Moreover, 
analogue 55 (solubility = 150 µM) showed a >7-fold improvement in solubility compared to 
its corresponding chlorinated analogue 53. Density functional theory (DFT) calculations 
revealed that in the lowest energy state, the morpholine-substituted analogues assume an anti-
coplanar conformation. These conformations disrupt molecular symmetry to reduce π–stacking 
and are thought to be responsible for the high solubility demonstrated by compounds 49 and 
55. Although some 3-dimension character was observed, compounds such as 28 exhibited poor 
solubility because of residual planarity (figure 3.12).  
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Code Structure DFT lowest energy conformation 
49 
 
  
 
55 
  
 
28 
 
 
Figure 3.12: Density functional theory (DFT)-optimized structure conformations and observed 
solubilities for compounds 49, 55, and 28 
 
 
 
 
 
Solubility = < 10 µM 
IC50 NF54 = 0.286 
µM 
 
 
Solubility = 105 µM 
IC50 NF54 = 0.250 
µM 
 
 
Solubility = 150 µM 
IC50 NF54 = 4.94 µM 
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3.3.2 In vitro gametocytocidal activity evaluation of SAR 2 analogues 
Although not all SAR 2 compounds were preliminarily screened for dual-point inhibition 
against the early and late stages of parasite gametocytogenesis, a few compounds demonstrated 
activity at 1.0 and 5.0 µM test concentrations. Details of these compounds and their 
gametocytocidal inhibitory effects at various concentrations are shown in figure 3.13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Reference drugs (1.0 µM)  Early gametocytes Late gametocytes 
1 Methylene blue 93% (luc) 90% (luc), 50% (ATP) 
2 Dihydroartemisinin 75% (luc) 70% (luc), 15% (ATP) 
3 MMV048  77% (n=3) 92% (n=3) 
Figure 3.13:  In vitro gametocytogenesis inhibitory effects of SAR 2.2 to 2.5 compounds 
against early- and late-stage PfNF54 gametocytes 
luc, parasite viability measured via luciferase reporter assay; ATP, parasite viability measured via ATP 
bioluminescence assay6 
 
Although analogues with polar functionalities such as the amide-substituted compound 45, the 
heterocyclic aromatic amine-substituted analogues 46 and 47, and the double-aminated 
analogues 48 and 50 demonstrated negligible activity, the lipophilic analogues derived from 
the 4-CF3Ph-substituted core scaffold demonstrated higher activity (compounds 51 to 55). 
Compound 52 demonstrated the highest potency.  
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3.3.3 In vitro antischistosomal evaluation of SAR 2 analogues 
The in vitro antischistosomal activities of SAR 2.1 and 2.2 analogues against adult 
schistosomes were evaluated. The analogues in this SAR study were obtained by modifying 
the LHS of compound 35. Although the analogues in this series demonstrated potent 
antischistosomal effects, reduced potency was observed for all compounds, including the 
resynthesized control sample compound 36, compared to the previously reported activity of 
front-runner compound 35 (data not shown). Details of these compounds and their 
antischistosomal activities (IC50 values) are presented in figure 3.14 below. 
 
Figure 3.14: In vitro antischistosomal activity of SAR 2.1 to 2.2 compounds against adult 
Schistosoma mansoni worms 
SAR 2.1, blue; SAR 2.2, brown 
Control: praziquantel, IC50 = 0.21 µM 
 
An unexpected significant difference in antischistosomal activities between the previously 
reported result for the front-runner GMP-19 (compound 35, IC50 = 0.210 μM) and the 
resynthesized sample (compound 36, IC50 = 1.04 μM), corresponding to a 5-fold difference in 
antischistosomal activity against the adult worms, was observed. However, these results were 
reconciled after a repeat analysis of the front-runner sample 35 alongside the resynthesized 
sample 36. In this controlled analysis, compound 35 demonstrated lower antischistosomal 
activity (IC50 = 1.24 μM) than originally reported (IC50 = 0.210 μM). 
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A modification that involved incorporating an electron-withdrawing group on the phenyl ring 
produced the less active intermediate compound 37 (IC50 = 1.41 μM). Similarly, reduced 
antischistosomal activity was observed when a nitro group was incorporated to produce 
compound 42 (IC50 = 1.23 μM). Furthermore, incorporating an electron-donating group such 
as an amino group, as demonstrated by compound 43, also resulted in lower potency (IC50 = 
1.26 μM). Despite the difference in the electronic nature of compounds 42 and 43, no 
significant difference in antischistosomal activity was observed. Thus, the nitro-substituted 
analogue 42 and its reduced form 43 showed similar activities against adult S. mansoni worms. 
Although the final aminated and amidated analogues did not show clear SARs, 1,1-
dioxidothiomorpholinyl-substituted analogue 41 exhibited the strongest antischistosomal 
activity (IC50 = 0.36 μM) compared to the morpholinyl-substituted analogue 39 (IC50 = 1.87 
μM). Similarly, the analogue 45 (IC50 = 0.850 μM) demonstrated a 2-fold increase in activity 
against adult worms compared to the analogue 44 (IC50 = 1.89 μM). 
The antiplasmodium and antischistosomal SARs of PBI analogues were explored and 
analogues displaying high antiplasmodium and antischistosomal activities were identified. 
Additionally, compound 52 was identified as an analogue with strong in vitro asexual blood-
stage antiplasmodium activity (IC50 < 0.012 μM) and dual activity at both the early and late 
stages of gametocytogenesis (>96% inhibition at 5.0 μM). Additionally, stage-specific activity 
against early-stage gametocytes (77% inhibition at 1.0 μM) was identified in compound 30. 
Moreover, the same compound showed potent sub-micromolar dual antiparasitic in vitro 
activity (30: IC50 = 0.045 μM in PfNF54, 72% early-stage gametocyte inhibition at 1.0 μM, 
and 69% schistosomal inhibition of S. mansoni NTS at 0.370 μM). Furthermore, compounds 
displaying sub-micromolar in vitro antischistosomal activity (41: IC50 = 0.360 μM) were 
identified, as well as compounds also showing highly improved kinetic solubility between 30 
and 85 μM (such as compound 45, IC50 = 0.270 in PfNF54, IC50 = 0.850 μM in adult S. 
mansoni). Additional details of the physicochemical properties and the exploration of certain 
factors affecting the solubility of PBI compounds are presented in the next chapter. 
 
 
 
 
 
 
Chapter 3 
 
 2018 MSc Thesis: Kelly Chisanga 98 
References: 
(1)  Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing Saturation as an 
Approach to Improving Clinical Success. J. Med. Chem. 2009, (52), 6752–6756. 
(2)  Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. 
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. 
Med. Chem. 2002, 45 (12), 2615–2623. 
(3)  Zhang, Y.-Y.; Liu, Y.; Mehboob, S.; Song, J.-H.; Boci, T.; Johnson, M. E.; Ghosh, A. 
K.; Jeong, H. Metabolism-Directed Structure Optimization of Benzimidazole-Based 
Francisella Tularensis Enoyl-Reductase (FabI) Inhibitors. Xenobiotica 2014, 44 (5), 
404–416. 
(4)  Pearson, J.; Dahal, U. P.; Rock, D.; Peng, C.-C.; Schenk, J. O.; Joswig-Jones, C.; Jones, 
J. P. The Kinetic Mechanism for Cytochrome P450 Metabolism of Type II Binding 
Compounds: Evidence Supporting Direct Reduction. Arch. Biochem. Biophys. 2011, 
511 (1–2), 69–79. 
(5)  Hill, A. P.; Young, R. J. Getting Physical in Drug Discovery: A Contemporary 
Perspective on Solubility and Hydrophobicity. Drug Discov. Today 2010, 15, 648–655. 
(6)  Reader, J.; Botha, M.; Theron, A.; Lauterbach, S. B.; Rossouw, C.; Engelbrecht, D.; 
Wepener, M.; Smit, A.; Leroy, D.; Mancama, D.; Coetzer, T. L.; Birkholtz, L.-M. 
Nowhere to Hide: Interrogating Different Metabolic Parameters of Plasmodium 
Falciparum Gametocytes in a Transmission Blocking Drug Discovery Pipeline towards 
Malaria Elimination. Malar. J. 2015, 14 (1), 213. 
(7)  Kamlet, M. J.; Doherty, R. M.; Abraham, M. H.; Marcus, Y.; Taft, R. W. Linear 
Solvation Energy Relationship. 46. An Improved Equation for Correlation and 
Prediction of Octanol/Water Partition Coefficients of Organic Nonelectrolytes 
(Including Strong Hydrogen Bond Donor Solutes). J. Phys. Chem. 1988, 92 (18), 5244–
5255. 
(8)  Why are the Nitro and Sulfone Groups Poor Hydrogen Bonders? 
https://docplayer.net/35923053-Why-are-the-nitro-and-sulfone-groups-poor-hydrogen-
bonders.html (accessed Oct 9, 2018). 
 
 
 
Chapter 4 
 
 
2018 MSc Thesis: Kelly Chisanga 99 
4. PHYSICOCHEMICAL EVALUATION AND STRUCTURE-PROPERTY 
RELATIONSHIPS  
4.1 Introduction 
A drug’s medical benefits depend entirely on its pharmacological effects and the duration of 
its action within the body. Specifically, the benefits of a drug are related to pharmacokinetic 
properties such as absorption, distribution, metabolism, and excretion (ADME). Ideally, the 
physicochemical properties of a drug-like molecule determine these ADME properties.1,2 Most 
importantly, aqueous solubility and lipophilicity remain pivotal physicochemical properties in 
determining how much of the drug is dissolved, permeates the lipophilic biological membranes, 
and is absorbed.1  
Lipinski’s rule of five has been devised to provide guidelines on the suitable characteristic 
properties of drug-like compounds. This rule is based on a study of oral drug leads that 
progressed into the advanced stages of clinical development. Generally, the rule provides 
guidelines on the inherent properties of drug-like compounds, such as the physical count of the 
hydrogen-bond donors (HBD, ideally ≤ 5) and the hydrogen-bond acceptors (HBA, ideally ≤ 
10). In addition, the rule emphasizes the importance of molecular weight (Mw, ideally ≤ 500 
g.mol-1), which, in addition to the number of HBDs and HBAs, affects lipophilicity. 
Lipophilicity is defined as the in silico calculated partition coefficient (cLogP), which should 
ideally be ≤ 5.3 
However, certain properties that are not addressed by the rule of five but also have a significant 
effect on solubility, such as the topological polar surface area (tPSA) and saturation (increase 
in sp3 character), have been evaluated and established. Although an increase in sp3 character 
has previously been studied and associated with molecular conformations that influence 
crystallinity and thus improve solubility and permeability,5 Veber et al. restricted the ideal total 
number of rotatable bonds to fewer than 10 and the optimal tPSA in the range 65 to 140 Å2.6 
Similarly, the introduction of chirality leads to the disruption of molecular planarity and 
influences the crystal packing of the compound, which lowers the melting point (Mp) and leads 
to improved solubility.4,7 
In this study, some of these intrinsic properties were evaluated to determine their effect on the 
solubility of PBI lead compounds. Parameters such as the Mp, cLogP, tPSA, and the high-
pressure liquid chromatography (HPLC) retention times (tR) were further evaluated. 
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4.2 Results and discussion 
4.2.1 Physicochemical characterization 
To minimize factors that may lead to uncertainties in the profiling of physicochemical 
properties, the purities of all the compounds used in this study were reassessed via HPLC in a 
single batch using the same HPLC buffer and solvent system, to ensure compounds were >95% 
pure. Results of the purity assessment for all compounds synthesized (n = 55) were found to 
be within 98.39 ± 2.58% at 95% confidence limit and are shown below in figure 4.1. The purity 
results were satisfactory, and all compounds displayed the minimum required purity. 
 
Figure 4.1: Purities of all compound synthesized (SAR 1.1 to 2.4) determined via high-
performance liquid chromatography (HPLC) 
This chart shows compliance with the 95% minimum purity requirement. 
LL, lower limit; UL, the upper limit  
 
4.2.2 Relationships between solubility, Mp, cLogP, and HPLC tR 
The solubilities and Mp were measured using appropriate techniques (outlined in Chapter 6), 
and the retention times were determined via HPLC. To ensure minimum uncertainties in the 
determination of the tR, compounds were analyzed in a single sequence using the same buffer 
and solvent system. The cLogP and the tPSA values were generated in silico using ChemDraw 
professional 16.0 and StarDropTM 64 softwares, respectively. Using Microsoft Excel 16.0, the 
statistical charts shown in figure 4.2 were produced to investigate the relationships between i) 
solubility and tPSA, ii) solubility and Mp, iii) solubility and cLogP, and iv) solubility and 
HPLC tR.
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Figure 4.2: Relationships between selected physicochemical properties 
A, solubility vs topological polar surface area (tPSA); B, solubility vs melting point; C, solubility vs calculated partition coefficient (cLogP); D, 
solubility vs high-performance liquid chromatography (HPLC) retention time (tR)
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Although a more accurate solubility determination method could have revealed clearer 
statistical correlations, the compound-specific inherent properties observed here appear to 
strongly influence the linear relationships shown in figure 4.2. An increase in tPSA is 
theoretically expected to improve hydrogen-bonding properties, and thus result in increased 
aqueous interactions and improved solubility. However, certain compounds such the nitro-
substituted analogue 42 demonstrated poor solubility (20 µM) and high tPSA (112.46 Å2). A 
similar result was observed with the sulfone-based analogue 41, which exhibited poor solubility 
(< 20 µM) despite having a high tPSA (128.08 Å2). Thus, the weak correlation (R2 = 0.272) 
between solubility and the tPSA was attributed to the unusual behaviour of analogues such as 
compounds 42 and 41 (figure 4.3), which, despite showing favourably high tPSA, 
demonstrated low solubility. Inherent factors that limit the solubility of sulfone- and nitro-
substituted analogues have been reported in the literature and are attributed to their weak 
hydrogen-bond interactions with water molecules. Despite having more hydrogen-bonding 
sites, the NO2- and SO2-substituted analogues show unfavourable hydration energies, thus 
leading to poor solvation.8 The unusual relationship between tPSA and solubility displayed by 
such compounds are thought to have skewed the correlation observed in figure 4.2A. 
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Figure 4.3: Selected PBI compound with their physicochemical properties  
Additionally, although weak, a positive correlation (R2 = 0.151) was observed between 
solubility and Mp, as demonstrated by the negative gradient shown in figure 4.2B. The negative 
slope observed is typical of the inverse linear relationship between solubility and Mp. 
Theoretically, the solubility of a chemical substance should increase as the Mp decreases. 
However, this theoretical expectation is limited by other factors that form part of the inherent 
properties of a compound. In addition to the number of rotatable bonds and saturation, which 
are thought to influence the Mp and in turn affect solubility, polar functionalities should 
increase optimally to facilitate hydrophilic interactions. In this regard, the saturated cyclohexyl-
substituted analogues 1 and 2 demonstrated poor solubility (<10 µM) although complying with 
Veber’s rules (<10 rotatable bonds) and demonstrating desirably low Mp (182 °C).  
Chapter 4 
 104 
2018 MSc Thesis: Kelly Chisanga 
The positive trend between solubility and cLogP (figure 4.2C) was the strongest correlation 
observed (R2 = 0.298) relative to that between other physicochemical parameters. Ideally, the 
solubility of a compound should vary inversely with cLogP, and a plot of solubility against 
cLogP is therefore expected to display a linear negative slope. Although this was observed in 
figure 4.2C, the inherent characteristics of different compounds will affect the in silico-
predicted lipophilicities (cLogP) differently. Based on these in silico-generated cLogP values, 
the experimental solubilities may vary and depart from theoretical expectations. This may be 
because of the inherent properties of certain compounds that the software does not consider. 
Such properties may include inductive electronic effects, which mostly upsurge the basicity of 
some non-hydrogen-containing functional groups such as tertiary amines. In addition, the 
software may not recognize the effect of anti-coplanar structural conformations, although these 
may strongly impact crystal packing, Mp, and solubility. The piperazinyl- and linear amine-
functionalized analogues 40 and 48 (cLogP = 6.55 and 4.96, solubility = 150 and 105 µM, for 
40 and 48, respectively, figure 4.3) are amongst the analogues that were thought to be affected 
by these software limitations.  
Another aberrant experimental result that is thought to be functional group-specific concerns 
the sulfone- and the piperazinyl-substituted analogues 40 and 41 (cLogP = 6.55 and 5.59, 
solubility = 150 and 20 µM, for 40 and 41, respectively). In these two cases, structures with 
lower cLogP values may theoretically be associated with higher solubilities, however, the 
opposite was observed here. These and other factors not discussed here are thought to have 
weakened these correlations. 
Similarly, aberrant relationships between solubility and cLogP were demonstrated by 
compounds 45 (cLogP = 4.97, solubility = 150 µM) and 53 (cLogP = 5.69, solubility = 100 
µM). Such compounds may have fewer hydrogen-bond donors but contain tertiary-substituted 
nitrogen atoms (3°) that are highly basic. The aberrant linear relationships between solubility 
and cLogP that are demonstrated by the nitro-, sulfonyl-, and tertiary nitrogen-substituted 
analogues9 are attributable to the weak correlation observed (R2 = 0.298). The fact that weak 
linear correlations were observed across all relationships indicates that several other factors 
including inductive effects, hydration, and crystal packing energies affect the solubility of these 
PBI compounds. 
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5. GENERAL SUMMARY  
The synthesis, solubility, and pharmacological profiling of PBI compounds were successfully 
conducted. As a result, a new series of N-benzyl-3-trifluoromethylpyrido[1,2-a]benzimidazole 
analogues was identified and widely explored, leading to the successful expansion of SAR and 
SPR studies. Established synthetic protocols were employed to synthesize target analogues, 
which were characterized using nuclear magnetic resonance spectroscopy [1H- and 13C-NMR] 
and HPLC coupled to mass spectrometry (HPLC-MS), and subjected to Mp determination. 
5.1 Summary of antiparasitic activities against PfNF54, PfK1, NTS, and adult S. mansoni 
worms 
In vitro antiplasmodium activities were assessed against the chloroquine-sensitive P. 
falciparum strain NF54 and the chloroquine-resistant strain K1. SAR 1.1 to 1.4 and SAR 2.1 
to 2.5 analogues were tested in vitro against asexual and sexual blood-stage PfNF54 malaria 
parasites. In addition to this evaluation, SAR 2.1 to 2.4 analogues were screened against the 
chloroquine-resistant P. falciparum strain K1. SAR 2.1 to 2.4 compounds demonstrated similar 
activities against both the PfNF54 and PfK1 strains. Furthermore, the in vitro antischistosomal 
activities of the analogues were evaluated against both NTS and adult S. mansoni. Except for 
compound 18, which showed dual activity against the juvenile and the adult schistosomes, all 
compounds in this series demonstrated variable activity against the two stages of parasite 
development (figure 5.1). Moreover, the solubility of the 55 analogues synthesized in SAR 1.1 
to 1.4 and 2.1 to 2.5 was assessed using the turbidimetric and HPLC-based kinetic solubility 
protocols.  
5.2 Summary of in vitro antiplasmodium and antischistosomal activities of SAR 1 
analogues 
i. Analogues possessing an unsubstituted phenyl ring in the core scaffold demonstrated poor 
antiplasmodium activity and showed a 2- to 14-fold decrease in potency relative to that of 
GMP-19. Similarly, these analogues also demonstrated weak inhibition of the early and 
late stages of gametocytogenesis. Moreover, the compounds exhibited weak inhibition of 
the growth of both NTS and the adult worms (10 to 55% inhibition at 1.0 µM).    
ii. Compounds containing the monosubstituted 8-chloro core PBI scaffold demonstrated poor 
activity with a 7- to >14-fold decrease in antiplasmodium activity compared to that of 
GMP-19. Similarly, the monosubstituted analogues also exhibited negligible 
gametocytocidal effects against both early- and late-stage parasites. Low antischistosomal 
activity was also observed (0 to 55% inhibition at 1.0 µM). 
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iii. Analogues derived from a 7,8-dichlorinated core PBI scaffold demonstrated significant 
improvement in both antiplasmodium and antischistosomal activities and showed a 2-, 4-, 
and 14-fold increase in potency relative to that of GMP-19. Analogues 7 (a most active 
compound from SAR 1.1) and 14 (a most active analogue from SAR 1.2) also exhibited 
improved gametocytocidal effects (78 and 85% inhibition in early- and late-stage 
gametocytes at 5.0 µM, respectively).  
iv. The 7,8-difluorinated core PBI scaffold (SAR 1.4) conferred the greatest antiplasmodium 
potency relative to that of GMP-19. In this regard, 15 of the 19 analogues from SAR 1.1 
to 1.3 showed sub-micromolar asexual blood stage antiplasmodium activities ranging 
between 0.022 and 0.940 µM. The following is noteworthy: 
- They exhibited 2- to 20-fold increases in asexual blood-stage antiplasmodium activity 
relative to that of the front-runner compound GMP-19  
- One compound 30 exhibited early-stage gametocytocidal activity, which was 
comparable to that of MMV048 (72 and 77% inhibition at 1.0 µM for 30 and 
MMV048, respectively) 
- Compound 30 demonstrated antischistosomal activity with a 69% NTS inhibition at 
0.37 µM 
5.2.1 Summary of structure-activity relationship 
i. Lipophilicity was identified as a key determinant of activity in this part of the SAR 
study. 
ii. Compounds containing benzylamine moieties with electron-rich hydrophilic groups 
exhibited poor antischistosomal and antiplasmodium activities against both the asexual 
and sexual stages. 
iii. Sulfonyl substitution and ring contraction compromised antischistosomal and 
antiplasmodium activities against both the asexual and sexual stages of parasite 
development. 
iv. Although further investigations may be required, R-enantiomers displayed stronger 
activities than their S-counterparts against both parasites. 
v. Para-substituted compounds demonstrated superior antiplasmodium activity, with 3-
fold increases in potency relative to their ortho-substituted counterparts. 
Various substitutions and their relative effects on antiplasmodium and antischistosomal 
activities are summarized below in figure 5.1 while the distribution of antiplasmodium activity 
for all the 55 compounds is shown in figure 5.3. 
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Figure 5.1: Antiplasmodium (IC50 (µM)) and antischistosomal (% inhibition at 1.00 µM) of 
the current PBI leads 
5.2.2 Summary of solubility studies 
Solubility studies were conducted using HPLC-based and turbidimetric kinetic solubility 
protocols. The melting points (Mp) were determined while predicted cLogP and the tPSA 
values were generated in silico for all analogues (figure 5.1) and compared to solubility. 
Findings were as follows:  
i. As expected all analogues bearing a lipophilic substituent, such as the saturated lipophilic 
hexylamine, analogues 1 and 2, and those containing chloro, fluoro, and methyl groups on 
the benzylamine ring, generally exhibited poor solubility (<10 µM). 
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ii. Chiral esters and their amide derivatives, analogues bearing a 2-carbon spacer (10 and 11), 
and the 5-membered heterocyclic-substituted analogue 34 demonstrated moderate to high 
solubility with 4- to 36-fold increases in solubility relative to that of GMP-19. 
5.3 Summary of antiparasitic activity and solubility studies for SAR 2 analogues 
Generally, the in vitro antiplasmodium and antischistosomal activities of SAR 2 analogues 
were improved. Analogues demonstrated up to a 36-fold increase in antiplasmodium potency 
relative to that of GMP-19. The following deductions were made: 
5.3.1 Summary of antiparasitic activity 
i. Antiplasmodium activity increased with lipophilicity as demonstrated by compound 53; 
- The presence of electron-rich hydrophilic groups led to a decrease in activity against 
both the asexual and sexual blood-stage. 
- Replacing the 4-OCF3Ph with hydrophilic amino moieties reduced the activity of 
C-3 CF3-substituted analogues as exemplified by compound 48. 
ii. The introduction of partially acidic substituent moieties such as the sulfonyl and amide 
groups (41 and 45: figure 5.2) increased antischistosomal activity. 
 
Figure 5.2: Antiparasitic activity and physicochemical profiles of selected SAR 2 analogues: 
cLogP (Black); tPSA (Red); NF54 (Blue); S. mansoni IC50 (µM: Brown); solubility (µM: Pink)
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Figure 5.3: Statistical summary and distribution of antiplasmodium activities for all synthesized compounds (n = 55) 
Activity ranges are in IC50 (µM) values against NF54 parasites
≤ 0.25, 
15, 
27%
0.25-0.50,
8, 
14%
0.50 - 0.75,
2, 
4%
0.75 - 1.0,
5, 
9%
1.0 - 2.0,
6, 
11%
2.0 - 4.0,
6, 
11%
>4.00, 
13, 
24%
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5.3.2 Summary of solubility studies 
i. Generally, all analogues possessing a morpholino group on the phenyl ring and an acyclic 
amino moiety on the pyridyl ring of the core scaffold demonstrated a >30-fold increase 
in solubility relative to that of GMP-19.  
ii. The introduction of amide functionalities on the phenyl ring of the core scaffold resulted 
in a >10-fold improvement in solubility relative to that of GMP-19. 
iii. Compounds containing the sulfonyl group exhibited poor solubility, with approximately 
4- and 7-fold reductions in aqueous solubility relative to that of analogous compounds 39 
and 40, respectively. 
5.3.3 General summary of the physicochemical property profiling 
i. In this study, cLogP, tPSA, and Mp were moderately correlated (R2 = 0.298, 0.272, and 
0.151, respectively), and were identified as suitable predictive parameters for solubility. 
ii. No correlation was observed between solubility and HPLC tR. 
5.4 Future work and recommendations 
5.4.1 Pharmacological profiling of SAR 1 and SAR 2 analogues 
Considering the high sub-micromolar antiplasmodium activity exhibited by the newly explored 
N-benzyl-3-trifluoromethylpyrido[1,2-a]benzimidazole compounds, the following should be 
investigated: 
i. Antischistosomal in vitro dose-response profiles (IC50) 
ii. Cytotoxicity and metabolic stability profiles 
iii. In vivo PK and efficacy profiles in appropriate animal models 
iv. PfK1 and cross-resistance profiles 
v. Mechanism of action studies through target identification 
5.4.2 Physicochemical profiling of SAR 1 and SAR 2 analogues 
Poor solubility was observed in the most potent analogues, thus requiring medicinal chemistry 
optimization studies. The proposed SAR 1 and SAR 2 analogues were designed to improve the 
tPSA while maintaining some degree of lipophilicity. 
5.4.3 Proposed SAR for physicochemical optimization of the -methylbenzyl-PBI series 
The recommendations are based on front-runner compounds 16, 17, 18, 27, and 30 as shown 
in figure 5.4. 
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Figure 5.4: Proposed compounds for physicochemical property optimization 
*Activity was determined as % inhibition at 0.37 µM, with 100% inhibition shown at 1.0 µM 
Compound 27 exhibited no activity at both 0.37 and 1.0 µM. 
5.4.4 Proposed SAR for physicochemical optimization of the SAR 2 series 
Recommendations are based on front-runner compound 52 as shown in figure 5.5. 
 
Figure 5.5: Proposed compounds for physicochemical properties optimization 
5.4.5 In silico prediction of the physicochemical properties of proposed analogues 
From this study, cLogP and tPSA were positively correlated with solubility. Therefore, the 
design of the new analogues aimed to maintain lipophilicity while increasing the tPSA. The 
details of the predicted physicochemical parameters including the tPSA (Å), cLogP, and 
calculated molar weights of the proposed new analogues for SAR 1 and SAR 2 are shown in 
figures 5.6 and 5.7, respectively.
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R Parameter/target        
 
65 ≤ tPSA ≤ 140 51.42 70.72 64.93 81.45 61.58 76.74 61.58 
cLogP ≤ 5 5.84 4.02 5.48 5.29 5.74 5.79 6.01 
Mol. Wt. ≤ 500 428.37 446.38 447.37 486.41 471.39 471.40 485.42 
30 NF54 / NTS* 0.045/ 69 - - - - - - - - - - - - 
 
        
cLogP ≤ 5 6.52 4.70 6.16 6.15 6.42 6.47 6.69 
Mol. Wt. ≤ 500 450.80 468.81 469.81 508.84 493.82 493.83 507.85 
18 NF54 / NTS* 0.051/ 31 - - - - - - - - - - - - 
 
R - - - - - - - - - - - - - - 
S - - - - - - - - - - - - - - 
 
        
cLogP ≤ 5 6.30 4.48 5.94 5.94 6.21 6.26 6.48 
Mol. Wt. ≤ 500 430.38 448.40 449.38 488.42 473.41 473.41 487.43 
27 NF54 / NTS* 0.099/ 0 - - - - - - - - - - - - 
 
R - - - - - - - - - - - - - - 
S - - - - - - - - - - - - - - 
 
        
cLogP ≤ 5 5.95 4.13 5.59 5.58 5.85 5.90 6.12 
Mol. Wt.  ≤ 500 434.35 452.36 453.34 492.35 477.37 477.37 491.40 
16 NF54 / NTS* 0.140/ 48 - - - - - - - - - - - - 
 R 0.022/ 35 - - - - - - - - - - - - 
S - - - - - - - - - - - - - - 
Figure 5.6: Future work and recommendations for SAR 1 
*Activity is expressed as % inhibition at 0.37 µM, with 100% inhibition shown at 1.0 µM; *% inhibition at both 0.37 and 1.0 µM;  
- - recommended assays for future work 
 
Chapter 5 
 
 
2018 MSc Thesis: Kelly Chisanga 114 
 
  
 
 
 
 
 
  
 
X Parameter/target        
 
65 ≤ tPSA ≤ 140 63.45 82.75 76.96 93.48 73.61 88.77 76.61 
clogP ≤ 5 5.79 4.66 3.11 5.04 5.02 5.06 5.29 
clogP ≤ 500 407.88 425.89 426.88 465.92 450.90 450.91 464.93 
         
 
65 ≤ tPSA ≤ 140 87.24 106.54 100.75 117.27 97.4 112.56 97.40 
clogP ≤ 5 5.08 3.95 2.40 4.33 4.31 4.35 4.58 
clogP ≤ 500 419.90 432.91 433.90 472.94 457.92 457.93 471.95 
 
        
65 ≤ tPSA ≤ 140 83.68 102.98 97.19 113.71 93.84 109.00 93.84 
clogP ≤ 5 4.69 3.56 2.01 3.93 3.91 3.95 4.18 
clogP ≤ 500 405.89 423.90 424.89 463.93 448.91 448.92 462.94 
 
        
65 ≤ tPSA ≤ 140 72.68 91.98 86.90 102.71 82.84 98.00 82.84 
clogP ≤ 5 5.00 3.88 2.32 4.25 4.23 4.28 4.50 
clogP ≤ 500 419.91 437.93 438.91 477.95 462.94 462.94 476.97 
 
        
65 ≤ tPSA ≤ 140 80.52 99.82 94.03 110.55 90.68 105.84 90.68 
clogP ≤ 5 4.06 2.93 1.38 3.31 3.28 3.33 3.55 
clogP ≤ 500 451.97 469.99 470.97 486.41 510.01 495.00 509.03 
Figure 5.7: Future work and recommendations for SAR 2
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6. EXPERIMENTAL 
6.1 Chapter Overview  
In Chapter six, supplementary experimental protocols and spectroscopic data for Chapters 2, 
3, and 4 are described. The Chapter starts with a description of chemical materials used, the 
instrumental and technical requirements for the testing after which a detailed spectroscopic 
characterization of all the synthesized intermediate and target molecules is covered. The 
chapter ends with the description of biological assay protocols used to generate biological data 
reported in this dissertation. 
6.2 Chemistry  
6.2.1 Reagents and Solvents 
All the commercially available chemicals and reagents were purchased from either Sigma-
Aldrich in South Africa or Combi-Blocks Limited in the United States of America (USA) and 
were used without further purification. All the anhydrous solvents such as 1,4-dioxane, 
dimethyl sulfoxide (DMSO), acetonitrile (CH3CN) and dimethylformamide (DMF) were 
purchased as such from Sigma Aldrich (South Africa). However, only tetrahydrofuran (THF) 
and ethanol which were purchased and used as analytical reagent (AR) grade and absolute 
(99.9%), respectively.  HPLC grade solvents such as CH3CN and methanol (MeOH) for HPLC-
MS mobile phase preparation were purchased from Romil Ltd (Cambridge, UK). 
6.2.2 Chromatography  
The progress of reactions was monitored by a combination of analytical thin layer 
chromatography (TLC) and HPLC-MS. The TLC plates employed were sourced from Merck 
(TLC Silica gel 60 F254 coated on aluminium sheets). The TLC plates were visualized under 
ultraviolet light (UV 254 and 366 nm). An Agilent LC-MS instrument with the following 
components was used to monitor the progress of reactions including per cent purity 
determinations: Agilent 1260® Infinity Binary Pump, Agilent 1260® Infinity Diode Array 
Detector, Agilent 1290® Infinity Column Compartment, Agilent 1260® Infinity Autosampler, 
Agilent 6120® Quadrupole LC/MS, and Peak Scientific® Genius 1050 Nitrogen Generator. An 
X-bridge® (C18, 2.5 µm, 3.0 mm (ID) x 50 mm length) column maintained at 35 °C was used.  
The chromatographic mobile phases composed of 10 mM aqueous ammonium acetate 
(NH4OAc) spiked with 0.4% acetic acid and 10 mM NH4OAc in methanol spiked with 0.4% 
acetic acid (figure 6.1). The mass spectra were acquired using electrospray ionisation (ESI) or 
atmospheric pressure chemical ionization (APCI) in the positive or negative ionisation modes, 
respectively depending on the nature of the compound.  
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Time                  
(min) 
% A % B 
Composition 
A B 
0.00-1.00 90 10 
10.0 mM NH4OAc              
(0.40% acetic acid 
buffer) 
10.0 mM NH4OAc                      
(0.40% acetic acid buffer)                      
in 90% HPLC grade CH3OH    
in H2O 
1.00-3.00 5 95 
3.00-5.00 5 95 
5.00-6.50 90 10 
6.50-7.00 90 10 
Figure 6.1: HPLC gradient conditions summary 
Biotage grade silica gel was employed for column chromatographic purifications on the 
Biotage Isolera One Flash Chromatography system. The manual glass tube columns employed 
Fluka high purity grade silica gel (pore size 60 Å, 70 – 230 mesh, 63 – 200 μm). Additionally, 
Analtech Uniplate preparative TLC (prep-TLC) plates (20 × 20 cm, 2000 microns) were used 
for prep-TLC purifications. The solvents used as mobile phases were AR grade and were used 
without further distillation. 
6.2.3 Spectroscopic characterization 
1H NMR and 13C NMR spectra were recorded on a Ultrashield-Plus Bruker or Varian Mercury 
300 (1H 300.1, 13C 75.5 MHz) or a Bruker (600 MHz) spectrometers. All 1H NMR and 13C 
NMR spectra were acquired at 30 °C in deuterated solvents (CDCl3, CD3OD, CD3CN, or 
DMSO-d6). The one-dimensional 
1H NMR and 13C NMR spectra were processed using 
MestReNova 6.2.1-7569. Multiplicity patterns are reported using the following abbreviations 
br s = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, 
ddd = doublet of doublet of doublets, dt = doublet of triplets. Coupling constants (J values) are 
reported in Hertz (Hz).  
6.2.4 Physical characterization 
Melting points were measured using a digital thermometer Reichert Jung THERMONOVAR. 
The 4-chlorophenyl boronic acid (m.p = 284 – 289 °C) was used as a melting point control 
sample and was read every ten measurements. An average melting point 285 – 291 °C (n = 6) 
was obtained. The recorded melting points were measured in duplicate and are an average of 
the clear point which is a temperature at which all solid material on the slides turns to liquid. 
All the final compounds were subjected to purity check experiments using HPLC-MS to ensure 
an acceptable level of purity (≥ 95%). 
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6.3 Synthesis and Characterization 
6.3.1 General procedure for the synthesis of benzimidazole acetonitrile intermediate 
compounds 1.1a – 2.2a 
A suitably substituted 1,2-diaminobenzene (1.0 equiv), ethyl cyanoacetate (3.0 equiv) and 
DMF (1.0 mL/ 0.100g sample) were stirred at 160°C for 3 hours. At the completion of the 
reaction, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, 
washed with 20mL portions of 5% lithium chloride (20 mL x 3), distilled water (20 mL x 3) 
and brine (10 mL x 3) in a separatory funnel. The treated organic layer was dried on anhydrous 
MgSO4, concentrated and finally dried in vacuo. For the nitro-substituted benzimidazole, the 
product was purified by trituration using toluene at 40-45 °C filtered and solid 2.1.2a was 
washed with diethyl ether and dried at ambient conditions. The toluene mixture was 
concentrated and solid was triturated using diethyl ether to obtain 2.1.1a. 
 
2-(6-chloro-1H-benzo[d]imidazol-2-yl)acetonitrile, 1.2a 
Compound 1.2a was obtained from 4-chloro-1,2-diaminobenzene (1.2) (2.5 g, 17.53 mmol, 1.0 
equiv), ethyl cyanoacetate (5.6 mL, 0.053 Mol., 3.0equiv ) as a brown 
solid (2.82 g, 84%); Rf (MeOH : DCM, 0.5 : 9.5) 0.26; 1H NMR (400 
MHz, Acetonitrile-d3) δ 12.9 (s, 1H, H5), 7.6 (d, J = 1.9 Hz, 1H, H4), 7.5 
(d, J = 8.6 Hz, 1H, H2), 7.2 (dd, J = 8.6, 1.9 Hz, 1H, H3), 4.17 (s, 2H, H1). 
13C NMR (101 MHz, Acetonitrile-d3) δ 145.9, 127.8, 122.9 (3C), 115.5, 18.7 (3C). HPLC-MS 
(ACI/ ESI): Purity =86%, tR = 0.74 min, m/z [M-H]
- = 190.0. 
 
2-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)acetonitrile, 1.3a 
Compound 1.3a was obtained from 4,5-dichlorobenzene-1,2-diamine (1.3) (0.088 g, 0.50 
mmol, 1.0 equiv) and ethyl cyanoacetate (0.170 g, 1.50 mmol, 3.0 equiv) 
as brown solid (0.073 g, 65 %); Rf (MeOH : DCM, 0.5 : 9.5) 0.30; 1H 
NMR (400 MHz, DMSO-d6) δ 12.9 (s, 1H, H4), 7.9 (s, 2H, H2, 3), 4.4 (s, 
2H, H1); 13C NMR (101 MHz, DMSO-d6) δ 148.4, 145.2, 143.4, 120.4, 
116.7, 116.0, 113.5, 110.2, 18.9; HPLC-MS (APCI/ESI): Purity = 90%, tR 
= 4.01 min, m/z [M+H]+ = 226.0. 
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2-(5,6-difluoro-1H-indol-2-yl)acetonitrile, 1.4a  
Compound 1.4a was obtained from 4,5-difluorobenzene-1,2-diamine (1.4) (3.48 g, 23.84 
mmol, 1.0 equiv ) and ethyl cyanoacetate (8.09 g, 71.49 mmol ml 3.0 equiv 
) as a deep red solid (2.98 g, 65%); Rf (MeOH : DCM, 1 : 9) 0.32; 1H NMR 
(300 MHz, DMSO-d6) δ 12.8 (s, 1H, H4), 7.6 (s, 2H, H2, 3), 4.4 (s, 2H, H1). 
13C NMR (101 MHz, DMSO-d6) δ 148.4, 147.4, 146.0, 116.8, 106.5 (2C), 
100.1 (2C), 18.9. HPLC-MS (ACI/ ESI): Purity = 90%, tR = 2.24 min, m/z 
[M-H]- = 192.1. 
 
2-(7-Chloro-1H-benzo[d]imidazole-2-yl)acetonitrile, 2.1.2a 
Compound 2.1.2a was obtained from 3-nitro-1,2-diaminobenzene (2.1) (5.0 g, 32.65 mol, 1.0 
equiv) and ethyl cyanoacetate (11.1 g, 97.45 mmol 3.0 equiv) as a 
yellowish solid (5.4 g, 82%); Rf (EtOAc : Hexane, 7 : 3) 0.43; 1H NMR 
(300 MHz, DMSO-d6) δ 8.2 (dd, J = 8.2, 1.0 Hz, 1H, H4), 8.1 (dd, J = 8.0, 
1.0 Hz, 1H, H2), 7.4 (t, J = 8.1 Hz, 1H, H3), 4.3 (s, 2H, H1); 13C NMR (151 
MHz, DMSO-d6) δ 149.2, 146.3, 133.4, 128.9, 127.3, 122.0, 119.5, 116.5, 
18.8. HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.06 min, m/z [M-H]
- = 200.9. 
 
2-(7-Chloro-1H-benzo[d]imidazole-2-yl)acetonitrile, 2.2a 
Compound 2.2a was obtained from 3-chloro-1,2-diaminobenzene (2.2) (2.6 g, 18.23 mol, 
1.0equiv ) and ethyl cyanoacetate (6.20 g, 54.70 mmol, 3.0 equiv) as a 
brown solid (2.8 g, 80%); Rf (EtOAc : Hexane, 7 : 3) 0.33; 1H NMR (300 
MHz, DMSO-d6) δ 13.0 (s, 1 H, H5), 7.5 (dd, J = 7.5, 1.1 Hz, 1H, H4), 7.3 
(dd, J = 7.8, 1.1 Hz, 1H, H2), 7.2 (t, J = 7.8 Hz, 1H, H3), 4.4 (s, 2H, H1). 
13C NMR (151 MHz, DMSO-d6) δ 149.2, 146.3, 133.4, 128.9, 127.3, 
122.0, 119.5, 116.5, 18.8. HPLC-MS (ACI/ ESI): Purity = 96%, tR = 1.71 min, m/z [M+H]
+ = 
191.9. 
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6.3.2 General procedure for the synthesis of hydroxy intermediates compounds (1.1b – 
2.4b) 
An appropriate benzimidazole acetonitrile (1.0 equiv), a suitably substituted β-keto ester (1.2 
equiv) and ammonium acetate (2.0 equiv) were stirred under reflux conditions at 145 °C for 2 
hours. Following completion of the reaction, the mixture was cooled to 70°C, followed by 
addition of 10 mL acetonitrile and stirring reaction product mixture stirred for a further 10 
minutes at that temperature. The treated reaction mixture was cooled to room temperature. The 
cooled reaction mixture was filtered, the resulting solid product was washed with cold 
acetonitrile (2-3 mL x 3), dry ether (3-5mL x 3) and finally, the product was dried at ambient 
conditions. The product was used in subsequent step without further purification. 
1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 1.1b 
Compound 1.1b was obtained from 1.1a (1.25 g, 7.95 mmol, 1.0 equiv) and ethyl 4,4,4-
trifluoro-3-oxobutanoate (1.76 g, 9.54 mmol, 1.2 equiv) and ammonium 
acetate (1.23 g, 15.90 mmol, 2.0 equiv) as a brown solid (0.88 g, 40%); 
Rf (EtOAc : Hexane, 3 : 7) 0.22; 1H NMR (300 MHz, DMSO-d6) δ 8.6 
(dd, J = 7.8, 1.6 Hz, 1H, H5), 7.6 (dd, J = 7.8, 1.6 Hz, 1H, H2), 7.6 – 7.5 
(dt, J = 7.8, 1.6 Hz, 1H, H3), 7.3 (dt, J = 7.7, 1.7 Hz, 1H, H4), 6.23 (s, 
1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 158.3 (3C), 148.3, 132.4, 127.8, 123.5, 116.8, 
114.6, 112.3, 111.2, 103.3 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 2.57 min, m/z 
[M+H]+ = 278.0. 
8-chloro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
1.2b 
Compound 1.2b was obtained from 1.2a (1.90 g, 9.92 mmol, 1.0 equiv) and ethyl 4,4,4-
trifluoro-3-oxobutanoate (2.19 g, 11.90 mmol, 1.2 Eq) as yellow solid 
(2.16 g, 70%); Rf (MeOH : DCM, 0.5 : 9.5) 0.20. 1H NMR (300 MHz, 
DMSO-d6) δ 8.5 (d, J = 2.2 Hz, 1H, H4), 7.7 (d, J = 8.6 Hz, 1H, H2), 7.5 
(dd, J = 8.4, 2.2 Hz, 1H, H3), 6.4 (s, 1H, H1). 13C NMR (101 MHz, 
DMSO-d6) δ 158.0, 127.7, 123.4 (2C), 117.9 (2C), 116.4 (2C), 114.2, 
112.4 (2C), 103.1 (2C). HPLC-MS (ACI/ ESI): Purity = 96%, tR = 2.95 min, m/z [M+H]
+ = 
309.9. 
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7,8-dichloro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile: 1.3b 
Compound 1.3b was obtained from 1.3a (0.113 g, 0.50 mmol, 1.0equiv) and ethyl 4,4,4-
trifluoro-3-oxobutanoate (0.110 g, 0.60 mmol, 1.2 equiv) and as grey 
solid (0.142 g, 82 %) Rf (EtOAc : Hexane 7 : 3) 0.36; 1H NMR (300 
MHz, DMSO-d6) δ 8.7 (s, 1H, H2), 7.7 (s, 1H, H1), 6.5 (s, 2H, H2, 3). 
13C NMR (101 MHz, DMSO) δ 170.9, 168.0, 158.0, 155.2, 145.2, 
130.2, 128.5, 124.0, 121.3, 116.7, 118.0, 117.7, 95.4. HPLC-MS 
(APCI/ESI): Purity = 96%, tR = 2.98 min, m/z [M+H]
 + = 346.0. 
 
7,8-difluoro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
1.4b. 
Compound 1.4b was obtained from 1.4a (2.86 g, 14.80 mmol, 1.0 equiv), ethyl 4,4,4-trifluoro-
3-oxobutanoate (3.26 g, 17.8 mmol, 1.2 equiv) as a brown solid (1.76 
g, 86%); Rf (EtOAc : Hexane, 7 : 3) 0.25; 1H NMR (300 MHz, 
DMSO-d6) δ 8.5 (dd, J = 10.3, 7.4 Hz, 1H, H2), 7.7 (dd, J = 10.0, 7.0 
Hz, 1H, H3), 6.4 (s, 1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 157.8, 
149.4, 129.7, 123.7, 114.7, 105.6 (2C), 102.7 (3C), 101.5 (3C). HPLC-
MS (ACI/ ESI): Purity = 99%, tR = 2.69 min, m/z [M-H]
- = 313.03. 
 
1-hydroxy-9-Nitro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
2.1.2b 
Compound 2.1.2b was obtained 2.1.2a (5.0 g, 25 mmol, 1.0 equiv) and ethyl 4,4,4-trifluoro-3-
oxobutanoate  (0.29 g, 4.6 ml 1.2 equiv) and ammonium acetate (3.9 
mg, 50 mmol, 2.0 equiv)  as red solid (3.4 g, 42%); Rf (EtOAc : Hexane, 
8 : 2) 0.25; 1H NMR (300 MHz, DMSO-d6) δ 9.0 (d, J = 8.0 Hz, 1H, 
H4), 8.3 (d, J = 8.3 Hz, 1H, H2), 7.5 (t, J = 8.2 Hz, 1H, H3), 6.4 (s, 1H, 
H1); 13C NMR (151 MHz, DMSO-d6) δ 158.5, 151.8, 139.7, 134.5, 
132.3, 123.7, 122.3 (2C), 121.9, 121.5, 114.9, 102.2, 67.4. HPLC-MS (ACI/ ESI): purity = 
99%, tR = 1.23 min, m/z [M+H]
+ = 323.0. 
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9-chloro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
2.2b 
Compound 2.2b was obtained from 2.2a (1.1 g, 5.6 mmol, 1.0 equiv), ethyl 4,4,4-trifluoro-3-
oxobutanoate (1.2 g, 6.8 mmol, 1.2 Eq) and ammonium acetate (0.97, 
12.5 mmol, 2.0 equiv) as a beigy solid (1.4 g, 80%); Rf (EtOAc : 
Hexane, 7 : 3) 0.32; 1H NMR (300 MHz, Chloroform-d3) δ 8.6 (dd, J = 
8.8, 1.2 Hz, 1H, H4), 7.8 (dd, J = 7.8, 1.2 Hz, 1H, H2), 7.5 (t, J = 7.9 
Hz, 1H, H3), 7.3 (s, 1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 166.0, 
125.8 (2C), 122.3 (2C), 121.6, 121.4 (2C), 119.7, 118.3, 117.0, 96.6 (2C); HPLC-MS (ACI/ 
ESI): Purity = 99%, tR = 2.63 min, m/z [M+H]
+ = 309.7. 
 
8-chloro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile, 2.4b 
Compound 2.4b was obtained from 1.2a (1.47 g, 7.67 mmol, 1.0 equiv) and ethyl 3-oxo-3-(4-
(trifluoromethyl)phenyl)propanoate (2.39 g, 9.20 mmol, 1.2 
equiv) as brown solid (1.72 g, 58%; Rf (EtOAc : Hexane, 7 
: 10) 0.27. 1H NMR (600 MHz, DMSO-d6) δ 8.6 (d, J = 2.0 
Hz, 1H, H4), 7.9 (d, J = 8.1 Hz, 2H, H6), 7.9 (d, J = 8.0 Hz, 
2H, H5), 7.6 (d, J = 8.4 Hz, 1H, H2), 7.4 (dd, J = 8.3, 2.1 Hz, 
1H, H3), 6.1 (s, 1H, H1). 13C NMR (151 MHz, DMSO-d6) δ 158.2, 151.8, 148.5, 141.4, 131.6, 
129.5 (3C), 127.2, 126.0 (3C), 123.2, 117.9, 116.4, 113.4, 111.8, 105.7, 105.5. HPLC-MS 
(ACI/ ESI): Purity = 98%, tR = 3.02 min, m/z [M+H]
+ = 388.0.  
 
6.3.3 General procedure for the synthesis of the chlorinated intermediates (1.1c – 2.4c) 
A mixture of an appropriate hydroxy intermediate compound (1.0 equiv) and phosphoryl 
oxychloride (POCl3: 20.0 equiv) was stirred at 130°C for 3 hours. On completion of the 
reaction, the reaction mixture was cooled to room temperature. The excess POCl3 was removed 
in vacuo. Ice cooled water (20 mL) was added to the treated reaction mixture with consistent 
stirring for 15 minutes. The mixture was neutralized using sodium bicarbonate, crude product 
filtered off, washed with water and dried at ambient conditions. The product was used in the 
subsequent step without further purification. 
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1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 1.1c  
Compound 1.1c was obtained from 1.1b (0.94 g, 3.39 mmol, 1.0 Eq) and  POCl3 (10.4 g, 67.82 
mmol, 20 Eq) as a yelow solid (0.812 g, 81%); Rf (EtOAc : Hexane, 1 
: 9) 0.35; 1H NMR (300 MHz, chloroform-d) δ 8.7 (dd, J = 7.8, 1.2 
Hz, 1H, H2), 8.6 (dd, J = 7.8, 1.2 Hz, 1H, H5), 7.8 (dt, J = 7.8, 1.3 Hz, 
1H, H3), 7.6 (dt, J = 8.1, 1.2 Hz, 1H, H4), 7.2 (s, 1H, H1). 13C NMR 
(101 MHz, DMSO-d6) δ 158.1, 148.0, 132.3, 127.8 (2C), 123.6 (2C), 
116.8 (2C), 112.3 (2C), 103.3 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.25 min, m/z 
[M+H]+ = 296.0. 
 
1,8-dichloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 1.3c 
Compound 1.3c was obtained from 1.3b (1.2 g, 3.9 mmol, 1.0 equiv) and POCl3 (1.3 g, 79 
mmol, 1.5 equiv) as yellow solid (0.7 g, 85%); Rf (EtOAc : Hexane, 
1.5 : 8.5) 0.21. 1H NMR (600 MHz, DMSO-d6) δ 8.7 (d, J = 1.1 Hz, 
1H, H4), 8.2 (d, J = 8.6 Hz, 1H, H2), 7.9 (s, 1H, H1), 7.7 – 7.6 (dd, J = 
9.1, 1.1 Hz 1H, H3). 13C NMR (101 MHz, DMSO-d6) δ 157.8, 148.6, 
132.0, 127.9, 123.6, 117.9, 116.2, 114.3, 113.6, 112.0, 103.7 (3C). 
HPLC-MS (ACI/ ESI): Purity = 91%, tR = 1.13 min, m/z [M-H]
- = 329.90. 
 
1,7,8-trichloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 1.3c  
Compound 1.3c was obtained from 1.3b (0.080 g, 0.23 mmol, 1.0 equiv) and POCl3 (0.71 g, 
4.6 mmol, 20.0 equiv) as yellow solid (0.080 g, 95 %) Rf (EtOAc : 
Hexane 1 : 9) 0.25; 1H NMR (300 MHz, DMSO-d6) δ 8.86 (s, 1H, H3), 
8.4 (s, 1H, H1), 7.9 (s, 1H, H2); 13C NMR (101 MHz, DMSO) δ 158.3 
(2C), 150.2 (4C), 139.2, 132.7, 124.3 (2C), 120.3, 117.4. HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 5.04 min, m/z [M-H]
- = 361.93. 
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1-chloro-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
1.4c 
Compound 1.4c was obtained from 1.4b (0.93 g, 3.0 mmol, 1.0 equiv) and phosphoryl 
oxychloride (9.11 g, 59.3 mmol, 20 equiv) as yellow solid (0.93 g, 
95%); Rf (EtOAc : Hexane, 1.5 : 8.5) 0.17; 1H NMR (300 MHz, 
DMSO-d6) δ 8.8 (dd, J = 11.0, 7.4 Hz, 1H, H2), 8.2 (dd, J = 10.7, 7.6 
Hz, 1H, H3), 7.9 (s, 1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 157.7, 
136.8, 112.4, 108.3 (2C), 107.8, 107.6, 105.4, 105.1, 103.0 (2C), 
101.5, 101.3. HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.80 min, m/z [M+H]
+ = 332.0. 
 
1-chloro-9-nitro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 2.1.2c 
Compound 2.1.2c was obtained from 2.1.2b (0.40 g, 1.4 mmol, 1.0 equiv) and POCl3 (2.6 g, 
28.0 mmol, 20.0 equiv) as a yellow solid (0.37 g, 78%); Rf (MeOH : 
DCM, 0.5 : 9.5) 0.25. 1H NMR (400 MHz, DMSO-d6) δ 7.8 (d, J = 8.1 
Hz, 1H, H4), 7.1 (t, J = 7.9 Hz, 1H, H3), 6.8 (d, J = 7.9 Hz, 1H, H2), 
6.2 (s, 1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 158.7, 148.0, 13.0, 
129.3, 123.7 (2C), 115.8, 111.1 (2C), 104.7 (2C), 100.3 (2C). HPLC-
MS (ACI/ ESI): Purity = 96%, tR = 1.04 min, m/z [M+H]
+ = 341.0. 
 
9-chloro-1((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo[4,5]-imidazo-
[1,2-a] pyridine-4-carbonitrile, 2.2c 
 Compound 2.2c was obtained from 2.2b, (0.85 g, 5.2 mmol, 1.0 equiv), and 4-
(trifluoromethoxy)aniline (0.92 g, 5.2 mmol, 2.0 equiv) as a yellow 
solid (0.80 g, 94%); Rf (DCM) 0.25; 1H NMR (300 MHz, chloroform-
d3) δ 8.6 (dd, J = 8.7, 0.9 Hz, 1H, H2), 7.8 (dd, J = 7.8, 0.9 Hz, 1H, 
H4), 7.5 (t, J = 8.7 Hz, 1H, H3), 7.3 (s, 1H, H1). 13C NMR (101 MHz, 
DMSO-d6) δ 158.9, 148.6, 133.2 (2C), 127.9, 123.6, 119.6, 116.2, 
114.3, 115.6, 111.0, 104.7 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 1.19 min, m/z 
[M+H]+ = 330.1. 
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1,8-dichloro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 
2.4c 
Compound 2.4c was obtained from 2.4b (1.30 g, 6.78 mmol, 1.0 equiv) and POCL3 (0.100 g, 
67.1 mmol, 20 equiv) as yellow solid (0.79 g, 58%); Rf 
(EtOAc : Hexane, 3 : 7) 0.22. 1H NMR (600 MHz, DMSO-
d6) δ 8.7 (d, J = 1.9 Hz, 1H, H4), 8.0 (d, J = 8.2 Hz, 2H, H6), 
8.0 (d, J = 8.3 Hz, 2H, H5), 8.0 (d, J = 8.7 Hz, 1H, H2), 7.7 
(dd, J = 8.8, 2.0 Hz, 1H, H3), 7.5 (s, 1H, H1). 13C NMR (151 
MHz, DMSO-d6) δ 148.8, 139.4, 135.1, 130.3 (3C), 127.3, 127.9, 126.3 (3C), 123.2, 121.6, 
119.5, 117.6, 115.8, 114.9, 113.4 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.08 min, 
m/z [M+H]+ = 406.0. 
6.3.4 General procedure for the aromatic nucleophilic amine coupling: synthesis of the 
final compounds 1-34 
A mixture of a chloro intermediate (1.1c – 2.4c: 1.0 equiv), an appropriate amine (2.0 equiv) 
and triethylamine (2.0 equiv) in tetrahydrofuran (THF) (2 mL/ 100mg sample) was reacted 
with continuous stirring in a microwave set at 150W, 80°C for 25 minutes. The cooled reaction 
mixture was transferred to a round bottom flask and concentrated in vacuo. The product was 
recrystallised in a minimum volume of acetone (or ethanol). Where purification was required, 
a column with a 25-30% ethyl acetate (EtOAc) in hexane eluent system was used to purify the 
compound. The appropriate fractions were reconstituted, concentrated and dried in vacuo.  
(R)-1-((1-cyclohexylethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile, 1 
Compound 1 was obtained from 1.1c (0.124 g, 0.42 mmol, 1.0 equiv) and S-1-cyclohexylethan-
1-amine (0.107 g, 0.84 mmol, 2.0 equiv) as yellow solid (0.109 g, 
67%), m.p 182 - 184 °C; Rf (EtOAc : Hexane, 3 : 7) 0.33. 1H NMR 
(400 MHz, DMSO-d6) δ 8.4 (dd, J = 7.8, 1.4 Hz, 1H, H5), 7.9 (dd, J 
= 7.8, 1.4 Hz, 1H, H2), 7.6 (m, 2H, H3, 6), 7.5 (dt, J = 7.8, 1.4 Hz, 1H, 
H4), 6.5 (s, 1H, H1), 3.9 (m, 1H, H8), 2.0 – 1.6 (m, 6H, H9, 10a, 11a, 12a), 
1.3 (d, J = 6.4 Hz, 3H, H7), 1.3 – 1.0 (m, 5H, H10e, 11e, 12e). 13C NMR 
(101 MHz, DMSO-d6) δ 150.2, 145.5, 128.4, 127.0 (2C), 121.5, 119.3, 115.9, 86.6, 55.2, 42.6, 
29.9, 29.2 (2C), 26.4 (2C), 26.3 (3C), 17.6 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 
3.27 min, m/z [M+H]+ = 387.1. 
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(S)-1-((1-cyclohexylethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile, 2 
Compound 2 was obtained from 1.1c (0.124 g, 0.42 mmol, 1.0 equiv) and R-1-cyclohexylethan-
1-amine (0.107 g, 0.84 mmol, 2.0 equiv) as yellow solid (0.117 g, 
72%), m.p 182 - 184 °C; Rf (EtOAc : Hexane, 3 : 7) 0.30. 1H NMR 
(400 MHz, DMSO-d6) δ 8.4 (d, J = 7.8, 1.4 Hz, 1H, H5), 7.9 (dd, J = 
7.8, 1.4 Hz, 1H, H2), 7.6 (m, 2H, H3, 6), 7.5 (dt, J = 7.8, 1.4 Hz, 1H, 
H4), 6.5 (s, 1H, H1), 3.9 (m, 1H, H8), 2.0 – 1.6 (m, 6H, H9, 10a, 11a, 12a), 
1.3 (d, J = 6.4 Hz, 3H, H7), 1.3 – 1.0 (m, 5H, H10e, 11e 12e). 13C NMR 
(101 MHz, DMSO-d6) δ 150.2, 145.5, 128.4, 127.0 (2C), 121.5 (2C), 119.3, 115.9, 86.6, 55.2, 
42.6, 29.6 (3C), 26.3 (4C), 17.6 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.47 min, m/z 
[M+H]+ = 387.1. 
 
Methyl (R)-2-((4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)amino)-2-
phenylacetate, 3 
Compound 3 was obtained from 1.1c (1.00 g, 3.38 mmol, 1.0 equiv) and methyl (R)-2-amino-
2-phenylacetate (1.36 g, 6.76 mmol, 2.0 equiv) as yellow solid 
(0.520g, 36%), m.p 224 - 226 °C; Rf (MeOH : DCM, 0.2 : 9.8) 0.21. 
1H NMR (600 MHz, DMSO-d6) δ 8.7 (dd, J = 8.4, 1.3 Hz, 1H, H2), 
7.9 (dd, J = 8.2, 1.3 Hz, 1H, H5), 7.7 – 7.6 (m, 3H, H4, 8), 7.6 (dt, J = 
7.9, 1.3 Hz, 1H, H3), 7.4 (t, J = 7.8 Hz, 2H, H9), 7.4 (m, 1H, H10), 6.3 
(s, 1H, H1), 5.9 (s, 1H, H7), 3.8 (s, 3H, H6). 13C NMR (151 MHz, 
DMSO-d6) δ 171.2, 149.0, 148.0, 136.5 (2C), 129.3 (3C), 128.9, 128.8, 128.1 (3C), 127.1 (2C), 
122.4 (2C), 116.3 (2C), 114.4, 53.4 (2C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 3.36 min, 
m/z [M+H]+ = 425.1. 
(R)-2-((4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)amino)-2-phenyl-
acetic acid, 41 
A solution of compound 3 (0.45 g, 1.06 mmol, 1.0 equiv) in methanol (1.0 mL) was heated to 
30 °C with continuous stirring. Potassium hydroxide (KOH: 0.12 mg, 2.12 mmol, 2.0 equiv) 
was added to the treated solution at that temperature and the reaction mixture was stirred for 
10 minutes. The reaction mixture was cooled to room temperature, diluted with deionised water 
(10 mL) after which it was acidified using hydrochloric acid (HCl: 0.12 g, 3.20 mmol, 3.0 
equiv). The organic residues were taken-up in ethyl EtOAc after which the aqueous phase was 
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removed using a separatory funnel. The EtOAc layer was washed with deionised water (20 mL 
x 3), brine (10 mL x 3), dried over Na2SO4 and was finally concentrated in vacuo. Compound 
4 was obtained as yellow solid (0.422 g, 97%), m.p 244 – 246 °C; Rf 
(MeOH : DCM, 1 : 9) 0.17. 1H NMR (600 MHz, DMSO-d6) δ 8.6 (dd, 
J = 8.2, 1.6 Hz, 1H, H2), 8.0 (dd, J = 8.2, 1.7 Hz, 1H, H5), 7.8 – 7.7 
(m, 3H, H4, 7), 7.6 (dt, J = 7.8, 1.7 Hz, 1H, H3), 7.4 (t, J = 7.8 Hz, 2H, 
H8), 7.4 (m, 1H, H9), 6.2 (s, 1H, H1), 5.8 (s, 1H, H6). 13C NMR (151 
MHz, DMSO-d6) δ 171.6, 148.6, 136.8, 129.3 (3C), 128.9, 128.6, 
128.0 (3C), 127.2 (2C), 122.4, 119.1, 115.5 (2C), 114.2, 88.7, 60.8 
(2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 3.06 min, m/z [M+H]
+ = 411.0. 
 
1-((1-(4-fluorophenyl)ethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-3-
carbonitrile, 6 
Compound 6 was obtained from 1.1c (0.087 g, 0.31 mmol, 1.0 equiv) and 1-(4-
fluorophenyl)ethan-1-amine (0.087 g, 0.63 mmol, 2.0 Eq) as yellow 
solid (0.079 g, 64%), m.p 181 – 183 °C; Rf (EtOAc : Hexane, 3 : 7) 
0.26. 1H NMR (400 MHz, DMSO-d6) δ 8.6 (dd, J = 7.8, 2.1 Hz, 1H, 
H2), 8.3 (s, 1H, H6), 7.9 (dd, J = 7.8, 2.0 Hz, 1H, H5), 7.7 (dt, J = 7.6, 
2.1 Hz, 1H, H4), 7.6 (dd, J = 8.3, 5.6 Hz, 2H, H10), 7.5 (dt, J = 7.8, 2.1 
Hz, 1H, H3), 7.5 (d, J = 8.5 Hz, 2H, H9), 6.2 (s, 1H, H1), 5.3 (q, J = 
6.9 Hz, 1H, H8), 1.8 (d, J = 6.7 Hz, 3H, H7). 13C NMR (151 MHz, DMSO-d6) δ 149.6, 145.6, 
139.2, 128.7 (3C), 127.1, 121.8 (2C), 119.5, 116.3 (2C), 115.8 (3C), 87.8 (2C), 53.6 (2C), 23.4 
(2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.05 min, m/z [M+H]
+ = 399.1. 
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(R)-1-((1-(4-fluorophenyl)ethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-3-carbonitrile, 7 
Compound 7 was obtained from 1.1c (0.100 g, 0.36 mmol, 1.0 equiv) and R-1-(4-
fluorophenyl)ethan-1-amine (0.100 g, 0.72 mmol, 2.0 Eq) as yellow 
solid (0.092 g, 64%), m.p 175 – 177 °C; Rf (MeOH : DCM, 1 : 9) 0.37. 
1H NMR (600 MHz, DMSO-d6) δ 8.6 (dd, J = 7.8, 2.1 Hz, 1H, H2), 8.0 
(s, 1H, H6), 7.9 (dd, J = 7.7, 1.8 Hz, 1H, H5), 7.7 (dd, J = 7.7, 5.4 Hz, 
2H, H10), 7.7 (dd, J = 8.4, 0.9 Hz, 2H, H9) 7.6 (dt, J = 7.8, 1.7 Hz, 1H, 
H3), 7.5 (dt, J = 7.8, 1.7 Hz, 1H, H4), 6.2 (s, 1H, H1), 5.2 (q, J = 6.7 
Hz, 1H, H8), 1.8 (d, J = 6.7 Hz, 3H, H7). 13C NMR (151 MHz, DMSO-d6) δ 149.6, 145.6, 139.2, 
128.7 (3C), 127.1, 121.8 (2C), 119.4, 116.3 (2C), 115.8 (3C), 87.8 (2C), 53.6 (2C), 23.4 (2C). 
HPLC-MS (ACI/ ESI): Purity = 98%, tR = 2.95 min, m/z [M+H]
+ = 399.1.  
 
(S)-1-((1-(4-fluorophenyl)ethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-3-carbonitrile, 8 
Compound 8 was obtained from 1.1c (0.100 g, 0.36 mmol, 1.0 equiv) and (S)-1-(4-
fluorophenyl)ethan-1-amine (0.100 g, 0.72 mmol, 2.0 equiv) as yellow 
solid (0.047 g, 33%), m.p 182 – 184 °C; Rf (EtOAc : Hexane, 3 : 7) 0.21. 
1H NMR (600 MHz, DMSO-d6) δ 8.6 (dd, J = 7.7, 1.7 Hz, 1H, H2), 8.1 
(s, 1H, H6), 7.9 (dd, J = 7.8, 1.8 Hz, 1H, H5), 7.7 (dd, J = 7.7, 5.4 Hz, 
2H, H10), 7.7 (dd, J = 8.5, 0.9 Hz, 2H, H9), 7.6 (dt, J = 7.8, 1.7 Hz, 1H, 
H3), 7.5 (dt, J = 7.9, 1.7 Hz, 1H, H4), 6.2 (s, 1H, H1), 5.2 (q, J = 5.9 Hz, 
1H, H8), 1.8 (d, J = 6.8 Hz, 3H, H7). 13C NMR (151 MHz, DMSO-d6) δ 149.6, 145.6, 139.2, 
128.7 (3C), 127.1, 121.8 (2C), 119.4, 116.4 (2C), 115.8 (3C), 87.8 (2C), 53.6 (2C), 23.4 (2C). 
HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.90 min, m/z [M+H]
+ = 399.1. 
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1-((1-(4-chlorophenyl)ethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-3-
carbonitrile, 9 
Compound 9 was obtained from 1.1c (0.14 g, 0.42 mmol, 1.0 Eq) and 1-(4-chlorophenyl)ethan-
1-amine (0.163 g, 0.85 mmol, 2.0 Eq) as yellow solid (0.119 g, 68%), 
m.p 185 – 187 °C; Rf (EtOAc : Hexane, 1 : 9) 0.27. 1H NMR (400 MHz, 
DMSO-d6) δ 8.6 (dd, J = 8.5, 1.9 Hz, 1H, H2), 8.3 (d, J = 6.4 Hz, 1H, 
H6), 7.9 (dd, J = 8.2, 1.7 Hz, 1H, H5), 7.6 (m, 3H, H4, 10), 7.5 (dt, J = 
7.8, 1.8 Hz, 1H, H3), 7.4 (d, J = 8.5 Hz, 2H, H9), 6.2 (s, 1H, H1), 5.2 (m, 
1H, H8), 1.8 (d, J = 6.7 Hz, 3H, H7). 13C NMR (101 MHz, DMSO-d6) δ 149.6, 148.2, 145.4, 
142.1 (3C), 132.4 (3C), 127.2 (2C), 121.7, 119.4 (2C), 116.5 (2C), 87.8, 53.4 (2C), 23.3 (2C). 
HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.97 min, m/z [M+H]
+ = 415.1. 
 
1-((2-hydroxyethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile, 1.1d 
Compound 1.1d was obtained from 1.1c (0.200 g, 0.70 mmol, 1.0 equiv) and 2-aminoethan-1-
ol (0.083 g, 1.35 mmol, 2.0 equiv) as yellow solid (0.147 g, 68%); Rf 
(MeOH : DCM, 0.1 : 9.9) 0.47. 1H NMR (600 MHz, DMSO-d6) δ 8.6 
(dd, J = 8.1, 1.5 Hz, 1H, H2), 7.8 (dd, J = 8.0, 1.6 Hz, 1H, H5), 7.6 (dt, 
J = 8.1, 1.5 Hz, 1H, H3), 7.4 (dt, J = 8.2, 1.5 Hz, 1H, H4), 6.4 (s, 1H, 
H1), 3.8 (t, J = 5.8 Hz, 2H, H7), 3.7 (t, J = 5.9 Hz, 2H, H8). 13C NMR 
(151 MHz, DMSO-d6) δ 150.7, 126.4 (2C), 121.1 (2C), 118.7 (2C), 
115.8 (2C), 86.6 (2C), 60.3 (2C), 47.3 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 2.97 
min, m/z [M+H]+ = 321.1. 
 
6.3.5 Synthesis of 1-((2-bromoethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 1.1e1 
A mixture of 1.1d (0.300 g, 0.94 mmol, 1.0 Eq) and triphenylphosphine (PPh3) (0.370 g, 1.41 
mmol, 1.5 Eq) in DMF (1.0 mL) was cooled to 0 °C with continuous stirring. 
Tetrabromomethane (CBr4) (0.470 g, 1.41 mmol, 1.5 Eq) was added to the reaction mixture at 
that temperature. The treated reaction mixture was stirred at room temperature for 1.5 hours in 
a sealed tube. The product was purified by column chromatography using 15% EtOAc in 
hexane. 
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Compound 1.1e was obtained as yellow solid (0.231 g, 64%); Rf (MeOH : DCM, 0.1 : 9.9) 
0.47. 1H NMR (600 MHz, DMSO-d6) δ 8.6 (dd, J = 8.3, 1.5 Hz, 1H, 
H5), 7.9 (dd, J = 8.1, 1.5 Hz, 1H, H2), 7.6 (dt, J = 8.2, 1.4 Hz, 1H, H3), 
7.5 (dt, J = 8.1, 1.5 Hz, 1H, H4), 6.6 (s, 1H, H1), 4.1 (t, J = 6.4 Hz, 2H, 
H6), 3.9 (t, J = 6.4 Hz, 2H, H7). 13C NMR (151 MHz, DMSO-d6) δ 
143.9, 134.5, 130.7, 128.1, 127.4, 122.1 (2C), 118.6 (2C), 115.8, 
114.3, 87.9 (2C), 45.6, 31.6. HPLC-MS (ACI/ ESI): Purity = 85%, tR 
= 3.29 min, m/z [M+H]+ = 383.0/ 385.0. 
 
6.3.6 General procedure for the synthesis of the two-carbon spaced (2-C between the 
PBI core scaffold-linked N and the -methylene carbon-linked N of the substituent 
benzylamine moiety) analogues- 10 and 11 
A mixture of 1.1e (1.0 equiv), the appropriate amine (1.2 equiv) and anhydrous potassium 
carbonate (K2CO3: 2.0 equiv) in acetonitrile (1.0 mL per 100 mg of the sample) were heated to 
79 °C with continuous stirring for 2.0 hours. The reaction mixture was cooled to room 
temperature, diluted with EtOAc and washed with deionized water (20 mL x 3), dried with 
brine and finally over Na2SO4. The organic layer was concentrated and dried in vacuo.  The 
product was purified by trituration in DCM. 
 
(S)-1-((2-((1-(4-fluorophenyl)ethyl)amino)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 10 
Compound 10 was obtained from 1.1d (0.100 g, 0.26 mmol, 1.0 equiv) and R-1-(4-
fluorophenyl)ethan-1-amine (0.035 g, 0.25 mmol, 1.2 equiv) as 
yellow solid (0.054 g, 58%); Rf (MeOH : DCM, 0.2 : 9.8) 0.28. 1H 
NMR (400 MHz, Methanol-d4) δ 8.4 (dd, J = 8.3, 1.8  Hz, 1H, H2), 
7.9 (dd, J = 8.3, 1.8 Hz, 1H, H5), 7.6 (dt, J = 8.2, 1.8  Hz, 1H, H3), 
7.5 (dt, J = 8.3, 1.8 Hz, 1H, H4), 7.6 (d, J = 6.8 Hz, 1H, H6), 7.7 (dd, 
J = 8.7, 5.5 Hz, 2H, H13), 7.2 (dd, J = 8.5, 5.6 Hz, 2H, H12), 6.3 (s, 
1H, H1), 4.5 (m, 1H, H11), 3.9 (s, 1H, H9), 3.3 (t, J = 5.7 Hz, 2H, 
H7), 2.0 (t, J = 5.9 Hz, 2H, H8), 1.7 (d, J = 6.9 Hz, 3H, H10). 13C NMR (101 MHz, Methanol-
d4) δ 132.5 (5C), 131.7 (5C), 129.7 (2C), 144.5 (4C), 143.2 (3C), 143.1, 142.6, 22.3 (2C). 
HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.90 min, m/z [M+H]
+ = 442.1. 
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(S)-1-((2-((1-(p-tolyl)ethyl)amino)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 11 
Compound 11 was obtained from 1.1d (0.120 g, 0.31 mmol, 1.0 equiv) and (R)-1-(p-
tolyl)ethan-1-amine (0.063 g, 0.37 mmol, 1.2 equiv) as yellow solid 
(0.087 g, 64%); Rf (MeOH : DCM, 0.1 : 9.9) 0.21. 1H NMR (400 
MHz, Methanol-d4) δ 8.1 (dd, J = 7.6, 1.9 Hz, 1H, H2), 7.6 (dd, J = 
8.3, 1.8 Hz, 1H, H5), 7.6 (dt, J = 8.2, 1.9 Hz, 1H, H3), 7.5 (dt, J = 
8.5, 1.9 Hz, 1H, H4), 7.6 (s, 1H, H6), 7.4 – 7.3 (d, J = 7.6 Hz, 2H, 
H12), 7.1 (d, J = 7.7 Hz, 2H, H13), 6.3 (s, 1H, H1), 4.5 (q, J = 6.9 
Hz, 1H, H11), 3.9 (s, 1H, H9), 3.3 (t, J = 5.7 Hz, 2H, H7), 2.3 (s, 3H, 
H14), 2.0 (t, J = 5.8 Hz, 2H, H8), 1.7 (d, J = 6.8 Hz, 3H, H10). 13C NMR (101 MHz, Methanol-
d4) δ 132.4 (4C), 131.7 (7C), 129.7, 128.7 (8C), 127.5, 127.0, 122.2, 18.1. HPLC-MS (ACI/ 
ESI): Purity = 99.40%, tR = 2.95 min, m/z [M+H]
+ = 438.1. 
 
 (R)-2-((8-chloro-4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)amino)-
2-phenylacetamide, 12 
Compound 12 was obtained from 1.3c (0.043 g, 0.13 mmol, 1.0 equiv) and 2-amino-2-
phenylacetamide (0.039 g, 0.26 mmol, 2.0 equiv) as orange solid 
(0.098 g, 74%), m.p 147 – 149 °C; Rf (MeOH : DCM, 1 : 9) 0.12. 1H 
NMR (600 MHz, DMSO-d6) δ 8.6 (s, 1H, H5), 8.5 (d, J = 2.5 Hz,  
1H, H4), 7.9 (d, J = 7.7 Hz, 1H, H2), 7.7 (dd, J = 7.8, 2.6 Hz, 1H, H3), 
7.56 (dd, J = 7.0, 2.3 Hz, 2H, H8), 7.5 (s, 2H, H6), 7.4 (t, J = 7.5 Hz, 
2H, H9), 7.4 (dt, J = 7.5, 2.4 Hz, 1H, H10), 6.1 (s, 1H, H1), 5.5 (s, 1H, 
H7). 13C NMR (151 MHz, DMSO-d6) δ 129.2 (5C), 128.7 (2C), 
128.3, 127.7 (6C), 121.9 (2C), 116.5, 115.7, 88.1 (3C). HPLC-MS 
(ACI/ ESI): Purity = 98%, tR = 3.23 min, m/z [M+H]
+ = 444.0. 
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Methyl-(R)-2-((8-chloro-4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-
yl)amino)-2-phenylacetate, 13 
Compound 13 was obtained from 1.3c (0.100 g, 0.30 mmol, 1.0 equiv) and methyl (R)-2-
amino-2-phenylacetate (0.100 g, 0.60 mmol, 2.0 equiv) as orange 
solid (0.121 g, 88%), m.p 183 – 187 °C; Rf (EtOAc : Hexane, 1 : 8) 
0.25. 1H NMR (600 MHz, DMSO-d6) δ 8.59 (s, 1H, H5), 7.9 (d, J = 
2.3 Hz, 1H, H4), 7.7 (d, J = 7.7 Hz, 1H, H2), 7.6 (dd, J = 7.8, 2.4 Hz, 
1H, H3), 7.5 (dd, J = 7.2, 2.4 Hz, 2H, H8), 7.4 (t, J = 7.5 Hz, 1H, H9), 
7.4 (dt, J = 7.5, 2.4 Hz, 1H, H10), 6.3 (s, 1H, H1), 6.0 (s, 1H, H7), 3.8 
(s, 3H, H6). 13C NMR (151 MHz, DMSO-d6) δ 170.9, 148.9 (2C), 
129.3 (6C), 128.2 (4C), 127.4, 122.4, 117.5, 114.1, 61.1 (3C), 53.5 (2C). HPLC-MS (ACI/ 
ESI): Purity = 99%, tR = 3.40 min, m/z [M+H]
+ = 459.0. 
 
8-chloro-1-((1-(4-(methylsulfonyl)phenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 14 
Compound 14 was obtained from 1.3c (0.150 g, 0.46 mmol, 1.0 equiv) and 1-(4-
(methylsulfonyl)phenyl)ethan-1-amine (0.182 g, 0.91 mmol, 2.0 
equiv) as yellow solid (0.163 g, 72%), m.p 139 - 143 °C; Rf 
(MeOH : DCM, 0.2 : 9.8) 0.18. 1H NMR (600 MHz, DMSO-d6) 
δ 8.7 (s, 1H, H5), 8.7 (d, J = 2.4 Hz, 1H, H4), 8.0 (d, J = 8.4 Hz, 
2H, H9), 7.9 (d, J = 8.1 Hz, 2H, H8), 7.6 (dd, J = 7.9, 2.4 Hz, 1H, 
H3), 7.5 (d, J = 8.3 Hz, 1H, H2), 6.2 (s, 1H, H1), 5.3 (q, J = 6.0 
Hz, 1H, H7), 3.2 (s, 3H, H10), 1.8 (d, J = 6.0 Hz, 3H, H6). 13C NMR (151 MHz, DMSO-d6) δ 
149.6, 140.5, 128.3, 127.7 (7C), 121.4, 117.4, 116.5, 88.9, 54.1 (2C), 50.2, 44.1 (3C), 23.4 
(2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.75 min, m/z [M+H]
+ = 491.0. 
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7,8-dichloro-1-((1-(4-fluorophenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 15 
Compound 15 was obtained from 1.3c (0.070 g, 0.19 mmol, 1.0 equiv) and 1-(4-
fluorophenyl)ethan-1-amine (0.053 g, 0.38 mmol, 2.0 equiv) as 
yellow solid (0.043 g, 48%), m.p 224 – 226 °C; Rf (EtOAc : 
Hexane, 3 : 7) 0.37. 1H NMR (600 MHz, DMSO-d6) δ 8.6 (s, 1H, 
H2), 8.4 (s, 1H, H4), 7.9 (s, 1H, H3), 7.6 (dd, J = 8.5, 5.4 Hz, 2H, 
H7), 7.2 (t, J = 8.9 Hz, 2H, H8), 6.3 (s, 1H, H1), 5.3 – 5.1 (m, 1H, 
H6), 1.8 (d, J = 6.7 Hz, 3H, H5). 13C NMR (151 MHz, DMSO-d6) 
δ 162.8, 149.9, 141.7, 138.9, 129.7, 128.8 (3C), 126.7 (2C), 125.5, 123.5, 115.7 (3C), 89.5 
(2C), 53.9 (2C), 23.2 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 3.13 min, m/z [M+H]
+ 
= 467.0. 
 
7,8-difluoro-1-((1-(4-fluorophenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 16 
Compound 16 was obtained from 1.4c (0.080 g, 0.26 mmol, 1.0 equiv) and 1-(4-
fluorophenyl)ethan-1-amine (0.071 g, 0.51 mmol, 2.0 equiv) as 
yellow solid (0.064 g, 56.5%), m.p 182-185 °C; Rf (EtOAc : 
Hexane, 1 : 1) 0.25. 1H NMR (400 MHz, DMSO-d6) δ 8.7 (dd, J = 
11.5, 7.2 Hz, 1H, H2), 8.3 (d, J = 6.2 Hz, 1H, H4), 8.0 (dd, J = 10.9, 
7.6 Hz, 1H, H3), 7.7 (dd, J = 8.6, 5.6 Hz, 2H, H7), 7.2 (t, J = 8.9 Hz, 
2H, H8), 6.2 (s, 1H, H1), 5.2 (m, 1H, H6), 1.8 (d, J = 6.7 Hz, 3H, 
H5). 13C NMR (101 MHz, DMSO-d6) δ 163.1, 149.2, 139.1, 128.8 (4C), 115.9 (4C), 106.2 
(2C), 105.4 (2C), 88.4 (2C), 53.5 (2C), 23.4 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 
2.95 min, m/z [M+H]+ = 435.0. 
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(R)-7,8-difluoro-1-((1-(4-fluorophenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo- 
[1,2-a]pyridine-4-carbonitrile, 17 
Compound 17 was obtained from 1.4c (0.046 g, 0.14 mmol, 1.0 equiv) and 1-(4-
fluorophenyl)ethan-1-amine (0.039 g, 0.28 mmol, 2.0 equiv) as 
yellow solid (0.029 g, 48%), m.p 210 - 212 °C; Rf (EtOAc : 
Hexane, 1 : 1) 0.24. 1H NMR (400 MHz, DMSO-d6) δ 8.7 (dd, J = 
11.2, 7.3 Hz, 1H, H2), 8.3 (d, J = 6.2 Hz, 1H, H4), 8.0 (dd, J = 11.0, 
7.7 Hz, 1H, H3), 7.6 (dd, J = 8.6, 5.6 Hz, 2H, H7), 7.2 (t, J = 8.9 
Hz, 2H, H8), 6.2 (s, 1H, H1), 5.2 (m, 1H, H6), 1.8 (d, J = 6.9 Hz, 
3H, H5). 13C NMR (101 MHz, DMSO-d6) δ 163.1, 149.3, 139.1, 128.8 (4C), 115.9 (4C), 106.3 
(2C), 105.4 (2C), 88.4 (2C), 53.6 (2C), 23.4 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 
2.96 min, m/z [M+H]+ = 435.0. 
 
1-((1-(4-chlorophenyl)ethyl)amino)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 18 
Compound 18 was obtained from 1.4c (0.080 g, 0.26 mmol, 1.0 equiv) and 1-(4-
chlorophenyl)ethan-1-amine (0.098 g, 0.51 mmol, 2.0 equiv) as 
yellow solid (0.080 g, 68%), m.p 182 – 184 °C; Rf (EtOAc : 
Hexane, 1 : 1) 0.18. 1H NMR (300 MHz, DMSO-d6) δ 8.7 (dd, J = 
11.4, 7.2 Hz, 1H, H2), 8.3 (d, J = 6.4 Hz, 1H, H4), 8.0 (dd, J = 11.0, 
7.6 Hz, 1H, H3), 7.6 (J = 8.5 Hz, 2H, H8), 7.4 (d, J = 8.5 Hz, 2H, 
H7), 6.2 (s, 1H, H1), 5.3– 5.1 (m, 1H, H6), 1.8 (d, J = 6.7 Hz, 3H, 
H5). 13C NMR (101 MHz, DMSO-d6) δ 149.2, 141.9, 132.5, 129.1 (3C), 128.7 (4C), 114.2, 
106.3 (2C), 105.4 (2C), 88.4 (2C), 53.5 (2C), 23.2 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, 
tR = 3.35 min, m/z [M-H]
- = 449.0. 
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(S)-7,8-difluoro-1-((1-phenylethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]py-
ridine-3-carbonitrile, 19 
Compound 19 was obtained from 1.4c (0.061 g, 0.18 mmol, 1.0 equiv) and 1-phenylethan-1-
amine (0.045 g, 0.37 mmol, 2.0 equiv) as yellow solid (0.025 g, 
34%), m.p 193 – 195 °C; Rf (EtOAc : Hexane, 3 : 7) 0.19. 1H NMR 
(400 MHz, DMSO-d6) δ 8.7 (dd, J = 11.3, 7.2 Hz, 1H, H2), 8.3 (s, 
1H, H4), 8.0 (dd, J = 11.6, 7.7 Hz, 1H, H3), 7.6 – 7.5 (dd, J = 7.5, 
2.1 Hz, 2H, H7), 7.4 (t, J = 7.3 Hz, 2H, H8), 7.3 (dt, J = 7.3, 2.2 
Hz, 1H, H9), 6.2 (s, 1H, H1), 5.2 (q, J = 6.6 Hz, 1H, H6), 1.8 (d, J 
= 6.8 Hz, 3H, H5). 13C NMR (101 MHz, DMSO-d6) δ 149.3, 143.0, 
129.2 (3C), 127.9 (2C), 126.6 (4C), 123.7, 106.4, 105.4 (2C), 88.4 
(2C), 54.3 (2C), 23.4 (2C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 2.98 min, m/z [M+H]
+ 
= 417.19. 
 
(R)-7,8-difluoro-1-((1-phenylethyl)amino)-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]py-
ridine-3-carbonitrile, 20 
Compound 20 was obtained from 1.4c (0.080 g, 0.24 mmol, 1.0 equiv) and 1-phenylethan-1-
amine (0.059 g, 0.48 mmol, 2.0 equiv) as orange solid (0.052 g, 
52%), m.p 210 – 212 °C; Rf (EtOAc : Hexane, 3 : 7) 0.20. 1H NMR 
(400 MHz, DMSO-d6) δ 8.7 (dd, J = 11.3, 7.2 Hz, 1H, H2), 8.4 (d, 
J = 6.4 Hz, 1H, H4), 8.0 (dd, J = 10.7, 7.7 Hz, 1H, H3), 7.6 – 7.5 
(dd, J = 7.5, 2.2 Hz, 2H, H7), 7.4 (t, J = 7.3 Hz, 2H, H8), 7.3 (dt, J 
= 7.4, 2.2 Hz, 1H, H9), 6.2 (s, 1H, H1), 5.2 (m, 1H, H6), 1.8 (d, J = 
6.7 Hz, 3H, H5). 13C NMR (101 MHz, DMSO-d6) δ 149.8, 149.3, 
143.0, 129.2 (3C), 127.9 (2C), 126.6 (3C), 114.3, 106.3 (2C), 
105.4 (2C), 88.4 (2C), 54.3, 23.4 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.98 min, 
m/z [M+H]+ = 417.19. 
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7,8-difluoro-1-((1-(4-(trifluoromethoxy)phenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]-
imidazo[1,2-a]pyridine-4-carbonitrile, 21 
Compound 21 was obtained from 1.4c (0.081 g, 0.24 mmol, 1.0 equiv) and 1-
phenylcyclopropan-1-amine (0.100 g, 0.49 mmol, 2.0 equiv) 
as yellow solid (0.053 g, 44%), m.p 213 – 215 °C; Rf (EtOAc 
: Hexane, 3 : 7) 0.25. 1H NMR (400 MHz, DMSO-d6) δ 8.7 
(dd, J = 11.3, 7.2 Hz, 1H, H2), 8.3 (d, J = 6.2 Hz, 1H, H4), 8.0 
(dd, J = 10.7, 8.0 Hz, 1H, H3), 7.7 (d, J = 7.7 Hz, 2H, H8), 7.4 
(d, J = 7.9 Hz, 2H, H7), 6.2 (s, 1H, H1), 5.3 (m, 1H, H6), 1.8 
(d, J = 6.7 Hz, 3H, H5). 13C NMR (101 MHz, DMSO-d6) δ 149.2, 148.0, 142.4, 128.7 (4C), 
121.7 (4C), 114.2, 106.3 (2C), 105.4 (2C), 88.4 (2C), 53.4 (2C), 23.2 (2C). HPLC-MS (ACI/ 
ESI): Purity = 99%, tR = 3.06 min, m/z [M+H]
+ = 501.0. 
 
7,8-difluoro-1-((1-(4-(methylsulfonyl)phenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]-
imidazo[1,2-a]pyridine-4-carbonitrile, 22 
Compound 22 was obtained from 1.4c (0.084 g, 0.27 mmol, 1.0 equiv) and 1-(4-
(methylsulfonyl)phenyl)ethan-1-amine (0.11 g, 0.54 mmol, 
2.0 equiv) as yellow solid (0.063 g, 46%), m.p 261 – 263 °C; 
Rf (EtOAc : Hexane, 0.5 : 9.5) 0.18. 1H NMR (400 MHz, 
DMSO-d6) δ 8.7 (dd, J = 11.3, 7.1 Hz, 1H, H2), 8.4 (s, 1H, 
H4), 8.0 (dd, J = 10.9, 7.0 Hz, 1H, H3), 8.0 (d = 8.8 Hz, 2H, 
H8), 7.9 (d, J = 8.5 Hz, 2H, H7), 6.3 (s, 1H, H1), 5.4 (q, J = 
7.5 Hz, 1H, H6), 3.2 (s, 3H, H9), 1.8 (d, J = 6.7 Hz, 3H, H5). 
13C NMR (101 MHz, DMSO-d6) δ 149.8, 149.2, 148.87, 141.8, 140.4, 127.8 (6C), 114.2, 106.4, 
105.5 (2C), 88.3, 53.7 (2C), 43.9 (2C), 23.1 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 
3.43 min, m/z [M-H]- = 493.0. 
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(R)-1-((1-(2-chlorophenyl)ethyl)amino)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imida- 
zo[1,2-a]pyridine-4-carbonitrile, 23 
Compound 23 was obtained from 1.4c (0.100 g, 0.30 mmol, 1.0 equiv) and (S)-1-(2-
chlorophenyl)ethan-1-amine (0.094 g, 0.60 mmol, 2.0 equiv) as 
yellow solid (0.117 g, 86%), m.p 232 - 235 °C; Rf (DCM) 0.24. 
1H NMR (400 MHz, DMSO-d6) δ 8.8 (dd, J = 11.3, 7.2 Hz,  1H, 
H2), 8.4 (s, 1H, H4), 8.0 (dd, J = 11.0, 7.0 Hz, 1H, H3), 7.8 (dd, J 
= 8.3, 3.0 Hz, 1H, H10), 7.6 (m, 1H, H9), 7.5-7.3 (m, 2H, H7, 8),  5.9 
(s, 1H, H1), 5.3 (q, J = 7.1 Hz, 1H, H6), 1.8 (d, J = 6.7 Hz, 3H, H5). 
13C NMR (101 MHz, DMSO-d6) δ 149.6, 149.0, 139.8, 131.8, 
129.9 (4C), 128.6 (2C), 128.2 (2C), 114.0, 105.5 (2C), 87.9 (2C), 
51.8 (2C), 21.9 (2C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 3.16 min, m/z [M-H]
- = 451.0. 
 
7,8-difluoro-1-((1-(2-hydroxyphenyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidzo[1,2-
a]pyridine-4-carbonitrile, 24 
Compound 24 was obtained from 1.4c (0.089 g, 0.29 mmol, 1.0 equiv) and 2-(1-
aminoethyl)phenol (0.100 g, 0.57 mmol, 2.0 equiv) as yellow 
solid (0.095 g, 76%), m.p 231 – 233 °C; Rf (MeOH : DCM, 3 
: 7) 0.21. 1H NMR (400 MHz, DMSO-d6) δ 10.1 (s, 1H, H11), 
8.7 (dd, J = 11.3, 7.2 Hz, 1H, H2), 8.3 (d, J = 6.7 Hz, 1H, H4), 
8.0 (dd, J = 11.0, 7.6 Hz, 1H, H3), 7.5 (dd, J = 7.7, 1.7 Hz, 1H, 
H10), 7.1 (dt, J = 7.8, 1.7 Hz, 1H, H9), 6.9 (dt, J = 8.2, 1.7 Hz, 
1H, H8), 6.8 (dd, J = 7.5, 1.7 Hz, 1H, H7), 6.4 (s, 1H, H1), 5.3 
(m, 1H, H6), 1.7 (d, J = 6.7 Hz, 3H, H5). 13C NMR (101 MHz, 
DMSO-d6) δ 154.5, 149.9, 149.1, 129.0 (2C), 128.4, 127.7, 123.5, 121.2, 120.1, 115.8, 114.4, 
106.2 (2C), 104.9 (2C), 87.8 (2C), 49.3, 22.1 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 
2.92 min, m/z [M+H]+ = 433.1. 
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(S)-1-((1-(2-chlorophenyl)ethyl)amino)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imida- 
zo[1,2-a]pyridine-4-carbonitrile, 25 
Compound 25 was obtained from 1.4c (0.100 g, 0.30 mmol, 1.0 equiv) and 1-(4-
(methylsulfonyl)phenyl)ethan-1-amine (0.0.094 g, 0.60 mmol, 
2.0 equiv) as yellow solid (0.101 g, 74%), m.p 231 - 233 °C; 
Rf (DCM) 0.23. 1H NMR (400 MHz, DMSO-d6) δ 8.8 (dd, J = 
11.5, 7.4 Hz, 1H, H2), 8.4 (s, 1H, H4), 7.8 (dd, J = 11.0, 7.0 Hz, 
1H, H3), 7.8 (dd, J = 8.9, 3.3 Hz, 1H, H10), 7.6 (m, 1H, H9), 
7.5-7.3 (m, 2H, H7, 8), 5.9 (s, 1H, H1), 5.2 (q, J = 6.7 Hz, 1H, 
H5), 1.8 (d, J = 7.1 Hz, 3H, H6). 13C NMR (101 MHz, DMSO-
d6) δ 149.2 (2C), 131.8, 130.7, 129.8 (4C), 128.3 (3C), 105.4 
(3C), 88.0 (3C), 52.0 (4C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 3.15 min, m/z [M-H]
- = 
451.0. 
 
1-((1-(2-chlorophenyl)ethyl)amino)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 26 
Compound 26 was obtained from 1.4c (0.20 g, 0.61 mmol, 1.0 equiv) and 1-(2-
chlorophenyl)ethan-1-amine (0.19 g, 1.22 mmol, 2.0 equiv) as 
yellow solid (0.150 g, 55.0 %), m.p 231 - 233 °C; Rf (EtOAc 
: Hexane, 4 : 6) 0.26. 1H NMR (400 MHz, DMSO-d6) δ 8.7 
(dd, J = 11.3, 7.2 Hz, 1H, H2), 8.4 (d, J = 6.5 Hz,  1H, H4), 7.8 
(dd, J = 10.9, 7.0 Hz, 1H, H3), 7.8 (dd, J = 8.3, 3.3 Hz, 1H, 
H10), 7.5 (m, 1H, H9), 7.4-7.3 (m, 1H, H7, 8), 5.9 (s, 1H, H1), 
5.3 (m, 1H, H5), 1.8 (d, J = 6.7 Hz, 3H, H6). 13C NMR (101 
MHz, DMSO-d6) δ 149.0, 139.7, 131.8, 129.9 (4C), 128.6 
(2C), 128.2 (2C), 114.0, 106.4, 105.4 (2C), 87.8 (2C), 51.8 (2C), 21.8 (2C). HPLC-MS (ACI/ 
ESI): Purity = 97.0%, tR = 3.18 min, m/z [M-H]
- = 451.1. 
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7,8-difluoro-1-((1-(p-tolyl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridi-
ne-4-carbonitrile, 27 
Compound 27 was obtained from 1.4c (0.070 g, 0.21 mmol, 1.0 equiv) and 1-(p-tolyl)ethan-1-
amine (0.057 g, 0.42 mmol, 2.0 equiv) as orange solid (0.074 
g, 82%), m.p 215 – 217 °C; Rf (DCM) 0.27. 1H NMR (400 
MHz, DMSO-d6) δ 8.68 (dd, J = 11.3, 7.2 Hz, 1H, H2), 8.3 (d, 
J = 5.7 Hz,  1H, H4), 8.0 (dd, J = 11.0, 7.6 Hz, 1H, H3), 7.5 (d, 
J = 7.8 Hz, 2H, H7), 7.2 (d, J = 7.8 Hz, 2H, H8), 6.3 (s, 1H, H1), 
5.1 (m, 1H, H6), 2.3 (s, 3H, H9), 1.8 (d, J = 6.7 Hz, 3H, H5). 13C 
NMR (101 MHz, DMSO-d6) δ 149.26, 139.9, 137.1, 129.7 (3), 
126.6 (4C), 106.2 (2C), 105.3 (2C), 88.4 (2C), 54.1 (2C), 23.1 (2C), 21.1 (2C). HPLC-MS 
(ACI/ ESI): Purity = 98%, tR = 3.07 min, m/z [M+H]
+ = 431.1. 
 
7,8-difluoro-1-((2-phenylpropan-2-yl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 28 
Compound 28 was obtained from 1.4c (0.10 g, 0.30 mmol, 1.0 equiv) and 2-phenylpropan-2-
amine (0.81 g, 0.60 mmol, 2.0 equiv) as orange solid (0.11 g, 
85%), m.p 197 – 199 °C; Rf (EtOAc : Hexane, 3 : 7) 0.36. 1H 
NMR (400 MHz, DMSO-d6) δ 8.5 (dd, J = 11.1, 7.3 Hz, 1H, 
H2), 8.4 (s, 1H, H4), 8.0 (dd, J = 11.0, 7.6 Hz, 1H, H3), 7.6 (dd, 
J = 9.7, 1.3 Hz, 2H, H6), 7.4 (t, J = 9.5 Hz, 2H, H7), 7.4 (dt, J = 
7.7, 1.3 Hz, 1H, H8), 5.6 (s, 1H, H1), 1.9 (s, 6H, H5). 13C NMR 
(101 MHz, DMSO-d6) δ 149.6, 129.2, 129.0 (5C), 127.8 (2C), 
127.2 (5C), 105.1 (2C), 88.6 (3C), 11.5 (3C). HPLC-MS (ACI/ 
ESI): Purity = 99.0%, tR = 3.77 min, m/z [M-H]
- = 429.1. 
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7,8-difluoro-1-((1-phenylpropyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridi-
ne-4-carbonitrile, 29 
Compound 29 was obtained from 1.4c (0.10 g, 0.30 mmol, 1.0 equiv) and 1-phenylpropan-1-
amine (0.81 g, 0.60 mmol, 2.0 equiv) as orange solid (0.11 g, 
85%), m.p 185 – 187 C; Rf (MeOH : DCM, 0.4 : 9. 6) 0.25. 1H 
NMR (400 MHz, DMSO-d6) δ 8.7 (dd, J = 11.3, 7.3 Hz, 1H, 
H2), 8.2 (s, 1H, H4), 7.9 (dd, J = 10.8, 7.7 Hz, 1H, H3), 7.6 (dd, 
J = 7.5, 1.3 Hz, 2H, H8), 7.4 (t, J = 7.6 Hz, 2H, H9), 7.3 (dt, J = 
7.7, 1.4 Hz, 1H, H10), 6.2 (s, 1H, H1), 4.8 (t, J = 5.6 Hz, 1H, H7), 
2.3 – 1.9 (m, 2H, H6), 0.8 (t, J = 7.4 Hz, 3H, H5). 13C NMR (101 
MHz, DMSO-d6) δ 148.5, 145.1, 129.4 (3C), 127.8 (2C), 125.7 
(4C), 114.1, 106.0 (3C), 90.5 (2C), 58.9, 29.6 (4C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 
3.13 min, m/z [M-H]- = 429.1. 
 
7,8-difluoro-1-((1-phenylcyclopropyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 30 
Compound 30 was obtained from 1.4c (0.080 g, 0.24 mmol, 1.0 equiv) and 1-
phenylcyclopropan- 1-amine (0.063 g, 0.48 mmol, 2.0 equiv) as 
yellow solid (0.066 g, 64%), m.p 182 – 184 °C; Rf (EtOAc : 
Hexane, 3 : 7) 0.17. 1H NMR (400 MHz, DMSO-d6) δ 9.0 (s, 1H, 
H4), 8.9 (dd, J = 11.7, 7.3 Hz, 1H, H2), 8.0 (dd, J = 11.0, 7.7 Hz, 
1H, H3), 7.3 (m, 4H, H6,7), 7.3 (dt, J = 7.2, 1.6 Hz, 1H, H8), 6.2 (s, 
1H, H1), 1.6 (s, 4H, H5). 13C NMR (101 MHz, DMSO-d6) δ 150.0 
(2C), 141.0, 129.0 (4C), 126.9, 124.9 (2C), 114.4, 106.2 (2C), 
105.2 (2C), 88.9 (2C), 38.0 (2C), 20.4 (3C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.99 
min, m/z [M+H]+ = 429.1. 
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7,8-difluoro-1-((2-(4-fluorophenyl)propan-2-yl)amino)-3-(trifluoromethyl)benzo[4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 31 
Compound 31 was obtained from 1.4c (0.045 g, 0.15 mmol, 1.0 equiv) and 1-phenylpropan-1-
amine (0.045 g, 0.30 mmol, 2.0 equiv) as orange solid (0.037 
g, 61 %), m.p 229 – 231 °C; Rf (MeOH : DCM, 4 : 6) 0.27. 1H 
NMR (400 MHz, DMSO-d6) δ 8.6 (dd, J = 11.2, 7.2 Hz, 1H, 
H2), 8.4 (s, 1H, H4), 8.1 (dd, J = 10.9, 7.6 Hz, 1H, H3), 7.7 (dd, 
J = 8.7, 5.5 Hz, 2H, H6), 7.3 (t, J = 8.8 Hz, 2H, H7), 5.6 (s, 1H, 
H1), 1.9 (s, 6H, H5). 13C NMR (101 MHz, DMSO-d6) δ 148.4, 
141.7, 141.3, 128.0 (4C), 123.9, 116.0 (4C), 114.0, 106.4, 
105.8 (2C), 90.4 (2C), 58.5, 29.7 (3C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.13 min, 
m/z [M+H]+ = 449.0. 
 
Methyl (S)-2-((3-cyano-7,8-difluoro-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-
yl)amino)-2-phenylacetate, 32 
Compound 32 was obtained from 1.4c (0.080 g, 0.26 mmol, 1.0 equiv) and methyl (S)-2-
amino-2-phenylacetate (0.084 g, 0.51 mmol, 2.0 equiv) as 
yellow solid (0.033 g, 28%), m.p 228 – 230 °C; Rf (EtOAc : 
Hexane, 4 : 6) 0.24. 1H NMR (400 MHz, DMSO-d6) δ 8.6 (dd, 
J = 9.4, 7.3 Hz, 1H, H2), 8.5 (dd, J = 8.8, 7.5 Hz, 1H, H3), 8.0 
(s, 1H, H4), 7.7 (dd, J = 7.4, 1.6 Hz, 2H, H7), 7.5 (t, J = 8.2 Hz, 
2H, H8), 7.4 (dt, J = 7.3, 1.7 Hz, 1H, H9), 6.3 (s, 1H, H1), 6.0 (s, 
1H, H5), 3.8 (s, 3H, H6). 13C NMR (101 MHz, DMSO-d6) δ 
149.3, 148.6 (3C), 129.3 (6C), 129.1 (2C), 128.3 (6C), 123.8, 
53.6 (3C).  HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.98 min, 
m/z [M-H]- = 459.0. 
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Methyl (R)-2-((3-cyano-7,8-difluoro-4-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-
yl)amino)-2-phenylacetate, 33 
Compound 33 was obtained from 1.4c (0.12 g, 0.36 mmol, 1.0 equiv) and methyl (S)-2-amino-
2-phenylacetate (0.12 g, 0.72 mmol, 2.0 equiv) as orange solid 
(0.070 g, 42%), m.p 232 – 235 °C; Rf (EtOAc : Hexane, 4 : 6) 
0.24. 1H NMR (400 MHz, DMSO-d6) δ 8.6 (dd, J = 9.4, 7.2 Hz, 
1H, H2), 8.5 (dd, J = 8.8, 7.6 Hz, 1H, H3), 8.0 (s, 1H, H4), 7.7 (dd, 
J = 7.4, 1.4 Hz, 2H, H7), 7.5 (t, J = 7.5 Hz, 2H, H8), 7.32 (dt, J = 
7.31, 1.63 Hz, 1H, H9)  6.3 (s, 1H, H1), 6.0 (s, 1H, H5), 3.8 (s, 3H, 
H6). 13C NMR (101 MHz, DMSO-d6) δ 149.4, 148.6 (2C), 129.3 
(7C), 129.1 (2), 128.3 (7), 124.0, 53.6 (2). HPLC-MS (ACI/ ESI): 
Purity = 98%, tR = 2.98 min, m/z [M-H]
- = 459.0. 
 
7,8-difluoro-1-((1-(1-methyl-1H-pyrazol-4-yl)ethyl)amino)-3-(trifluoromethyl)benzo[4,5]-
imidazo[1,2-a]pyridine-4-carbonitrile, 34 
Compound 34 was obtained from 1.4c (0.10 g, 0.30 mmol, 1.0 equiv) and 1-(1-methyl-1H-
pyrazol-4-yl)ethan-1-amine (0.075 g, 0.60 mmol, 2.0 equiv) as 
yellow solid (0.098 g, 78%), m.p 233 – 235 °C; Rf (EtOAc : 
Hexane, 3 : 7) 0.18. 1H NMR (400 MHz, DMSO-d6) δ 8.6 (dd, J 
= 11.4, 7.2 Hz, 1H, H2), 8.3 – 8.2 (d, J = 7.0 Hz, 1H, H4), 8.0 (dd, 
J = 11.0, 7.7 Hz, 1H, H3), 7.8 (s, 1H, H8), 7.5 (s, 1H, H7), 6.5 (s, 
1H, H1), 5.2 (m, 1H, H6), 3.8 (s, 3H, H9), 1.7 (d, J = 6.7 Hz, 3H, 
H5). 13C NMR (101 MHz, DMSO-d6) δ 150, 149.2, 137.3 (2C), 
129.2 (2C), 123.6, 123.1, 114.4, 106.2 (2C), 105.2 (2C), 88.0 (2C), 46.5 (2C), 22.2 (2C). 
HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.07 min, m/z [M-H]
- = 419.1. 
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1-((4-(trifluoromethoxy)phenyl)amino)-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile, GMP-19 (36) 
Compound 36 was obtained from 1.1c (0.079 g, 0.27 mmol, 1.0 Eq) and 4-
(trifluoromethoxy)aniline (0.054 g, 0.53 mmol, 2.0 Eq) as a yellow 
solid (0.091 g, 77%); Rf (EtOAc : Hexane, 1 : 1) 0.43; 1H NMR 
(400 MHz, DMSO-d6) δ 8.8 (dd, J = 7.7, 1.2 Hz, 1H, H5), 7.7 (dd, 
J = 8.1, 1.1 Hz, 1H, H2), 7.6 (dt, J = 7.7, 1.7 Hz, 1H, H3), 7.4 (t, J 
= 8.8, 1.9 Hz, 1H, H4), 7.3 (d, J = 8.3 Hz, 2H, H7), 7.2 (d, J = 8.7 
Hz, 2H, H6), 6.2 (s, 1H, H1). 13C NMR (151 MHz, DMSO-d6) δ 
149.3, 145.8, 130.2, 126.7 (2C), 124.9 (4C), 122.8 (4C), 122.4 
(2C), 116.0 (2C), 114.5, 92.7 (2C). HPLC-MS (ACI/ ESI): Purity 
= 99%, tR = 3.06 min, m/z [M+H]
+ = 437.0. 
 
9-chloro-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo-
[1,2-a]pyridine-4-carbonitrile, 37 
Compound 37 was obtained from 2.2c (0.85 g, 2.58 mmol, 1.0 equiv) and 4-
(trifluoromethoxy)aniline (0.91 g, 5.16 mmol, 3.0 equiv) as a 
yellow solid (0.57 g, 47%); Rf (EtOAc : Hexane, 7 : 3) 0.35; 1H 
NMR (300 MHz, DMSO-d6) δ 8.6 (d, J = 8.4 Hz, 1H, H4), 7.7 (d, 
J = 8.0 Hz, 1H, H2), 7.5 (d, J = 0.5 Hz, 4H, H5, 6), 7.4 (t, J = 8.2 
Hz, 1H, H3), 6.4 (s, 1H, H1). 13C NMR (101 MHz, DMSO-d6) δ 
149.1 (2C), 145.8, 129.9 (2), 127.0 (2C), 124.9, 123.7, 123.1, 
123.0, 122.7 (2C), 120.4, 119.7, 117.4 116.1 (3C), 114.0. HPLC-
MS (ACI/ ESI): Purity = 99%, tR = 3.37 min, m/z [M+H]
+ = 471.0. 
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9-nitro-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 42 
Compound 42 was obtained from 2.1.2c (0.36 g, 1.07 mmol, 1.0 equiv) and 4-
(trifluoromethoxy)aniline (0.38 g, 2.14 mmol, 2.0 equiv) as a 
yellow solid (0.24 g, 47%); Rf (EtOAc: Hexane, 4 : 6) 0.32; 1H 
NMR (400 MHz, DMSO-d6) δ 9.1 (d, J = 8.3 Hz, 1H, H4), 8.4 (d, 
J = 8.2 Hz, 1H, H2), 7.6 (t, J = 8.3 Hz, 1H, H3), 7.5 – 7.4 (d, J = 
8.5 Hz, 2H, H6), 7.4 (d, J = 8.6 Hz, 2H, H5), 6.4 (s, 1H, H1). 13C 
NMR (101 MHz, DMSO-d6) δ 151.6, 149.2, 145.5, 132.1, 124.6 
(4), 123.2 (2C), 123.0 (6C), 120.9, 114.7, 94.8 (2C). HPLC-MS 
(ACI/ ESI): Purity =99%, tR = 3.31 min, m/z [M+H]
+ = 482.0. 
 
9-amino-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 43 
A mixture of compound 42 (0.22 g, 0.46 mmol, 1.0 equiv) and ammonium chloride (0.26 g, 
4.60 mmol 10.0 equiv) and iron (0.26 g, 4.60 mmol, 10.0 equiv) in a 1:1 methanol-water 
solution (2.0 mL) was stirred at 65 °C for 45 minutes. The reaction mixture was cooled to room 
temperature after which it was taken up in ethyl acetate (10.0 mL). The treated reaction mixture 
was filtered through celite, washed with deionised water (20 mL x 3), dried with brine (10 mL 
x2) and finally dried over MgSO4. The organic layer was concentrated and dried in vacuo. The 
product was purified by flash-chromatography using EtOAc.  
Compound 43 was obtained as a yellow solid (0.19 g, 90%); Rf (MeOH (NH3): DCM, 1 : 9) 
0.28; m.p 223 – 226 °C; 1H NMR (400 MHz, Acetonitrile-d3) δ 7.8 
(dd, J = 8.4, 0.8 Hz, 1H, H2), 7.4 (d, J = 0.5 Hz, 4H, H7, 8), 7.2 (dd, 
J = 8.4, 7.7 Hz, 1H, H3), 6.8 (dd, J = 7.7, 0.8 Hz, 1H, H4), 6.2 (s, 
1H, H1), 5.5 (s, 1H, H6), 3.3 (s, 2H, H5). 13C NMR (101 MHz, 
Acetonitrile-d3) δ 138.6, 133.2, 128.4, 127.0, 125.2, 122.1 (2C), 
122.5 (2C), 118.6, 108.9 (2C), 104.4 (2C), 90.0 (2C), 29.8 (4C). 
HPLC-MS (ACI/ ESI): Purity = 97%, tR =  1.22 min, m/z [M+H]
+ 
= 452.0. 
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6.3.7 General procedure for the synthesis of the amide derivatives - compounds 44 and 
452 
A mixture of a suitable carboxylic acid (1.5 equiv), N,N-dimethylpyridin-4-amine (DMAP) 
(1.5 equiv) and N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (1.5 
equiv) in 0 °C cooled dichloromethane (1.0 mL per 100 mg of compound) was stirred at 0 °C 
for 5 minutes after which the temperature was increased to 17 – 25 °C (ambient temperature) 
for 15 minutes. The amine was added to the treated reaction mixture and stirring was continued 
at that temperature for 1.5 hours. The product was washed with three portions of 10 mL 
deionised water, filtered, washed using diethyl ether and finally dried on the filter paper at 
ambient conditions. 
 
(R)-1-((2-morpholino-2-oxo-1-phenylethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo-
[1,2-a]pyridine-4-carbonitrile, 5 
Compound 5 was obtained from compound 4 (0.078 g, 0.19 mmol, 1.0 equiv) and 1, 1-
dioxidothiomorpholine (0.039 g, 0.29 mmol, 1.5 equiv) as 
yellow solid (0.038 g, 38%), m.p 322 – 324 °C; Rf (EtOAc : 
Hexane, 0.1 : 9.9) 0.19. 1H NMR (600 MHz, DMSO-d6) δ 8.6 
(dd, J = 7.9, 1.77 Hz, 1H, H2), 8.5 (dd, J = 8.2, 1.4 Hz, 1H, H5), 
8.0 (s, 1H, H6), 7.8 (dd, J = 7.4, 1.2 Hz, 2H, H10), 7.7 (m, 2H, 
H3, 4), 7.5 (t, J = 7.6 Hz, 2H, H11), 7.4 (m, 1H, H12), 6.5 (s, 1H, 
H1), 6.4 (s, 1H, H7), 4.3 - 3.8 (m, 4H, H9), 3.4 – 2.9 (m, 4H, 
H8). 13C NMR (151 MHz, DMSO-d6) δ 168.8, 147.9, 147.4, 
145.7, 136.1, 129.6 (4C), 128.3 (3C), 127.3, 122.5, 120.1, 
114.4 (2C), 86.9 (2C), 57.0 (2C), 43.8, 42.3 (3C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 
3.14 min, m/z [M+H]+ = 528.1. 
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9-(((((tert-butoxycarbonyl)oxy)glycyl)oxy)amino)-1-((4-(trifluoromethoxy)phenyl )amino)-
3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 44 
Compound 44 was obtained from compound 43 (0.06 g, 0.13 mmol, 1.0 equiv) and N-(tert-
butoxycarbonyl)-N-ethylglycine (0.040 g, 0.20 mmol, 1.5 
equiv) as a beige solid (0.072 g, 81%), m.p 219 – 221 °C; Rf 
(EtOAc : Hexane, 6:4) 0.35. 1H NMR (300 MHz, Acetonitrile-
d3) δ 9.0 (s, 1H, H5), 8.4 (dd, 8.4, 1.1 Hz, 1H, H2), 8.2 (dd, J = 
8.0, 1.2 Hz, 1H, H4), 7.3 (d, J = 7.9 Hz, 2H, H11), 7.3 (t, J = 8.3 
Hz,  1H, H3), 7.2 (d, J = 7.6 Hz, 2H, H10),  6.1 (s, 1H, H1), 3.6 
(s, 2H, H6), 3.1 (q, J = 7.2 Hz, 2H, H8), 1.5 (s, 9H, H7), 1.2 (t, 
J = 6.5 Hz, 3H, H9). 13C NMR (101 MHz, Acetonitrile-d3) δ 
152.8, 150.4, 127.6, 123.8 (3C), 122.2 (3C), 120.0 (2C), 112.0, 110.9 (2C), 89.1 (3C), 80.0, 
53.3, 31.1 (2C), 29.8 (3C), 27.6 (5C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.37 min, m/z 
[M-H]- = 635.0. 
 
tert-butyl (2-((4-cyano-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl) benzo[4,-
5]imidazo[1,2-a]pyridin-9-yl)amino)-2-oxoethyl)(ethyl) carbamate, 45 
Compound 45 was obtained from compound 43 (0.06 g, 0.13 mmol, 1.0 equiv) and (tert-
butoxycarbonyl)glycine (0.035 g, 0.20 mmol, 1.5 Eq) as an 
orange solid (0.029 g, 37%), m.p 215 – 218 °C; Rf (MeOH 
: DCM, 1 : 9) 0.18. 1H NMR (300 MHz, Acetonitrile-d3) δ 
9.0 (s, 1H, H5), 8.4 (dd, J = 8.3, 0.9 Hz, 1H, H2), 8.3 (dd, J 
= 8.0, 1.2 Hz, 1H, H4), 7.3 (d, J = 7.9 Hz, 2H, H9), 7.3 (t, J 
= 8.1 Hz, 1H, H3), 7.2 (d, J = 7.7 Hz, 2H, H8), 6.1 (s, 1H, 
H1), 4.1 (s, 2H, H6), 1.5 (s, 9H, H7). 13C NMR (101 MHz, 
Acetonitrile-d3) δ 168.5, 149.9, 127.2, 124.3 (3C), 122.3 (3C), 120.4, 114.2 (2C), 111.9, 89.8 
(3C), 80.0, 51.5 (2C), 43.5 (3C), 30.8, 29.8, 27.6 (3C). HPLC-MS (ACI/ ESI): Purity = 99%, 
tR = 3.35 min, m/z [M-H]
- = 607.0. 
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1-((5,6-dimethoxypyrimidin-4-yl)amino)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 46 
Compound 46 was obtained from 1.4c (0.15 g, 0.45 mmol, 1.0 equiv) and 5,6-
dimethoxypyrimidin-4-amine (0.14 g, 0.90 mmol, 2.0 equiv) as 
yellow solid (0.093 g, 46%), m.p 299 – 302 °C; Rf (EtOAc : 
Hexane, 3 : 7) 0.18. 1H NMR (400 MHz, DMSO-d6) δ 8.4 (s, 1H, 
H4), 8.3 (dd, J = 10.7, 7.5 Hz, 1H, H2), 8.3 (dd, J = 8.7, 6.9 Hz, 1H, 
H3), 6.1 (s, 1H, H1), 4.2 (s, 3H, H7), 4.0 (s, 3H, H6). 13C NMR (101 
MHz, DMSO-d6) δ 153.9, 145.2 (2C), 127.4, 119.2 (2C), 113.6, 
111.1, 104.4, 106.2 (3C), 105.2 (3C), 88.0 (2C), 46.5 (2C). HPLC-
MS (ACI/ ESI): Purity = 97%, tR = 3.17 min, m/z [M+H]
+ = 451.1 
 
7,8-difluoro-1-((2-fluoropyridin-4-yl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 47 
Compound 47 was obtained from 1.4c (0.10 g, 0.30 mmol, 1.0 
equiv) and 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-amine (0.075 g, 
0.60 mmol, 2.0 equiv) as yellow solid (0.098 g, 78%), m.p > 300 
°C; Rf (EtOAc : Hexane, 3 : 7) 0.18. 1H NMR (400 MHz, DMSO-
d6) δ 8.2 (d, J = 7.7 Hz, 1H, H6), 8.4 (dd, J = 10.9, 7.4 Hz, 1H, 
H2), 7.8 (dd, J = 7.8, 6.6 Hz, 1H, H3), 6.8 (d, J = 7.6 Hz, 1H, H5), 
6.5 (d, J = 7.3 Hz, 1H, H4), 6.2 (s, 1H, H1). 13C NMR (101 MHz, 
DMSO-d6) δ 166.4, 165.3 (2C), 147.5 (3), 128.1, 121.2, 119.0, 
113.9, 113.1, 106.2 (2C), 99.1 (2C), 88.0 (3C). HPLC-MS (ACI/ ESI): Purity = 96%, tR = 3.03 
min, m/z [M-H]- = 409.0 
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8-chloro-1-((2-methoxyethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile, 2.2d 
Compound 2.2d was obtained from 2.2c (0.11 g, 0.32 mmol, 1.0 equiv) and 2-methoxyethan-
1-amine (0.048 mL, 0.64 mmol, 2.0 equiv) as yellow solid 
(0.063 g, 53%); Rf (EtOAc : Hexane, 4 : 6) 0.12. 1H NMR (400 
MHz, DMSO-d6) δ 8.7 (d, J = 2.2 Hz, 1H, H4), 8.6 (d, J = 8.8 
Hz, 1H, H2), 8.0 (dd, J = 8.9, 2.2 Hz, 1H, H3), 6.6 (s, 1H, H1), 
3.9 (t, J = 5.4 Hz, 2H, H6), 3.7 (t, J = 5.4 Hz, 2H, H5), 3.4 (s, 
3H, H7). 13C NMR (101 MHz, DMSO-d6) δ 150.3, 127.2, 120.1, 
118.3, 116.9 (2C), 115.2, 87.2 (2C), 70.9 (2C), 58.7 (2C), 44.0 
(3C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 3.11 min, m/z 
[M+H]+ = 369.0. 
 
1-((2-(diethylamino)ethyl)amino)-8-morpholino-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 49 
Compound 2.2d was obtained from 2.2c (0.088 g, 0.27 mmol, 1.0 equiv) and N1, N1-
diethylethane-1,2-diamine (0.037.3 g, 0.32 mmol, 1.2 Eq) as 
an orange solid (0.062 g, 56%), m.p 238 – 240 °C; Rf (EtOAc 
: Hexane, 7 : 3) 0.22. 1H NMR (400 MHz, DMSO-d6) δ 7.9 
(d, J = 2.3 Hz, 1H, H4), 7.8 (s, 1H, H5), 7.7 (d, J = 9.4 Hz, 1H, 
H2), 7.3 (dd, J = 8.9, 2.3 Hz, 1H, H3), 6.31 (s, 1H, H1), 3.63 
(t, J = 6.1 Hz, 2H, H6), 2.98 (t, J = 6.33 Hz, 2H, H7), 2.9 – 2.7 
(q, J = 7.2 Hz, 4H, H8), 1.1 (t, J = 7.2 Hz, 6H, H9). 13C NMR 
(101 MHz, DMSO-d6) δ 155.9, 149.8, 141.7, 130.2, 119.8 
(2C), 117.6, 102.2 (3C), 85.7, 73.8 (2C), 66.7 (2C), 51.1, 46.7, 11.4 (2C). HPLC-MS (ACI/ 
ESI): Purity = 96%, tR = 2.56 min, m/z [M-H]
- = 409.8/ 410.0. 
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8-chloro-1-((2-(diethylamino)ethyl)amino)-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo 
[1,2-a]pyridine-4-carbonitrile, 50 
Compound 50 was obtained from 2.4c (0.11 g, 0.27 mmol, 1.0 equiv) and N1, N1-diethylethane-
1,2-diamine (0.063 g, 0.54 mmol, 2.0 equiv) as yellow solid 
(0.083 g, 63%); Rf (EtOAc : Hexane, 1 : 1) 0.20. 1H NMR 
(600 MHz, DMSO-d6) δ 8.7 (d, J = 2.1 Hz, 1H, H4), 8.6 (dd, 
J  = 8.9, 2.1 Hz, 1H, H3), 8.0 (d, J = 8.2 Hz, 2H, H11), 8.0 
(d, J = 8.3 Hz, 2H, H10), 7.8 (s, 1H, H5), 7.6 (d, J = 8.9 Hz, 
1H, H2), 6.3 (s, 1H, H1), 3.6 (t, J = 6.3 Hz, 2H, H6), 2.9 (t, J 
= 6.3 Hz, 2H, H7), 2.7 (q, J = 7.1 Hz, 4H, H8), 1.0 (t, J = 7.1 
Hz, 6H, H9). 13C NMR (151 MHz, DMSO-d6) δ 149.4, 141.9, 130.0 (3), 129.0 (2), 126.0 (3), 
121.6, 117.3, 114.1, 111.8, 91.7, 51.2 (2), 46.8 (3), 41.7 (2), 12.1 (3). HPLC-MS (ACI/ ESI): 
Purity = 92%, tR = 2.85 min, m/z [M+H]
+ = 486.1. 
 
tert-Butyl (2-((8-chloro-4-cyano-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridin-1-yl)amino)ethyl)(ethyl)carbamate, 51 
Compound 51 was obtained from compound 2.4c (0.110 g, 0.27 mmol, 1.0 equiv) and tert-
butyl (2-aminoethyl)(ethyl)carbamate (0.102 g, 0.54 mmol, 2.0 
equiv) as yellow solid (0.134 g, 89%), m.p 235 – 237 °C; Rf 
(EtOAc : Hexane, 3 : 7) 0.27. 1H NMR (600 MHz, DMSO-d6) 
δ 8.7 (d, J = 2.2 Hz, 1H, H4), 8.6 (dd, J = 8.9, 2.1 Hz, 1H, H3), 
8.0 (d, J = 8.2 Hz, 2H, H12), 7.9 (d, J = 8.3 Hz, 2H, H11), 7.8 
(s, 1H, H5), 7.6 (d, J = 8.6 Hz, 1H, H2), 6.4 (s, 1H, H1), 3.7 (t, 
J = 6.2 Hz, 2H, H6), 3.6 (t, J = 6.4 Hz, 2H, H7), 3.3 (q, J = 6.97 
Hz, 2H, H9), 1.2 (s, 9H, H8), 1.1 (t, J = 8.7 Hz, 3H, H10). 13C 
NMR (151 MHz, DMSO-d6) δ 155.7, 151.1, 149.1, 130.0 (2C), 126.8, 126.0 (2C), 120.6, 120.0, 
118.2, 116.2, 115.2, 91.2, 79.4, 46.4 (2C), 45.3, 42.6 (3C), 28.4 (4C), 13.9, 9.0 (2C). HPLC-
MS (ACI/ ESI): Purity = 99%, tR = 3.37 min, m/z [M+H]
+ = 558.1. 
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6.3.8 General procedure for the synthesis of the final compounds 38 – 41, 48, 49, 53 and 
54 using the palladium (0) catalysed amine coupling (Buchwald-Hartwig reaction)1  
A mixture of an aryl-halide (2.3d, 2.3e, 37, 50 – 52: 1.0 equiv), tris(dibenzylideneacetone) 
dipalladium (0) (Pd2dba3: 0.1 equiv), RuPhos (0.2 equiv), cesium carbonate (Cs2CO3: 3.0 
equiv) and the appropriate amine (2.0 equiv) in anhydrous 1,4-dioxane in a sealed tube was 
flushed with nitrogen gas for 15 minutes. The treated reaction mixture was heated to 110 °C 
for aliphatic cyclic amines and at 120 °C for an aromatic amine for 8-16 hours at respective 
temperatures with continuous stirring. The excess solvent was removed in vacuo and the 
resulting residue taken up in ethyl acetate, washed with lithium chloride (20 mL x 3), deionized 
water (20 mL x 3), brine (10 mL x 3), dried over anhydrous magnesium sulphate (MgSO4), 
filtered through celite, concentrated and dried in vacuo to obtain solid residues. A column was 
used where the compound needed further purification. 
 
 9-(pyrimidin-2-ylamino)-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 38 
Compound 38 was obtained from compound 37 (0.080 g, 0.17mmol, 1.0 equiv) and 2-amino 
pyrimidine (0.019 g, 0.20 mmol, 1.2 equiv) as a yellow solid 
(0.031 g, 34%); m.p 242 – 244 °C; Rf (EtOAc : Hexane, 3 : 7) 
0.32; 1H NMR (300 MHz, Acetonitrile-d3) δ 9.0 (s, 1H, H7), 
8.8 (s, 1H, H8), 8.6 (d, J = 5.04 Hz, 2H, H6), 8.3 (dd, J = 8.0, 
0.9 Hz, 1H, H2), 8.2 (t, J = 8.7 Hz, 1H, H3), 7.5 (d, J = 8.2 Hz, 
2H, H9), 7.4 (dd, J = 8.7, 0.8 Hz, 1H, H4), 7.4 (d, J = 7.8 Hz, 
2H, H10), 7.0 (t, J = 4.9 Hz, 1H, H5), 6.4 (s, 1H, H1). 13C NMR 
(151 MHz, DMSO-d6) δ 158.8, 157.9 (3C), 152.2 (4C), 144.8, 
143.5, 142.8 (2C), 138.7 (3C), 132.3, 132.3 (2C), 122.8, 118.2 
(2C), 114.2, 98.5 (2C). HPLC-MS (ACI/ ESI): Purity = 98%, tR = 3.27 min, m/z [M+H]
+ = 
530.1. 
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9-morpholine-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo [4,5]imida-
zo[1,2-a]pyridine-4-carbonitrile, 1.7b 
Compound 39 was obtained from 37 (0.10 g, 0.21 mmol, 1.0 equiv) and morpholine (0.037 g, 
0.42 mmol, 2.0 equiv) as a yellow solid (0.022 g, 20%), m.p 
212 – 215 °C; Rf (EtOAc : Hexane, 7 : 3) 0.21; 1H NMR (300 
MHz, DMSO-d6) δ 8.9 (s, 1H, H7), 8.1 (dd, J = 7.3, 1.9 Hz, 1H, 
H2), 7.5 (d, J = 8.7 Hz, 2H, H8), 7.4 (d, J = 8.6 Hz, 2H, H9), 7.4 
(t, J = 8.2 Hz, 1H, H3), 7.2 (dd, J = 8.1, 2.1 Hz, 1H, H4), 6.4 (s, 
1H, H1), 3.9 (m, 4H, H5), 3.5 (m, 4H, H6). 13C NMR (151 MHz, 
DMSO-d6) δ 148.8, 148.6, 148.1, 147.7, 147.3, 145.9, 130.0, 
124.8 (2C), 123.1, 122.8 (2C), 114.2, 66.7 (2C), 50.6 (2C). 
HPLC-MS (ACI/ ESI): Purity = 98%, tR = 3.20 min, m/z 
[M+H]+ = 522.0. 
 
tert-Butyl 4-(4-cyano-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo-
[4,5]imidazo[1,2-a]pyridin-9-yl)piperazine-1-carboxylate, 2.2d 
Compound 2.2d was obtained from 37 (0.15 g, 0.32 mmol, 1.0 equiv) and tert-butyl piperazine-
1-carboxylate (0.12 g, 0.64 mmol, 1.2 Eq) as a orange solid 
(0.070 g, 35%), m.p 185 – 187 °C; Rf (EtOAc : Hexane, 3 : 7) 
0.29; 1H NMR (300 MHz, DMSO-d6) δ 8.8 (s, 1H, H8), 8.5 (d, 
J = 8.9 Hz, 2H, H9), 8.4 (dd, J = 8.6, 2.0 Hz, 1H, H2), 8.2 (d, J 
= 8.9 Hz, 2H, H10), 7.4 (t, J = 8.3 Hz, 1H, H3), 6.8 (dd, J = 7.9, 
2.0 Hz, 1H, H4), 5.7 (s, 1H, H1), 4.2 (m, 4H, H7), 4.1 (m, 4H, 
H6) 1.3 (s, 9H, H5). 13C NMR (101 MHz, DMSO-d6) δ 163.7, 
153.8, 143.3 (3C), 133.2 (3C), 127.5 (3C), 123.7, 122.6, 122.1, 
121.8, 120.4 (4C), 105.5, 99.3 (2C), 77.9, 49.2 (2C), 26.7 (4C). HPLC-MS (ACI/ ESI): Purity 
= 98%, tR = 3.19 min, m/z [M-H]
- = 618.7. 
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9-(1,1-dioxidothiomorpholino)-1-((4-(trifluoromethoxy)phenyl)amino)-3-trifluoromethyl)-
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile, 41 
Compound 41 was obtained from 37 (0.056 g, 0.12 mmol, 1.0 equiv) and thiomorpholine-1,1- 
dioxide (0.032 g, 0.24 mmol 2.0 equiv) as orange solid (0.021 
g, 30%), m.p > 300 °C; Rf (EtOAc : Hexane, 1 : 1) 0.36; 1H 
NMR (400 MHz, Acetonitrile-d3) δ 8.0 (dd, J = 7.5, 2.2 Hz, 
1H, H2), 7.4 (d, J = 9.2 Hz, 2H, H7), 7.4 (d, J = 9.4 Hz, 2H, 
H8), 7.3 (t, J = 8.2 Hz, 1H, H3), 7.1 (dd, J = 7.5, 2.2 Hz, 1H, 
H4), 6.3 (s, 1H, H1), 4.2 (t, J = 5.2 Hz, 4H, H6), 3.2 (t, J = 5.2 
Hz, 4H, H5). 13C NMR (151 MHz, Acetonitrile-d3) δ 148.7, 
146.6, 146.3, 140.0, 138.2, 136.9, 136.7, 129.8, 125.5 (2C), 
123.3, 122.7 (3C), 121.4, 121.4, 113.8, 113.2, 108.6, 90.5, 51.0 
(2C), 48.5 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.23 min, m/z [M+H]
+ = 570.0. 
 
1-((2-methoxyethyl)amino)-8-morpholino-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]py-
ridine-4-carbonitrile, 48 
Compound 48 was obtained from 2.2d (0.060 g, 0.16 mmol, 1.0 equiv) and morpholine (0.043 
g, 0.49 mmol, 3.0 equiv) as an orange solid (0.023 g, 35%), m.p 
185 - 188; Rf (EtOAc : Hexane, 8 : 2) 0.36. 1H NMR (400 MHz, 
Methanol-d4) δ 8.2 (d, J = 9.2 Hz, 1H, H2), 7.3 (d, J = 2.0 Hz, 
1H, H6), 6.8 (dd, J = 8.4, 2.0 Hz, 1H, H3), 6.6 (s, 1H, H1), 4.0 
– 3.9 (m, 4H, H4), 3.9 (t, J = 5.7 Hz, 2H, H8), 3.6 (t, J = 5.7 Hz, 
2H, H7), 3.4 (s, 3H, H9), 3.4 – 3.3 (m, 4H, H5). 13C NMR (101 
MHz, Methanol-d4) δ 130.1, 118.6, 113.8, 112.2, 107.9, 102.5, 85.8 (2C), 71.6, 69.9, 66.6 (3C), 
57.9, 50.5 (2C), 49.3, 42.9 (2C), 36.8. HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.95 min, m/z 
[M+H]+ = 420.0. 
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1-((2-(diethylamino)ethyl)amino)-8-morpholino-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile, 49 
Compound 49 was obtained from 2.2d (0.058 g, 0.14 mmol, 1.0 equiv) and N1, N1-
diethylethane-1,2-diamine (0.015 g, 0.17 mmol, 1.2 equiv) as 
an orange solid (0.022 g, 33%), m.p 232 – 235 °C; Rf (EtOAc 
: Hexane, 8 : 2) 0.17. 1H NMR (400 MHz, DMSO-d6) δ 7.9 (d, 
J = 2.1 Hz, 1H, H6), 7.7 (d, J = 8.9 Hz, 1H, H2), 7.3 (dd, J = 
8.9, 2.1 Hz, 1H, H3), 6.2 (s, 1H, H1), 3.9 – 3.8 (m, 4H, H4), 3.6 
(t, J = 6.1 Hz, 2H, H7), 3.2 – 3.1 (m, 4H, H5), 3.0 (t, J = 5.9 Hz, 
2H, H8), 2.9 (q, J = 7.2 Hz, 4H, H9), 1.1 (t, J = 7.0 Hz, 6H, 
H10). 13C NMR (101 MHz, DMSO-d6) δ 150.6, 146.8, 139.9, 129.7, 118.8 (2C), 117.6, 102.2, 
85.7, 66.7 (3C), 51.0 (5C), 46.6(3C), 11.2 (3C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.94 
min, m/z [M-H]- = 459.1. 
 
tert-Butyl (2-((4-cyano-8-morpholino-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridin-1-yl)amino)ethyl)(ethyl)carbamate, 54 
Compound 54 was obtained from 51 (0.11 g, 0.20 mmol, 1.0 equiv) and morpholine (0.034 g, 
0.39 mmol, 2.0 equiv) as orang solid (0.073 g, 60%), m.p 
235 – 237 °C; Rf (EtOAc : Hexane, 3 : 7) 0.22. 1H NMR 
(600 MHz, DMSO-d6) δ 8.4 (s, 1H, H7), 8.0 (d, J = 8.2 Hz, 
2H, H14), 7.9 (d, J = 8.3 Hz, 2H, H13), 7.9 (d, J = 2.1 Hz, 
1H, H6), 7.7 (d, J = 8.9 Hz, 1H, H2), 7.4 (dd, J = 9.0, 2.1 
Hz, 1H, H3), 6.5 (s, 1H, H1), 3.8 (m, 4H, H5), 3.8 (t, J = 6.2 
Hz, 2H, H8), 3.6 (t, J = 6.1 Hz, 2H, H9), 3.1 (m, 4H, H4), 
3.2 (q, J = 10.0 Hz, 2H, H10), 1.2 (s, 9H, H12), 1.1 (t, J = 
9.9 Hz, 3H, H11). 13C NMR (151 MHz, DMSO-d6) δ 150.7, 141.3, 130.0 (3C), 126.0 (3C), 
118.1, 117.5, 116.0, 111.7, 102.6, 100.7, 92.5, 79.4, 66.6 (3C), 50.7 (2C), 49.3, 45.3, 42.7 (3C), 
28.4 (4C), 13.9 (2C). HPLC-MS (ACI/ ESI): Purity = 99%, tR = 3.71 min, m/z [M+H]
+ = 609.2. 
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6.3.9 General procedure for the amino-group deprotection: synthesis of compounds 40, 
52 and 553 
A solution of 4 M HCl in 1,4-dioxane (1.0 mL per 100 mg sample) was added to a solution of 
an appropriate carbamate analogue. The reaction mixture was stirred for 1 hour from 0 °C to 
room temperature (17 - 25 °C). The completion of the reaction was confirmed by TLC and 
HPLC-MS after which excess 1, 4-dioxane and HCl were removed in vacuo. The compound 
residue was basified to pH 11 by a steady addition of saturated solution of sodium bicarbonate 
(NaHCO3). The organic residues were taken up in ethyl acetate (EtOAc) after which the 
aqueous phase was removed using a separatory funnel. The EtOAc layer was washed with 
deionised water (20 mL x 3), brine (10 mL x 3), dried over MgSO4 and was finally concentrated 
in vacuo. 
 
9-(piperan-1-yl)-1-((4-(trifluoromethoxy)phenyl)amino)-3-(trifluoromethyl)benzo [4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 40 
Compound 40 was obtained from 2.2d (0.050 g, 0.080 mmol, 1.0 equiv) and HCl in dioxane 
(0.012 g, 0.096mmol, 1.2 equiv) as a brown solid (0.036 g, 
87%), m.p: ND; Rf (MeOH : DCM, 0.5 : 9.5) 0.21; 1H NMR 
(300 MHz, DMSO-d6) δ 8.9 (s, 1H, H8), 8.5 (d, J = 8.8 Hz, 2H, 
H9), 8.4 (dd, J = 8.3, 2.0 Hz, 1H, H2), 8.2 (d, J = 8.8 Hz, 2H, 
H10), 7.4 (t, J = 8.1 Hz, 1H, H3), 6.8 (d, J = 7.9, 2.0 Hz, 1H, 
H4), 5.7 (s, 1H, H1), 4.1 (m, 4H, H7), 3.7 (m, 4H, H6) 1.1 (s, 
1H, H5). 13C NMR (101 MHz, DMSO-d6) δ 163.7, 143.3 (2C), 
133.2 (3C), 127.5 (3C), 123.7, 122.6, 122.1, 121.8, 120.4 (4C), 
105.5, 99.3 (2C), 49.1 (2C), 45.9 (2C). HPLC-MS (ACI/ ESI): 
Purity = 98%, tR = 2.95 min, m/z [M+H]
+ = 521.1. 
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8-chloro-1-((2-(ethylamino)ethyl)amino)-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo-
[1,2-a]pyridine-4-carbonitrile, 52 
Compound 52 was obtained from compound 51 (0.070 g, 0.13 mmol, 1.0 equiv) and 4.0 M 
HCl in 1, 4-dioxane (0.70 mL) as yellow solid (0.057 g, 
96%), m.p 226 - 228 °C; Rf (MeOH : DCM, 0.1 : 9.9) 0.17. 
1H NMR (600 MHz, DMSO-d6) δ 8.6 (s, 1H, H5), 8.4 (d, J = 
2.2 Hz, 1H, H4), 8.0 (d, J = 8.5 Hz, 2H, H11),  8.0 (d, J = 8.6 
Hz, 2H, H10), 7.9 (dd, J = 8.6, 2.0 Hz, 1H, H3), 7.6 (d, J = 
8.6 Hz, 1H, H2), 6.4 (s, 1H, H1), 3.9 (t, J = 6.2 Hz, 2H, H6), 
3.4 (t, J = 6.0 Hz, 2H, H7), 3.1 (q, J = 6.2 Hz, 2H, H8), 1.3 (t, 
J = 6.2 Hz, 3H, H9). 13C NMR (151 MHz, DMSO-d6) δ 151.2, 148.9, 141.6, 130.1 (3C), 127.0, 
126.0 (2C), 125.4, 120.9, 120.0, 118.2, 117.1, 116.7, 115.7, 91.8, 91.6, 45.1, 45.0, 42.9, 42.9, 
11.3. HPLC-MS (ACI/ ESI): Purity = 99%, tR = 2.97 min, m/z [M-H]
- = 458.1. 
 
1-((2-(ethylamino)ethyl)amino)-8-morpholino-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imi-
dazo[1,2-a]pyridine-4-carbonitrile, 55 
Compound 55 was obtained from compound 54 (0.07 g, 0.12 mmol, 1.0 equiv) and 2.0m HCl 
in 1, 4-dioxane (0.5 mL) as orange solid (0.041 g, 
70%), m.p 192 – 195 °C; Rf (MeOH : DCM, 0.4 : 9.6) 
0.18. 1H NMR (600 MHz, DMSO-d6) δ 8.4 (s, 1H, 
H7), 8.0 (d, J = 8.7 Hz, 2H, H14), 7.9 (d, J = 8.7 Hz, 
2H, H13), 7.8 (d, J = 8.9 Hz, 1H, H2), 7.4 (dd, J = 9.0, 
2.1 Hz, 1H, H3), 7.3 (d, J = 2.2 Hz, 1H, H6), 6.3 (s, 
1H, H1), 3.9 (m, 4H, H4), 3.8 (t, J = 6.3 Hz, 2H, H8), 
3.3 (t, J = 6.2 Hz, 2H, H9), 3.3 – 3.2 (m, 4H, H5), 3.1 (q, J = 7.2 Hz, 2H, H11), 1.3 (s, 1H, H10), 
1.2 (t, J = 7.2 Hz, 3H, H12). 13C NMR (151 MHz, DMSO-d6) δ 149.6, 142.0, 130.0 (3C), 126.0 
(2C), 119.0, 117.4, 115.8, 103.4, 102.7, 90.6, 66.7 (3C), 50.9, 49.75, 45.4 (2C), 42.9 (2C), 26.5, 
26.2, 22.2, 11.9 (2C). HPLC-MS (ACI/ ESI): Purity = 97%, tR = 3.19 min, m/z [M+H]
+ = 509.2. 
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6.4 Biological assays 
6.4.1 In vitro asexual blood stage antiplasmodium assay 
Compounds were screened against multidrug-resistant (K1) and sensitive (NF54) strains of P. 
falciparum in vitro using the modified [3H]-hypoxanthine incorporation assay.4 P. falciparum 
was cultivated in a variation of the medium previously described,5,6 consisting of RPMI 1640 
supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM 
hypoxanthine and 100 μg/mL neomycin. Human erythrocytes served as host cells. Cultures 
were maintained at 37 °C in an atmosphere of 3% O2, 4% CO2 and 93% N2 in humidified 
modular chambers. Compounds were dissolved by sonication in DMSO (10 mg/mL) and 
diluted in hypoxanthine-free culture medium. Infected erythrocytes (100 μL per well with 2.5% 
hematocrit and 0.3% parasitemia) were added to each drug titrated in 100 μL duplicates over a 
64-fold range. After 48 hours incubation, 0.5 μCi of [3H]hypoxanthine in 50 μL medium was 
added and plates were incubated for an additional 24 hours. Parasites were harvested onto 
glass-fibre filters and radioactivity was counted using a Betaplate liquid scintillation counter 
(Wallac, Zurich). The results were recorded as counts per minute (cpm) per well at each drug 
concentration and expressed as a percentage of the untreated controls. Fifty per cent inhibitory 
concentrations (IC50) were estimated by linear interpolation.
7 
 
6.5.2 In vitro gametocytocidal assay 
6.4.2.1 Luciferase Reporter Assay 
Two transgenic parasite lines (NF54-PfS16-GFP-Luc and NF54-Mal8p1.16-GFP-Luc) were 
used in the luciferase assays which facilitated stage-specific determination of gametocytocidal 
activity. Gametocytes were produced according to Reader et al.8 On days 5 and 10 which 
respectively represent > 90% of early stage (I – III) and > 90% of late stage (IV and V) 
gametocytes, drug assays were set up. In both cases, 2 – 3% gametocytaemia and 1.5% 
haematocrit culture were used with a 48-hour drug pressure in a gas chamber (90% N2, 5% O2 
and 5% CO2) at 37ºC. To 20 μL parasite lysates, 50 μL of luciferin substrate (Promega 
Luciferase Assay System) was added at room temperature. Luciferase activity was determined 
by detection of resulting bioluminescence at an integration constant of 10 seconds using the 
GloMax®-Multi+ Detection System with Instinct® Software. Methylene blue and 
dihydroartemisinin were used as controls. 
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6.4.2.2 ATP assay 
In the ATP assay, late-stage gametocytes (IV and V, primarily stage V) were enriched using 
density gradient centrifugation and magnetic separation. Dilutions for the compounds were 
prepared in triplicate in 96-well plates. To each well, about 50,000 gametocytes in the glucose-
rich complete medium were added to make a final volume of 100 μL where after the plates 
were incubated at 37 °C in a humidified gas chamber (90% N2, 5% O2 and 5% CO2) for 24 
hours. The BacTiter-Glo™ assay (Promega) was then carried out in accordance with the 
manufacturer’s guidelines at room temperature in the dark with assay substrate incubated for 
10 minutes to detect ATP levels. The GloMax®-Multi+ Detection System with Instinct® 
Software was used to detect bioluminescence at an integration constant of 0.5 seconds. 
Methylene blue and dihydroartemisinin were used controls. 
 
6.5 Solubility Determination 
6.5.1 Kinetic Solubility Employing HPLC 
Using a miniaturised shake flask method,10 solubility assays were obtained from a 10 mM stock 
solutions of the test compounds dissolved in DMSO, calibration standards (10 - 220 μM in 
DMSO) were prepared. The 10 mM stock solutions were also used to spike (1:50) duplicate 
aqueous samples in phosphate buffered saline (pH 6.5). The DMSO was dried off in a GeneVac 
(MiVac, 90 min, 37 °C) after which the samples were incubated while shaking for 20 hours at 
25 °C. Thereafter, the solutions were filtered, and their absorbance measured using HPLC-
DAD (Agilent 1200 Rapid Resolution HPLC with a diode array detector). The calibration 
standards were used to plot the calibration curves, which were used to determine the solubility 
of the aqueous samples. 
 
6.5.2 Kinetic (Turbidimetric) Solubility11 
A phosphate buffered saline (PBS) solution comprising 0.14 M NaCl, 0.003 M KCl and 0.01 
M phosphate buffer (pH 7.4) was prepared by dissolving one intact PBS buffer tablet in 1 L of 
water. Particulate contaminants were removed by filtering the solution through a 0.22 μm nylon 
filter and the pH verified using a pH meter. Stock solutions (10 mM) of test compounds were 
prepared by dissolving in DMSO. Using a 96-well plate, serial dilutions of the compounds in 
DMSO were prepared in triplicate starting from 8 mM to 0.25 mM (predilution plate). 
Secondary serial dilutions (5 – 200 μM) in DMSO and PBS buffer, also in triplicate, were 
prepared by pipetting 4 μL aliquots from the predilution plate to corresponding wells in the 
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secondary plate containing 196 μL DMSO and PBS buffer (final volume of 200 μL in each 
well). The serial dilutions in DMSO acted as controls to make sure the test compounds in 
solution did not absorb electromagnetic radiation at the test wavelength. The plate was covered 
and incubated for 2 hours in an oven maintained at 37 °C. The absorbance values of the wells 
were then measured by a UV-Visible Multiskan Go 1510-05438 spectrometer (Thermo 
Scientific). The values were then corrected by subtracting the absorbance of the blank wells 
containing only DMSO and 2% DMSO in PBS. The corrected absorbance values were plotted 
as a function of concentration using excel. A constant absorbance value of 0 at all 
concentrations indicates the compound is soluble at all concentrations. Insoluble compounds 
will precipitate and cause turbidity the absorbance of which was measured by a UV-Visible 
spectrometer. Solubility was taken to be that concentration above which the test compound 
precipitates from solution causing a sustained upward deviation of absorbance values from 
zero. 
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